2011 Anniversary Yearbook - EUFEPS today and history

EUFEPS Yearbook 2011
20 th Anniversary Issue
European Federation for Pharmaceutical Sciences
Veddesta Business Center, Veddestavägen 13, Järfälla, Sweden
www.eufeps.org

EUFEPS
Inaugural Meeting
in Strasbourg,
France
European Federation for Pharmaceuti
1 st European
Congress of
Pharmacetucal
Sciences,
Amsterdam,
The Netherlands
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
First issue
of EUFEPS
NewsLetter
European Journal
of Pharmaceutical
Sciences � �f�cial
Scienti�c Journal
2 nd European
Congress of
Pharmacetucal
Sciences, Berlin,
Germany
Progress Overview
3 rd European
Congress of
Pharmacetucal
Sciences, Edinburgh,
United Kingdom
EUFEPS
Individual
Membership
4 th European
Congress of
Pharmacetucal
Sciences, Milan,
Italy
New Safe
Medicies
Faster
Position
Paper
Permanent
Secretariat,
Stockholm,
Sweden
EUFEPS Online
New Safe
Medicies Faster
Initiative
Workshop
5 th European
Congress of
Pharmacetucal
Sciences,
Budapest,
Hungary
Millennial
Pharmaceutical
Sciences World
Congress,
San Fransisco,
USA
www.eu

cal Sciences
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Full-time
Secretary-
General/
Executive
Director
6 th European
Congress of
Pharmacetucal
Sciences,
Stockholm,
Sweden
European
Commision 6 th
Framework
Programme for
Research and
Technological
Development
2002–2006
CIRR
Safety Sciences
Poition Paper
Safety Sciences
Workshop I,
Brussels,
Belgium
7 th
European
Congress of
Pharmacetucal
Sciences,
Brussels,
Belgium
2 nd
Pharmaceutical
Sciences World
Congress, Kyoto,
Japan
EUFEPS
Course
DataBase
Safety
Sciences
Network
1 st EUFEPS
Flash
feps.org
1 st
Pharmaceutical
Sciences Fair
and Exhibition,
Nice, France
1 st BBBB
Conference, Sifok,
Hungary
QbD and
PAT Sciences
Network
European
Pharma Sciences
Leadership Forum
(EuPSLF)
Initiative
EUFEPS
Institutional
Membership
Bioavailability
and
Biopharmaceutics
Network
Safety Sciences
Workshop II,
Vienna, Austria
2 nd BBBB
Conference,
Tartu, Estonia
3 rd
Pharmaceutical
Sciences World
Congress,
Amsterdam,
The Netherlands
EUFEPS
Vienna Branch
Office for
In-Silico
Systems and
Learning
European
Commision 7 th
Framework
Programme for
Research and
Technological
Development
2008–
EUFEPS
Senate
Innovative
Medicines
Initiative (IMI)
Joint
Undertaking
EUFEPS
FIP (BPS)
Membership
(observer since
inauguration)
2 nd
Pharmaceutical
Sciences Fair
and Exhibition,
Nice, France
3 rd BBBB
Conference,
Antalia, Turkey
Environment
and
Pharmaceuticals
Network
PharmacoGenetics
and
PharmacoGenomics
Research
Network
3 rd
Pharmaceutical
Sciences Fair
and Exhibition,
Prag,
Czech Republic
4 th BBBB
Conference,
Bled, Sloveina
Food-Drug
Synergy
Network
4th Pharmaceutical
Sciences World
Congress,
New Orleans,
USA
Nano
Medicines
Network
20 Years

© Janssen Pharmaceutica NV 2010
Janssen Pharmaceutica NV
Janssen Research & Development,
A Division of Janssen Pharmaceutica NV,
Turnhoutseweg 30, B-2340 Beerse, Belgium
www.janssenpharmaceutica.com - www.jnjpharmarnd.com
Dr. Paul Janssen
Patients are Waiting

Pharma Ingredients & Services Custom Synthesis Excipients Active Ingredients
Thorsten Cech knows the importance
of the right combination.
Thorsten Cech,
an enabler in excipients
Kollicoat ® Smartseal 30 D – Active Protection.
Kollicoat Smartseal 30 D is the first aqueous dispersion for taste masking and moisture protection.
• Smart protection from unpleasant taste
• Effective sealing against moisture
• Fast release of active ingredients
• Easy and economical film coating
Isn’t it time you had a partner who knows how to open up new opportunities? Contact us
via e-mail at pharma-ingredients@basf.com or visit www.pharma-ingredients.basf.com
Pharma Ingredients & Services. Welcome to more opportunities.
03_RZ_BASF_AZ_190x130mm_Smartseal_EUFEPSYearbook_Iso.indd 1 18.01.11 10:15
World-class R&D in Göteborg and Manchester
Make the connection
Based in Mölndal on the outskirts of Göteborg and in Alderly Park/Macclesfield near Manchester, our research sites are more than
simply state-of-the-art locations for much of our R&D. They’re home to scientists and researchers who value collaboration: global
centres for R&D excellence; brain trusts; ideas hubs.
We’re creating a vibrant, inspirational workspace where research-led ideas can be conceived. And it’s not just the buildings that are
carefully designed either. From our way of working to the way we speak to each other, every aspect of the professional environment
has been considered.
By 2012 we expect to have filled hundreds of vacancies for people across discovery and development – from scientists who
have strong disease knowledge and expertise in drug discovery, to experienced drug developers in clinical, pharmaceutical and
regulatory fields. In fact, we’re recruiting now – in dozens of different areas, from predictive science to supply chain management.
Here, you’ll have the chance to make connections with brilliant minds, great ideas and health-enhancing discoveries. So if you
really want to make a positive difference to future health research, we’d like to welcome you into our new home.
For more information and to apply please go to www.astrazenecacareers.com
www.astrazenecacareers.com

EUFEPS Yearbook
2011
20 th Anniversary
Issue

The Gamlen Tablet Press
The world’s first, bench top, computer
controlled tablet press
With the new Mini-Coater system,
you can achieve superior coating at
very small batch sizes, thus reducing
research and development costs
considerably. With three interchangeable
pans, the system is extremely flexible
and ready for immediate operation.
Aqueous and solvent processing
Plug & Play
Optional qualification package
for clinical samples
Exceptionally attractive price
Fluid Bed Systems
Vertical Granulators
Product Handling
Pan Coaters
Process & factory planning
Services
FEAsibility
tEsts
Applications include:
Manufacture of test product
batches
Pre-formulation studies
Formulation comparisons
Salt selection studies
Intrinsic dissolution studies
Excipient compatibility samples
Manufacture of clinical trial
materials
Telephone: +44 (0) 115 912 4271
Web address: www.compressibility.com
Email: sales@compressibility.com
World-Class Tablet Coating
in a Bench Top Tablet Coater
CliniCAl
sAMPlE
FilM-
COAting
Glatt GmbH
Process Technology
Werner-glatt-straße 1
79589 binzen / germany
Phone: +49 7621 6 64 0
Fax: +49 7621 6 47 23
eMail: info@glatt.com
www.glatt.com
GMPC I Mini-Coater
The new GMPC I Mini-
Coater makes world-class
coating results possible
for extremely small batch
sizes of 500-2000 g.
Smart and simple to use.
the complete housing can be disassembled
and reassembled in seconds.
7221_568 AD MINI-COATER OSC 130x90 r1.indd 1 12.05.11 10:39
Key Features:
Easy to use
Virtually maintenance free
Minimal losses (

List of Contents
1. Contact Information including Secretariat 9
2. President’s Foreword 10
3. Mission, Membership and Operational Platforms 11
4. Member Societies 12
5. Individual Membership Representatives to Council 24
6. EUFEPS Statutes 25
7. Executive Committee 30
8. Advisory Committees 32
9. EUFEPS Networks 34
10. Awards and Prizes 38
11. European Pharmaceutical Scientist Prize 41
12. PharmSciFair 2011 42
13. Sample Meetings 43
14. EUFEPS in EU Projects 44
15. EUFEPS Senate 45
16. EUFEPS on the Global Scene 46
17. Sponsorship Recognition 48
18. Executive Committee Membership 1991–2011 49
19. History of EUFEPS 50

Sustainable sponsorship of EUFEPS gratefully acknowledged
1 3/6/08 5:49 am Page 1
1 3/6/08 5:49 am Page 1
1 3/6/08 5:49 am Page 1
Publisher of the SolarPACES Publisher 2011of
the
Editeur du Guide des Biotechnologies 2008
Abstracts Book
Publisher of the SolarPACES 2011
Abstracts Book
12 Place Carnot
93110 Rosny Sous Bois
Publisher Publisher of EUFEPS
of the the SolarPACES Directory
SolarPACES 2011
European Office:
2011
Editeur Société OSC du Guide des Biotechnologies 2008
Abstracts Book
29, rue Politzer Book
94100 Saint Maur
France
European Office:
FRANCE
Tél : (+33) 01 70 71 63 84 Société OSC
12 Place Fax
Place Carnot : (+33) 01 77 72 27 59
Carnot
29, rue Politzer
Email :contact@osc-edition.com
93110 94100 Saint Maur
93110 Rosny Web Sous :www.osc-edition.com
Bois
FRANCE
France
FRANCE
Tel: Tél : (+33) 01 70 71 63 84
Tel: (+33) 01.70.71.63.84
Fax:(+33) Fax : (+33) 01 77 72 27 59
Fax:(+33) 01.77.72.27.59
12 Place Carnot
Publisher of the Biotechnology Industry
E-mail: Email 93110 Guide
:contact@osc-edition.com
E-mail: contact@osc-edition.com 93110 Rosny 2008
Rosny Sous Bois
contact@osc-edition.com
Web: Web :www.osc-edition.com
FRANCE
Web: www.osc-edition.com
North American Office:
Tel: (+33) 01.70.71.63.84
Publisher Publisher of the the SolarPAC
Editeur du Guide des Biotechnolo
Abstracts Book
Tel: (+33) 01.70.71.63.84
Fax:(+33) 01.77.72.27.59
E-mail: contact@osc-edition.com
Web: www.osc-edition.com
European Office:
Société OSC
29, rue Politzer
94100 Saint Maur
France
Tél : (+33) 01 70 71 63 8
Tel: (+33) 01.70.71.63.84
OSC Associates
Fax:(+33) Fax : (+33) 01 77 72 27 5
Fax:(+33) 01.77.72.27.59
269 S. Beverly Drive,
E-mail:
Suite 630
Email :contact@osc-edition.c
E-mail: contact@osc-edition.com
Beverly Hills, California 90212
Web:
U.S.A.
Web :www.osc-edition.com
Web: www.osc-edition.com
Tel: +1 (310) 878-2285
Publisher Fax: +1 (310) of 861-1986 the Biotechnology Industry Guide 2008

Address
EUFEPS
Veddesta Business Center
SE-175 72 Järfälla (Stockholm) Sweden
Tel + 46 8 50582040
Fax + 46 8 4113217
Email secretariat@eufeps.org
Visiting Address
1. Contact information
Veddesta Business Center,
Veddestavägen 13, 4th floor, Järfälla (Stockholm) Sweden
Staff
Hans H. Linden, MSc
Executive Director
Tel office + 46 8 50582040
Tel mobile + 46 708 799813
Email hans.linden@eufeps.org
Per Öhrngren, MSc
Office Manager
Tel mobile + 46 708 766113
Email per.ohrngren@eufeps.org
Editor EUFEPS Online
Hans H. Linden, MSc
Editor EUFEPS Newsletter
Vacant
Editor-in-Chief European Journal of Pharmaceutical Sciences
Professor Arto Urtti
Viikki Drug Discovery Technology Center
University of Helsinki, Helsinki, Finland
Email arto.urtti@helsinki.fi
Editor Per Öhrngren
Current Hans H. Linden
Editorial Team
Historic Daan J.A. Crommelin
Layout Camilla Boquist/Lådan&Co, Stockholm, Sweden
9

2. PRESIDENT’S INTRODUCTION
Democratically, moderated organisations that seek to serve member societies for the
benefit of science must be an engine of change for good in Europe. We live in a constantly
changing world and as age demographics change, the burden of health care becomes more
pressing. The faster development of effective and safe medicines for all has been the watchword
of EUFEPS since the beginning, and the efforts of previous generations of scientists
associated with our twenty-year old organisation have achieved much in the path towards
this goal.
Europe is periodically beset by upheavals, in part mirroring changes elsewhere in the world,
especially America. Changes in legislation for cheaper medicines have a knock-on effect on
our industry and the nature of the pharmaceutical market changes. Processes requiring expensive
raw material and low-cost labour move steadily east, leaving Europe to contemplate
the nature of its pharmaceutical sciences.
There is no doubt that we will be faced with the challenges of innovation in medicines, which
extends through advanced products, through systems of monitoring health, personalised
medicines, concern for our environment and the adoption of science-led regulation. This
generates a need for better education and training and communication and a more intellectually
nimble workforce, able to adapt to new demands in the industry. Our academic institutions
must reflect these changes and be more cognisant of the changing requirements and
skill sets needed and avoid complacency. At any time in history, a seed change is either with
us or just around the corner and EUFEPS exists to help its member organisations to realise
new goals though interactions such as PharmSciFair and specialist distillation of information
in networks.
The future of EUFEPS depends on the enthusiasm of its membership. As a not-for-profit
organisation, contributing to EUFEPS does not bring personal financial riches, but it does
provide satisfaction that we are helping the next generations through mentorship and discussion.
Being part of this august and worthy organisation is exhausting but fun and it is so
easy to get deeply involved. I urge you to do so and promise that the deep satisfaction you
will gain in making new connections and discovering science directions will amply offset the
commitment of time.
With best wishes,
Clive G Wilson F.A.P.S., F.C.R.S.
President
European Federation of Pharmaceutical Sciences – EUFEPS
10

3. Mission, membership and operational platforms
The mission of the European Federation for Pharmaceutical Sciences (EUFEPS) is to serve
and advance excellence in the pharmaceutical sciences and innovative drug research in
Europe, including in training and education, and to represent the interests of scientists
engaged in drug research and development, drug regulation, drug utilisation, and drug
policy making.
Member Societies, Member Institutions and Individual Members are EUFEPS membership
categories.
EUFEPS is the only pan-European body to represent the interests of scientists in industry,
academia, government and other institutions engaged in drug research, development,
regulation and policymaking through Europe. It is an organisation for and run by
scientists, forming a wide-range network and actively contributing to the ideals of the
European pharmaceutical scientific community. The recruitment of younger generations of
pharmaceutical scientists for EUFEPS activities is another prime goal. As regional organisation
EUFEPS is bridging between the national and the global levels.
To achieve its objectives EUFEPS initiates and runs European projects and networks.
It organises, co-organises and co-sponsors congresses, conferences, workshops and
courses on specialised or general themes, including many sessions in the Pharmaceutical
Sciences Fair and Exhibition (PharmSciFair).
The European Journal of Pharmaceutical Sciences is the Official Scientific Journal of
EUFEPS.
Operational platforms of EUFEPS:
�� Membership
�� Networks
�� Senate
�� Research and Policy Collaboration
�� The PharmSciFair
�� Meetings and Events
�� Education and Training
�� Communication
�� Finance and Funding
�� President’s Conference
�� Council and Open Forum
�� Executive Committee
�� Central Office
11

4. Member Societies
Academy of Pharmaceutical Sciences of Great Britain – APSGB
Academy of Pharmaceutical Sciences
Academy
of Great
of Pharmaceutical
Britain – APSGB
Sciences of Great Britain – APSGB
Mission To stimulate development of, and promote the pharmaceutical sciences.
Mission To stimulate development of, and promote the pharmaceutical sciences.
To stimulate development of, and promote the
To
pharmaceutical
promote interaction
sciences.
and collaboration between the multidisciplinary subjects which constitute
To promote interaction and collaboration between the multidisciplinary subjects which constitute the
To promote interaction and collaboration between
the pharmaceutical
the multidisciplinary
sciences.
subjects which constitute the
pharmaceutical To express the views sciences. of pharmaceutical scientists at national and international levels.
pharmaceutical sciences.
Country To United express Kingdom the views of pharmaceutical scientists at national and international levels.
To express the views of pharmaceutical scientists at national and international levels.
Country Organisation (new) founded United 2000 Kingdom
United Kingdom
Organisation EUFEPS Member (new) Society founded 2000 1991
2000
EUFEPS Number Member of members Society 1991 500
1991
Number Postal address of members 500 840 Melton Road, Thurmaston, Leicester LE4 8BNUnited Kingdom
500
Postal Tel address 840 +44 Melton 116 2692299 Road, Thurmaston, Leicester LE4 8BNUnited Kingdom
840 Melton Road,
Tel Fax
Thurmaston, Leicester LE4
+44
8BNUnited
116 2692299 2640141
Kingdom
+44 116 2692299
Fax Email +44 info@apsgb.org
116 2640141
+44 116 2640141
Email info@apsgb.org
eddie.french@pfizer.com
info@apsgb.org Website eddie.french@pfizer.com
www.apsgb.co.uk
eddie.french@pfizer.com
Website
President (January 1, 2011)
www.apsgb.co.uk
Professor Martin Snowden
www.apsgb.co.uk
President
Secretary
(January
(January
1,
1,
2011)
2011)
Professor
Bob Seager
Martin Snowden
Professor Martin Activities Snowden 2011-2012 PS Industrial Insights, April 14–15, 2011, Pfizer, Sandwich UK
Secretary (January 1, 2011) Bob Seager
Bob Seager
APS Inhalation 2011, July 4–6, 2011, University of Bath, Bath UK
Activities 2011-2012 PS Industrial Insights, April 14–15, 2011, Pfizer, Sandwich UK
PS Industrial Insights, April 14–15, 2011, Pfizer, UK-PharmSci Sandwich 2011 UK The Science of Medicines, August 30–September 2, 2011, East Midlands
APS Inhalation 2011, July 4–6, 2011, University of Bath, Bath UK
APS Inhalation 2011, July 4–6, 2011, University Conference of Bath, Centre, Bath UKNottingham
UK
UK-PharmSci 2011 The Science of Medicines, August 30–September 2, 2011, East Midlands
UK-PharmSci 2011 The Science of Medicines, PS August & APS 30–September Drugs in the Lungs, 2, 2011, September/October, East Midlands 2011
Conference Centre, Nottingham UK
Conference Centre, Annual Nottingham conferences UK2011-
PS & APS Drugs in the Lungs, September/October, 2011
PS & APS Drugs 2012in
the Lungs, September/October, 2011
Annual National conferences meeting2011-2012 2011-
2012 Official journal
National meeting2011-2012
Official journal
Association de de Pharmacie Galénique Industrielle – APGI – APGI
Mission
Mission
Country
Country
Organisation founded
Organisation founded
EUFEPS Member Society
EUFEPS Member Society
Number
Number
of
of
members
members
Postal
Postal
address
address
Tel Tel
Fax Fax
Email Email
APGI is an association accessible to all, academics and persons in industry, who are concerned
with APGI pharmaceutical is an association technology, accessible and to all, the academics design, formulation and persons and in industry, pharmacotechnical,
who are concerned
biopharmaceutical with pharmaceutical and technology, pharmacokinetic and the design, assessment formulation of dosage and pharmacotechnical,
forms and delivery systems,
whether biopharmaceutical pharmaceutical and pharmacokinetic or dermopharmaceutical. assessment of dosage forms and delivery systems,
whether pharmaceutical or dermopharmaceutical.
France
France
1964
1964
1991
1991
300
300
5,
5,
Rue
Rue 4B
4B
Clément,
Clément,
FR-92290
FR-92290
Chateuay-Malabry,
Chateuay-Malabry,
France
France
+33 1 46602510
+33 6 29366739
+33 1 46835308
apgi.asso@u-psud.fr
juergen.siepmann@univ-lille2.fr
Website www.apgi.org
President (January 1, 1, 2011) Professor Juergen Siepmann
Secretary (January 1, 1, 2011) Odile Odile Chambin
Activities 2011-2012 Partner Organisation Organisation of PharmSciFair, June 13–17, 2011, Prague CZ CZ
Annual conferences 2011- 8th World Meeting on Pharmaceutics, Biopharmaceutics and and Pharmaceutical Technologes,
March
2012
19–22 March 19–22 2012, Istabul 2012, Istabul TR TR
Skin and Formulation, Lyon FR FR
National meeting2011-2012
Official journal
Poorly Soluble Drugs Woarkshop, September 15, 15, Lille Lille FR FR
12

Austrian Pharmaceutical Society – ÖPhG
Austrian Pharmaceutical Society – ÖPhG – ÖPhG
Mission In order to intensify the the contact between the the universities, the the pharmaceutic industry industry and and health health
Mission authorities In order to
authorities as intensify
as well as the
as hospital contact
hospital and between
and public public pharmacies, the universities,
pharmacies, the the
the ÖPhG pharmaceutic
ÖPhG holds holds presentations, industry and
presentations, scientific health
scientific
congresses authorities as
congresses and well
and seminars as hospital
seminars on on a and
a regular public
regular basis. pharmacies, the ÖPhG holds presentations, scientific
basis.
Country Country Austria congresses and seminars on a regular basis.
Austria
Organisation
Organisation Country
founded
founded 1979 Austria
1979
EUFEPS Organisation Member founded Society 1991 1979
EUFEPS Member Society 1991
Number EUFEPS of Member members Society 700 1991
Number of members 700
Postal Number address of members Department 700 für Pharmakognosie, Univ. Wien, Althanstraße 14, AT-1090 Wien, Austria
Postal address Department für Pharmakognosie, Univ. Wien, Althanstraße 14, AT-1090 Wien, Austria
Tel Postal address +43 Department 1 4277 55207 für Pharmakognosie, Univ. Wien, Althanstraße 14, AT-1090 Wien, Austria
Tel +43 1 4277 55207
Fax Tel +43 1 4277 9552 55207
Fax +43 1 4277 9552
Email Fax office@oephg.at
+43 1 4277 9552
Email hermann.stuppner@uibk.ac.at
office@oephg.at
gerhard.f.ecker@univie.ac.at
hermann.stuppner@uibk.ac.at
Website www.oephg.at
gerhard.f.ecker@univie.ac.at
Website President Website (January 1, 2011) Prof. www.oephg.at Dr. Hermann Stuppner
President Secretary President (January 1, 1, 2011) Prof. Prof. Dr. Dr. Sabine Hermann Hermann Glasl-Tazreiter
Stuppner
Secretary Activities Secretary (January 2011-2012 (January 1, 2011) Participation Prof. Dr. Dr. Sabine in the Glasl-Tazreiter
PharmSciFair, June 13–16, 2011, Prague CZ
Activities 2011-2012 Summer Participation School in the DRUG PharmSciFair, DESIGN, September June 13–16, 11–16, 2011, 2011 Prague CZ CZ
SEGGAUER Summer School Fortbildungstage, DRUG DESIGN, Oktober September 8–9, 2011 11–16, 2011 2011
Annual conferences 2011- SEGGAUER Fortbildungstage, Oktober 8–9, 8–9, 2011 2011
Annual 2012 Annual conferences 2011-
2012 National 2012 meeting2011-2012 Joint Meeting of the Austrian and German Pharmaceutical Societies,September 21–23, 2011,
National National meeting2011-2012 University Joint Meeting of Innsbruck, of the Austrian Innsbruck and and German AT German Pharmaceutical Societies,September 21–23, 21–23, 2011, 2011,
Official journal Scientia University Pharmaceutica
of Innsbruck,
Innsbruck,
Innsbruck
Innsbruck
AT
AT
Official
Official
journal
journal
Scientia
Scientia
Pharmaceutica
Pharmaceutica
Belgian Society of Pharmaceutical Sciences – BSPS
Belgian Society of Pharmaceutical Sciences – BSPS
Belgian Society of Pharmaceutical Sciences – BSPS
Mission The Belgian Society of Pharmaceutical Sciencesaims at supporting and promoting research in
Mission Pharmaceutical The Belgian Society Sciences of of Pharmaceutical both at the national Sciencesaims and international at at supporting level. and and promoting promoting research research in in
Country Belgium Pharmaceutical Sciences both at at the the national and and international level. level.
Country Organisation Country founded 1951 Belgium
Organisation EUFEPS Organisation Member founded Society 1994 1951
EUFEPS Number EUFEPS of Member members Society 300 1994
Number Postal Number address of
of
members
members Stevinstraat 300
300 137, BE-1000 Brussels, Belgium
Postal Tel Postal
address
address +32 Stevinstraat
Stevinstraat 2 6094625 137,
137,
BE-1000
BE-1000
Brussels,
Brussels,
Belgium
Belgium
Tel Fax Tel +32
+32 2 2854285 6094625
6094625
Fax Email Fax saevels.jan@mail.apb.be
+32 2 2854285
+32 2 2854285
Email
Email veronique.preat@uclouvain.be
saevels.jan@mail.apb.be
saevels.jan@mail.apb.be
Website www.bgfw.be
veronique.preat@uclouvain.be
veronique.preat@uclouvain.be
Website
President Website (January 1, 2011) Professor www.bgfw.be
www.bgfw.be
Veronique Preat
President
Secretary President
(January
(January 1, 1,
1,
2011)
2011)
J. Professor
Professor
Saevels, Veronique
Veronique
F. Prohoroff Preat
Preat
Activities Secretary 2011-2012 (January 1, 2011) BSPS J. Saevels, bi-annual F. Prohoroff National Prize of Pharmaceutical Sciences
Secretary Activities (January 2011-20121, 2011) J. Saevels, F. Prohoroff
BSPS bi-annual International National Prize Prize of Pharmaceutical Sciences
Activities 2011-2012
Annual
BSPS bi-annual Prize Pharmacist International National
and
Prize
Doctor Prize of Pharmaceutical
NEDELJKOVIC
Sciences
Conference
BSPS Annual bi-annual Prize travel Pharmacist International
grants and Doctor Prize NEDELJKOVIC
Annual conferences 2011- Four-yearly
Annual Conference Prize
International travel Pharmacist grantsSymposium
and Doctor
on
NEDELJKOVIC
Drug Analysis
2012 Annual conferences 2011- Conference Four-yearly International travel grantsSymposium
on Drug Analysis
Annual National 2012 conferences meeting2011-2012 2011- Forum Four-yearly for Pharmaceutical International Symposium Sciences, May on 12–13, Drug Analysis 2011, Spa BE
2012
Official National journal meeting2011-2012 Forum for Pharmaceutical Sciences, May 12–13, 2011, Spa BE
National Official journal meeting2011-2012 Forum for Pharmaceutical Sciences, May 12–13, 2011, Spa BE
Official journal
13

Croatian Pharmaceutical Society – CPhS
Croatian Pharmaceutical Society – CPhS CPhS
Mission Development of pharmaceutical profession, stimulating professional and scientific work, running
Mission Development continuing education of pharmaceutical courses, organising profession, professional stimulating and professional scientific events, and scientific publishing work, journals runningand
Mission continuing books, Development promoting education of pharmaceutical and courses, advancing organising profession, all forms professional of stimulating pharmaceutical and professional scientific education, events, and cooperation scientific publishing work, with journals running health and
books, institutions, continuing promoting education Croatian and Pharmaceutical courses, advancing organising all forms Chamber professional of pharmaceutical and other and associations, scientific education, events, adhering cooperation publishing to ethical with journals healthand
institutions, principles, books, promoting Croatian development and Pharmaceutical advancing of the perception all forms Chamber of of honour, pharmaceutical and other dignity associations, and education, responsibility adhering cooperation of pharmaceutical
to ethical with health principles,
development vocation. institutions, Croatian of the perception Pharmaceutical of honour, Chamber dignity and and other responsibility associations, of pharmaceutical adhering to ethical vocation.
Country Country Croatia principles, development of the perception of honour, dignity and responsibility of pharmaceutical
Organisation founded 1858 1858 vocation.
EUFEPS Country Member Society 1991 1991 Croatia
Number Organisation of of members founded 1800 1800 1858
Postal EUFEPS address Member Society Masarykova 1991 2, 2, HR-10000 Zagreb, Croatia
Tel Number Tel of members +385 1800 +385 1 1 4872849
Fax Postal Fax address +385 Masarykova +385 1 1 4872853 2, HR-10000 Zagreb, Croatia
Email Tel hfd-fg-ap@zg.t-com.hr
+385 1 4872849
Fax mladar@solar.pharma.hr
+385 1 4872853
Website Email www.hfd-fg.hr
hfd-fg-ap@zg.t-com.hr
President (January 1, 1, 2011) Mag. mladar@solar.pharma.hr
Mag. Pharm. Kresimir Rukavina
Secretary Website Secretary (January 1, 1, 2011) PhD www.hfd-fg.hr
PhD Mag. Pharm. Maja Jakševac-Mikša
Jakševac-Mikša
Activities President 2011-2012 (January 1, 2011) International Mag. Pharm. Conference Kresimir Rukavina on Drug Information, September 29–30, 2011, Dubrovnik HR
Secretary (January 1, 2011) Workshop PhD Mag. on Pharm. on Dissolution Maja Jakševac-Mikša
and Bioequivalence, October 3–5, 2011
Annual Activities conferences 2011-2012 2011- International Conference on Drug Information, September 29–30, 2011, Dubrovnik HR
2012 2012
Workshop on Dissolution and Bioequivalence, October 3–5, 2011
National Annual meeting2011-2012
conferences meeting2011-2012 2011-
Official
2012 Official journal Farmaceutski glasnik
National meeting2011-2012
Acta Acta pharmaceutica
Official journal Farmaceutski glasnik
Acta pharmaceutica
Czech Pharmaceutical Society
Czech Pharmaceutical Society
Mission
Mission
Mission
Country
Organisation founded
EUFEPS Country Member Society
Number Organisation Number of of members founded
Postal EUFEPS address Member Society
Number of members
Tel Tel Postal address
Fax Fax
Email Email Tel
Website Website Fax
President President Email
(January (January 1, 1, 2011) 2011)
Website
Secretary Secretary (January (January 1, 1, 2011) 2011)
President
Activities Activities 2011-2012 2011-2012 (January 1, 2011)
Secretary
Annual
Annual
conferences
conferences (January 1,
2011-
2011- 2011)
2012
2012 Activities 2011-2012
National
National Annual conferences
meeting2011-2012
meeting2011-2012 2011-
2012
National meeting2011-2012
Official journal
Official journal
The main objective of the Czech Pharmaceutical Society is to collect, develop, and promote new
The concepts main objective in pharmaceutical of the Czech science Pharmaceutical and to apply Society them to health is to collect, care. To develop, achieve and its basic promote new
concepts objectives, The main in objective pharmaceutical activities of directed the Czech science at the Pharmaceutical dissemination and to apply Society them of information to is health to collect, of care. the develop, To latest achieve results and its promote ofbasic
objectives, new
activities pharmaceutical concepts directed in pharmaceutical research at the dissemination and science all other and related of to information apply sciences them of to are the health pursued. latest care. results It To participates achieve of pharmaceutical its in basic educational research
and objectives, activities all other in activities close related co-operation sciences directed at are with the pursued. research dissemination It and participates educational of information in educational institutions of the latest in activities the results field in of close cooperation
pharmaceutical with research sciences. and and educational all other related institutions sciences in the are field pursued. of pharmaceutical It participates sciences. in educational
Czech activities Republic in close co-operation with research and educational institutions in the field of
1875 pharmaceutical sciences.
1991 Czech 1991 Republic
240 1875
Faculty 1991 of of Pharmacy, Charles University, University, Heyrovského Heyrovského 1203, CZ-500 05 Hradec Králové, Czech
Republic 240
+420 Faculty 495 495 of 067403 Pharmacy, Charles University, Heyrovského 1203, CZ-500 05 Hradec Králové, Czech
+420 Republic
495 495 067162
ludek.jahodar@faf.cuni.cz
+420 495 067403
en.cfs-cls.cz
+420 495 067162
ludek.jahodar@faf.cuni.cz
Prof. Prof. Dr. Dr. Luděk Jahodář, CSc
en.cfs-cls.cz
Prof. Prof. Dr. Dr. Petr Petr Solich, Solich, CSc. CSc.
Prof.
2011 2011 Dr.
PharmSciFair, Luděk Jahodář,
June June CSc
13–17, 2011, Prague CZ
Prof. Dr. Petr Solich, CSc.
2011 PharmSciFair, June 13–17, 2011, Prague CZ
Synthesis
Synthesis
and
and
Analysis
Analysis
of
of
drugs,
drugs,
Brno,
Brno,
September
September 2011
2011
Congress o Community Pharmacists, Pilsen, October 14–16, 2011
Congress o Community Pharmacists, Pilsen, October 14–16, 2011
Hospital Synthesis Pharmacy and Analysis meeting, of drugs, November Brno, September 2011, Brno 2011 CZ
Hospital Pharmacy meeting, November 2011, Brno CZ
Symposium Congress o Community of Clinical Pharmacy, Pharmacists, November Pilsen, 2011, October Mikulov 14–16, CZ2011
Symposium of Clinical Pharmacy, November 2011, Mikulov CZ
Česká Hospital a Pharmacy slovenská meeting, farmacie November 2011, Brno CZ
Česká Symposium a slovenská of Clinical farmacie Pharmacy, November 2011, Mikulov CZ
Official journal Česká a slovenská farmacie
14

Finnish Pharmaceutical Society
Finnish Pharmaceutical Society
Mission
Mission
Country
Country Organisation founded
Organisation EUFEPS Member founded Society
The aim of the society is to promote the pharmaceutical sciences, pharmaceutical research and
the The applications aim of the society of these is in to Finland. promote the pharmaceutical sciences, pharmaceutical research and
Finland the applications of these in Finland.
1887 Finland
1991 1887
EUFEPS Number Member of members Society 320 1991
Number Postal address of members Fredrikinkatu 320 61, SF-00100 Helsinki, Finland
Postal Tel address
Tel Fax
Fredrikinkatu 61, SF-00100 Helsinki, Finland
Fax Email leena.peltonen@helsinki.fi
Email Website www.pro.tsv.fi/finpharmsociety/mainengl.htm
leena.peltonen@helsinki.fi
Website President (January 1, 2011) Dr www.pro.tsv.fi/finpharmsociety/mainengl.htm
Tom Wikberg
President Secretary (January 1, 2011) Dr Leena Tom Wikberg Peltonen
Secretary Activities (January 2011-20121, 2011)
Activities 2011-2012
Annual conferences 2011-
Annual 2012 conferences 2011-
2012 National meeting2011-2012
National Official journal meeting2011-2012
Official journal
Helsinki Dr Leena Drug Peltonen Research Congress, September 2011
FinMedChem Helsinki Drug Conference, Research Congress, September September 15–16, 2011 2011
FinMedChem Conference, September 15–16, 2011
German Pharmaceutical Society – DPhG
German Pharmaceutical Society – DPhG
Mission Promote pharmaceutical sciences and and interdisciplinary way way of of thinking.
Country Germany
Organisation founded 1890 1890
EUFEPS Member Society Society 1991
Number of of members 10000 10000
Postal address DPhG Geschäftsstelle, Hamburger Allee 26–28, DE-60486 Frankfurt/Main, Germany
Tel Tel +49 69 71915960
Fax Fax +49 69 719159629
Email
Website
President (January 1, 1, 2011)
Secretary
Secretary
(January
(January
1,
1,
2011)
2011)
Activities
Activities
2011-2012
2011-2012
Annual conferences 2011-
Annual
2012
conferences 2011-
2012
National meeting2011-2012
National
Official journal
meeting2011-2012
Official journal
info@dphg.de
holzgrab@pharmazie.uni-wuerzburg.de
www.dphg.de
Prof. Dr. Manfred Schubert-Zsilavecz
Prof. Dr.
Dr.
Andreas
Andreas
Link
Link
Focus
Focus on
on
further
further
education
education
(400
(400
lectures
lectures
each
each
year
year
all
all
over
over
Germany)
Germany)
General statements, support of young scientists, press activities, and advise legislative and
General statements, support of young scientists, press activities, and advise legislative and
administrative bodies
administrative bodies
Close collaboration with foreign scientific societies
Close collaboration with foreign scientific societies
Annual Conference, together with the Austrian Pharmaceutical Society, September20–23,
Annual
Innsbruck
Conference,
AT
together with the Austrian Pharmaceutical Society, September20–23,
Innsbruck
Post-Graduate-Meeting,
AT
Mars 30–April 2, 2011, Heringsdorf DE
Post-Graduate-Meeting,
Pharmazie in unserer Zeit
Mars 30–April 2, 2011, Heringsdorf DE
Pharmazie in unserer Zeit
15

Hellenic Society of Medicinal Chemistry – HSMC
Hellenic Society of Medicinal Chemistry – HSMC
Mission Advancement of research in Medicinal Chemistry and Drug Design, promotion of cooperation
between scientists of related fields and consulting on relevant subjects.
Mission Country Greece Advancement of research in Medicinal Chemistry and Drug Design, promotion of cooperation
Organisation founded 1980 between scientists of related fields and consulting on relevant subjects.
Country EUFEPS Member Society 1998 Greece
Organisation Number of members founded 107 1980
EUFEPS Postal address Member Society Department 1998 of Pharmaceutical Chemistry, Panepistimiopolis Zografou, GR-15771 Athens,
Number of members Greece 107
Postal Tel address +30 Department 210 7274530 of Pharmaceutical Chemistry, Panepistimiopolis Zografou, GR-15771 Athens, Greece
Tel Fax +30 210 7274747 7274530
Fax Email
Email Website
Website President (January 1, 2011)
President Secretary (January 1, 1, 2011)
Secretary Activities (January 2011-20121, 2011)
Activities
Annual conferences
2011-2012
2011-
2012
Annual conferences 2011-
National meeting2011-2012
2012
Official journal
National meeting2011-2012
Official journal
tsantili@pharm.uoa.gr
+30 210 7274747
www.pharm.auth.gr/helsocmedchem/
tsantili@pharm.uoa.gr
Prof. www.pharm.auth.gr/helsocmedchem/
Dr Anna Tsantili-Kakoulidou
Assoc. Prof. Dr Prof. Anna Dr. Tsantili-Kakoulidou
Sotiris Nikolaropoulos
15th Assoc. Hellenic Prof. Dr. Symposium Sotiris Nikolaropoulos
on Medicinal Chemistry, 2012, Patras GR
15th Hellenic Symposium on Medicinal Chemistry, 2012, Patras GR
Hungarian Society for Pharmaceutical Sciences – HSPS
Hungarian Society for Pharmaceutical Sciences – HSPS
Mission
Mission
The goals of the Society are
The – facilitation goals of of the the Society advancement are of professional conditions of pharmaceutical education, drug
– research facilitation and of health the advancement care. of professional conditions of pharmaceutical education, drug
research – to enhance and the health quality care. of standards in community and hospital pharmacy in order to improve
– the to safety enhance of drug the quality therapy of and standards distribution. in community and hospital pharmacy in order to improve the
safety – to encourage of drug therapy the improvement and distribution. of the scientific and professional knowledge of pharmacists.
– to standing encourage for the the interests improvement of pharmaceutical of the scientific profession and professional and enhancing knowledge its social of prestige. pharmacists.
– standing to promote for the the health interests education of pharmaceutical and healthy life-style profession in the and population. enhancing its social prestige.
Country – Hungary to promote the health education and healthy life-style in the population.
Country Organisation founded Hungary 1924
Organisation EUFEPS Member founded Society 1924 1991
EUFEPS Number Member of members Society 1991 315
Number Postal address of members 315 POB 480, HU-1447 BudapestHungary
Postal Tel address POB +36 1 480, 2350999 HU-1447 BudapestHungary
Tel Fax +36 1 2350999 4831465
Fax Email
Email
Website
Website President (January 1, 2011)
President Secretary (January (January 1, 1, 2011) 2011)
Secretary Activities (January 2011-2012 1, 2011)
Activities 2011-2012
Annual conferences 2011-
2012
Annual conferences 2011-
2012
National meeting2011-2012
Official journal
National meeting2011-2012
Official journal
+36 titkarsag@mgyt.hu
1 4831465
titkarsag@mgyt.hu
meeting@mgyt.hu
meeting@mgyt.hu
www.mgyt.hu
www.mgyt.hu
Prof. Dr Zoltán Vincze
Prof. Dr Sarolta Dr Zoltán Márkus Vincze
Dr Organisation Sarolta Márkus of training lectures for pharmacists (ten times a year)
The Hungarian National Committee of Pharmaceutical Care (Postgrad.edu. in pharmaceutical
Organisation of training lectures for pharmacists (ten times a year)
care)
The Hungarian National Committee of Pharmaceutical Care (Postgrad.edu. in pharmaceutical
Organising Contest for Young Pharmacists in Practice – In memoriam Mátyás Rozsnyay
care)
Organising Contest for Young Research Fellows – in memoriam Otto Clauder
Organising Contest for Young Pharmacists in Practice – In memoriam Mátyás Rozsnyay
Conferences of the Sections of the Society:Drug Analysis, Pharmacognosy, Pharmaceutical
Organising
Technology,
Contest
Drug Research,
for Young
History
Research
of Pharmacy
Fellows – in memoriam Otto Clauder
Conferences of of the the Hospital Sections Pharmacy of the Society:Drug Organization Analysis, and Industrial Pharmacognosy, Pharmacy Organization Pharmaceutical of the
Technology, Society Drug Research, History of Pharmacy
Conferences of the Hospital Pharmacy Organization and Industrial Pharmacy Organization of the
Society Gyógyszerészet
Acta Pharmaceutica Hungarica
Gyógyszerészet
Acta Pharmaceutica Hungarica
16

Country Israel
EUFEPS Member Society
Country Email
EUFEPS Member Society
1993
ahoffman@cc.huji.ac.il
Israel
1993
Email ahoffman@cc.huji.ac.il
Israel Society of Clinical Pharmacy and Biopharmaceutics – ISCPB
Israel Society of Clinical Pharmacy and Biopharmaceutics – ISCPB
Italian Society for for Pharmaceutical Sciences –SISF –SISF
Mission
Mission
Contribute to the progress in all aspects of the pharmaceutical science.
Contribute Stimulate (motivate) to the progress the collaboration in all aspects between of the researchers pharmaceutical from science. diffeent areas which cooperate
Stimulate in the drug (motivate) discovery the and collaboration development between process. researchers from diffeent areas which cooperate in
the Cooperate drug discovery with the and State development Authorities on process. matters of general interest on the pharmaceutical area.
Cooperate Protect and with valorize the State (expoloit) Authorities the moral on and matters scientific of general aspects interest in the on development, the pharmaceutical production area.
Protect and dispensation and valorize of the (expoloit) drug. the moral and scientific aspects in the development, production and
Country dispensation Italia of the drug.
Country Organisation founded Italia 1953
Organisation EUFEPS Member founded Society 1953 1991
EUFEPS Number Member of members Society 1991 125
Number Postal address of members 125 Viale Abruzzi 32, IT-20133 Milano, Italy
Postal Tel address Viale +39 02 Abruzzi 49635252 32, IT-20133 Milano, Italy
Tel Fax +39 02 49635252 49633384
Fax Email
Email
Website
Website President (January 1, 2011)
President
Secretary
(January
(January
1,
1,
2011)
2011)
Secretary
Activities
(January
2011-2012
1, 2011)
Annual conferences 2011-
Activities 2011-2012
2012
Annual conferences 2011-
National meeting2011-2012
2012
National
Official
meeting2011-2012
journal
Official journal
+39 rodolfo.paoletti@unimi.it
02 49633384
rodolfo.paoletti@unimi.it
sis@comm2000.it
sis@comm2000.it
www.sisf.it
www.sisf.it Professor Rodolfo Paoletti
Professor
Alberico L.
Rodolfo
Catapano
Paoletti
Alberico
Meeting
L.
organization
Catapano
grant for research
National Forum Pharma Research and Innovation
Meeting organization grant for research
National Forum Pharma Research and Innovation
HTA in oncology
Clinical research in diabetology
HTA in oncology
Clinical research in diabetology
The Netherlands Association of Pharmaceutical Sciences – NVFW
The Netherlands Association of Pharmaceutical Sciences – NVFW
Mission The vision of the NVFW is to promote the pharmaceutical sciences in its broadest sense. The
Mission
Country
Country Organisation founded
Organisation EUFEPS Member founded Society
EUFEPS
Number
Member
of members
Society
Number
Postal address
of members
Postal address
Tel
Fax
Tel
Email
Fax
Email
Website
President (January 1, 2011)
Website
Secretary (January 1, 2011)
President
Activities
(January
2011-2012
1, 2011)
Secretary Annual conferences (January 1, 2011- 2011)
Activities 2012 2011-2012
Annual National conferences meeting2011-2012 2011-
2012 Official journal
National meeting2011-2012
Official journal
The Society vision stimulates of the NVFW those research is to promote areas, the that pharmaceutical are of special sciences relevance in for its drug broadest discovery sense. andThe
Society development. stimulates It especially those research focuses on areas, optimising that are the of interplay special relevance between the for different drug discovery researchand
development. disciplines involved It especially in drug focuses innovation. on optimising the interplay between the different research
disciplines The Netherlands involved in drug innovation.
The 1987Netherlands
1987 1991
1991
250
250
Universitair Medisch Centrum Groningen, Pathologie & Medische Biologie, Sectie Medische
Biologie, Hanzeplein 1 (EA11), NL-9713 GZ Groningen, The Netherlands
Universitair Medisch Centrum Groningen, Pathologie & Medische Biologie, Sectie Medische
+ 31 503618043
Biologie, Hanzeplein 1 (EA11), NL-9713 GZ Groningen, The Netherlands
+ 31 503619911
+ 31 503618043
h.vromans@uu.nl
+ 31 503619911
r.j.kok@uu.nl
h.vromans@uu.nl
www.nvfw.nl
r.j.kok@uu.nl
www.nvfw.nl
Dr Robbert Jan Kok
Dr Robbert Jan Kok
17

Norwegian Pharmaceutical Society
Norwegian Pharmaceutical Society
Mission Norwegian Pharmaceutical Society’s main purposes are to influence the development of
Mission Norwegian Pharmacy Pharmaceutical and Pharmaceutical Society’s main Sciences purposes and are to to promote influence collaboration the development amongst ofall
Norwegian members of Pharmacy the pharmaceutical and Pharmaceutical profession. Sciences and to promote collaboration amongst all
Country members Norway of the pharmaceutical profession.
Country Organisation founded
Organisation EUFEPS Member founded Society
EUFEPS Number Member of members Society
Number Postal address of members
Postal Tel address
Tel Fax
Fax
Email
Email
Website
President (January 1, 2011)
Website
Secretary (January 1, 2011)
President (January 1, 2011)
Activities 2011-2012
Secretary (January 1, 2011)
Activities 2011-2012
Annual conferences 2011-
2012
Annual National conferences meeting2011-2012 2011-
2012
National Official journal meeting2011-2012
Official journal
Norway 1924
1924 1992
1992 515
515 Postboks 5070, Majorstuen, NO-0301 Oslo, Norway
Postboks +47 21 620223 5070, Majorstuen, NO-0301 Oslo, Norway
+47 21 22 608173 620223
+47
farm-sel@online.no
22 608173
farm-sel@online.no
www.nfs.no
Mrs Britt Wolden
www.nfs.no
Ms Rønnaug Larsen
Mrs Britt Wolden
Annual Conference for all Norwegian Pharmacists
Ms Rønnaug Larsen
Managing Council of Ethics and Codes of Ethics for Norwegian Pharmacists
Annual
Administrate
Conference
and hand
for
out
all Norwegian
Annual Scholarships
Pharmacists
to Norwegian Pharmacists
Managing Award Crux Council Venenifera, of Ethics the highest and Codes homage of Ethics for Norwegian for Norwegian Pharmacists Pharmacists
Administrate Farmasidagene,November and hand out 2–4, Annual 2011 Scholarships to Norwegian Pharmacists
Award Farmasidagene, Crux Venenifera, November the 7–9, highest 2012homage
for Norwegian Pharmacists
Farmasidagene,November General assembly Mars 22, 2–4, 2011 2011
Farmasidagene, General assembly, November Mars, 2012 7–9, 2012
General assembly Mars 22, 2011
General assembly, Mars, 2012
Pharmaceutical Society of Denmark
Pharmaceutical Society of Denmark
Mission To promote pharmaceutical science
Mission To promote influence pharmaceutical developments of science pharmacy in Denmark
To enhanceand influence developments promote the of pharmaceutical pharmacy in Denmark role
Country To Denmark enhanceand promote the pharmaceutical role
Country Organisation founded Denmark 1912
Organisation EUFEPS Member founded Society 1912 1991
EUFEPS
Number of
Member
members
Society 1991
650
Postal address Rygårds Alle 1, DK-2900 Hellerup, Denmark
Number of members 650
Tel +45 39463600
Postal address Rygårds Alle 1, DK-2900 Hellerup, Denmark
Fax +45 39463639
Tel +45 39463600
Email pd@pharmadanmark.dk
Fax +45
laa@farma.ku.dk
39463639
Email
Website
pd@pharmadanmark.dk
www.farmaceutisk-selskab.dk
President (January 1, 2011)
laa@farma.ku.dk
Dr Søren Ilsøe-Kristensen
Website Secretary (January 1, 2011) www.farmaceutisk-selskab.dk
President Activities (January 2011-20121, 2011) Dr Pricing Søren of medicinal Ilsøe-Kristensen products
Secretary (January 1, 2011) Supplementary diet pills versus herbal remedies
Activities 2011-2012 Pricing Clinical of Studies medicinal in China products and India
Supplementary Stem cell therapydiet
pills versus herbal remedies
Clinical The role Studies of pharma-economics in China and India in the design of drug profile
Annual conferences 2011- Stem cell therapy
2012
The role of pharma-economics in the design of drug profile
Annual National conferences meeting2011-2012 2011-
2012 Official journal
National meeting2011-2012
Official journal
18

Annual conferences 2011-2012
National meeting 2011-2012
Official journal
The role of pharma-economics in the design of drug profile
Polish Pharmaceutical Society
Mission Improving scientific and professional skills of Pharmacists
Promoting scientific advances in pharmaceutical sciences among Pharmacists
Encouraging and supporting pharmacists involvement in scientific work, .Represent the interests of
academic and Pharmacists engaged in drug research, drug regulation and drug policy making.
Country Poland
Organisation founded 1947
EUFEPS Member Society 1991
Number of members 250
Postal address Zarzad Glowny, Ul. Dluga 16, PL-00-238 Warsaw Poland
Tel +48 22 8311542
Fax +48 22 8310243
Email zarzad@ptfarm.pl
roledzka@op.pl
Website www.ptfarm.pl
President (January 1, 2011) Prof. Dr hab. Janusz Pluta
Secretary (January 1, 2011) Vice president: Prof. Dr hab. Jan Pachecka, Prof. Dr hab. Daria Orszulak-Michalak
Activities 2011-2012 Diferent kind of training and education courses conected with the specilization for persons working in
pharmacy, hospital pharmacy, industry, toxicology, bromatology, pharmacology,pharmaceutical
analytics, plant drug and other places in health service were organised.
Also are organising permanent training courses for all pharmaceutists.
Annual conferences 2011-2012 XXIX Conference of Hospital Pharmacy, May 29–June 1, 2011, Wisła PL
XX Conference History of Pharmacy, June 2–5, 2011, Zakopane PL
XX Symposium Section of Bromatology, September 21–23, 2011, Białystok PL
XII Conference of Oncological Pharmacy, October 16–19, 2011, Międzyzdroje PL
National meeting 2011-2012
Official journal Farmacja Polska,
Acta Poloniae Pharmaceutica
Drug Research
Bromatologia i Chemia Toksykologiczna
Portuguese Society for Pharmaceutical Sciences – SPCF
Portuguese Society for Pharmaceutical Sciences – SPCF
Mission
Mission
To promote, develop and publish the study, teaching, research and applications of the
Pharmaceutical To promote, develop Sciences and by publish providing the a study, platform teaching, for exchange research of the and information applications and of promotion the
of Pharmaceutical scientific interests Sciences in the multidisciplinary by providing a platform environment for exchange of Pharmaceutical of the information Sciences; and facilitating promotion
the of scientific development interests of cooperation in the multidisciplinary with fellow international environment institutions; of Pharmaceutical organising scientific Sciences; facilitating
sessions; the development publishing of scientific cooperation material with pertaining fellow international to Pharmaceutical institutions; Sciences. organising scientific
Country Portugal sessions; publishing scientific material pertaining to Pharmaceutical Sciences.
Country Organisation founded Portugal
Organisation EUFEPS Member founded Society 2000
EUFEPS Number Member of members Society 200 2000
Number Postal address of members Faculdade 200 de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, PT-1649-003 Lisboa,
Postal address Portugal Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, PT-1649-003 Lisboa,
Tel +351 Portugal 21 7946400 ext. 14333
Tel Fax +351 21 21 7946472 7946400 ext. 14333
Fax
Email jagmorais@ff.ul.pt
+351 21 7946472
Website www.goempresas.com/sociedade_portuguesa_de_ciencias_farmaceuticas.html
Email jagmorais@ff.ul.pt
President (January 1, 2011) Professor José A. Guimarães Morais
Website www.goempresas.com/sociedade_portuguesa_de_ciencias_farmaceuticas.html
Secretary (January 1, 2011) Professor Rogério Sá Gaspar
President (January 1, 2011) Professor José A. Guimarães Morais
Activities 2011-2012 Co-sponsorship of several scientific meetings
Secretary (January 1, 2011) Professor Rogério Sá Gaspar
Annual conferences 2011- October 12–15 2011
Activities 2012 2011-2012 Co-sponsorship of several scientific meetings
Annual National conferences meeting 2011-2012 2011-2012October October 12–15 2011 2011
National Official journal meeting 2011-2012 Revista October Portuguesa 12–15 2011de
Farmácia
Official journal Revista Portuguesa de Farmácia
19

Romanian Society of Pharmaceutical Sciences
Romanian Society of Pharmaceutical Sciences
Mission
Mission
Facilitation
Facilitation
of
the
the national
national
and
and
international
international
pharmaceutical
pharmaceutical
scientific
scientific
information
information
exchange.
exchange.
Collaboration
Collaboration
among
among the
the
national
national
branches
branches
of
of
the
the
Society
Society
by
by
attending
attending
conferrences
conferrences
and
and symposia
on
symposia
scientific
on
pharmaceutical
scientific pharmaceutical
topics.
topics.
Promoting national scientific pharmaceutical research.
Promoting national scientific pharmaceutical research.
Synchronising the Romanian pharmaceutical field with the international ones.
Synchronising the Romanian pharmaceutical field with the international ones.
Country Romania
Country Romania
Organisation founded 1934
Organisation founded 1934
EUFEPS Member Society 2005
EUFEPS Member Society 2005
Number of members 380
Number of members 380
Postal address Str. Traian Vuia nr. 6, sector 2 Bucuresti, Romania
Postal address Str. Traian Vuia nr. 6, sector 2 Bucuresti, Romania
Tel +40 720054214
Tel
Fax
+40
+40
720054214
264 595770
Fax
Email
+40
sleucuta@yahoo.com
264 595770
Email
Website
sleucuta@yahoo.com
Website
President (January 1, 2011) Professor Sorin-Emilian Leucuta, PhD
President Secretary (January (January 1, 1, 2011) 2011) Professor Professor Sorin-Emilian Niculina Mitrea Leucuta, Vasilescu PhD
Secretary Activities (January 2011-20121, 2011) Professor Symposiums Niculina organised Mitrea by Vasilescu national branches of the Society
Activities Annual conferences 2011-2012 2011- Symposiums General Assembly, organised March by 2011 national branches of the Society
Annual 2012 conferences 2011- General Assembly, March 2011
2012 National meeting2011-2012
National Official journal meeting2011-2012 Farmacia
Official journal Farmacia
Slovak Pharmaceutical Society
Slovak Pharmaceutical Society
Mission
Country Slovak
Organisation founded
EUFEPS Member Society 1991
Number of members
Number of members
Postal address Faculty Of Pharmacy, Comenius University, Odbojarov 10, SK-83232 Bratislava, Slovakia
Postal address Faculty Of Pharmacy, Comenius University, Odbojarov 10, SK-83232 Bratislava, Slovakia
Tel + 421 2 50117170
Tel + 421 2 50117170
+ 421 2 50117229
+ 421 2 50117229
Fax +42 7 60388
Fax
Email
+42
cizmarik@fpharm.uniba.sk
7 60388
Email cizmarik@fpharm.uniba.sk
grancai@fpharm.uniba.sk
Website
grancai@fpharm.uniba.sk
Website President (January 1, 2011) Prof. Dr. J. Čižmárik, PhD
President Secretary (January 1, 2011) Prof. Dr. D. J. Grančai Čižmárik, PhD
Secretary Activities (January 2011-20121,
2011) Prof. Dr. D. Grančai
Activities Annual conferences 2011-2012 2011-
Annual 2012 conferences 2011-
2012 National meeting2011-2012
National Official journal meeting2011-2012
Official journal
20

Slovenian Pharmaceutical Society – SFD
Slovenian Pharmaceutical Society – SFD
Mission
Mission
Country
Country
Organisation founded
Organisation
EUFEPS Member
founded
Society
EUFEPS
Number
Member
of members
Society
Number Postal address of members
Postal Tel address
Tel Fax
Fax Email
Email
Website
Website President (January 1, 2011)
President Secretary (January 1, 2011) The SFD is the most important link between different segments of the Slovenian pharmaceutical
The SFD is the most important link between different segments of the Slovenian pharmaceutical
community (employed in industry, pharmacy services, educational institutions and administrative
community (employed in industry, pharmacy services, educational institutions and administrative
services.
services.
Slovenia
Slovenia
1950
1950
1994
1994
150
150 Dunajska 184 A, SI-1000 Ljubljana, Slovenia
Dunajska + 386 (0)1 184 5692601 A, SI-1000 Ljubljana, Slovenia
+ 386 (0)1 569 5692601 26 02
+ info@sfd.si 386 (0)1 569 26 02
info@sfd.si
ales.mrhar@ffa.uni-lj.si
ales.mrhar@ffa.uni-lj.si
www.sfd.si
www.sfd.si Gašper Marc
Gašper Jelka Dolinar Marc
Secretary Activities (January 2011-20121, 2011) Jelka Professional DolinarEvents,
Publishing and Social Events
Activities Annual conferences 2011-2012 2011- Professional 4BBBB International Events, Conference Publishing and on Pharmaceutical Social Events Sciences, 2011
Annual 2012 conferences 2011- 4BBBB International Conference on Pharmaceutical Sciences, 2011
2012 National meeting2011-2012 Annual 1-3 days’ national professional events, organised by the Society and its Sections
National meeting2011-2012 Annual (Community 1-3 days’ Pharmacy national Section, professional Section events, of Pharmaceutical organised by Technologists, the Society and Section its Sections of Clinical
(Community Pharmacists, Pharmacy Pharmaceutical Section, Technicians Section of Pharmaceutical Technologists, Section of Clinical
Official journal Pharmacists, Farmacevtski Pharmaceutical vestnik Technicians
Official journal Farmacevtski vestnik
Spanish Society of Pharmaceutics and Pharmaceutical Technology –
SEFIG Spanish Society of Pharmaceutics and Pharmaceutical Technology –
SEFIG
Mission SEFIG has as its missions the following.
1. To contribute to the professional development of its members by means of the exchange of
knowledge and methods.
2. To analyse and to debate the problems that its members have jointly and to propose possible
solutions to the same ones.
3. To foment the necessary critical reflection on the problems that the Industrial Pharmacy and the
Pharmaceutical Technology raises, in the different professional areas. To collaborate actively with
national and international associations which aims are coincidental or parallel.
4. To promote cooperative and mutualists movements among its affiliates.
5. To promote all those means and actions that facilitate the communication of works and
researches in the field of t the Industrial Pharmacy and the Pharmaceutical Technology and related
sciences.
6. To support all those steps that lead to the human and professional enrichment of its partners and
of the society in general.
Country Spain
Organisation founded 1988
EUFEPS Member Society 2000
Number of members 196
Postal address Dept. Farmacia y Tecnologia Farmaceutica, Facultad de Farmacia, Universidad de Santiago de
Compostela, ES-15782-Santiago de Compostela, Spain
Tel
Fax
Email
Website
President (January 1, 2011)
Secretary (January 1, 2011)
Activities 2011-2012
+34 981563100
+34 981547148
presidente@sefig.org
jmirache@unav.es
secretario@sefig.org
http://www.sefig.org/EN/
Juan Manuel Irache Garreta
Carmen Álvarez Lorenz
Co-sponsor the 4th Mission SEFIG has as its missions the following.
1. To contribute to the professional development of its members by means of the exchange of
knowledge and methods.
2. To analyse and to debate the problems that its members have jointly and to propose possible
solutions to the same ones.
3. To foment the necessary critical reflection on the problems that the Industrial Pharmacy and
the Pharmaceutical Technology raises, in the different professional areas. To collaborate actively
with national and international associations which aims are coincidental or parallel.
4. To promote cooperative and mutualists movements among its affiliates.
5. To promote all those means and actions that facilitate the communication of works and
researches in the field of t the Industrial Pharmacy and the Pharmaceutical Technology and
related sciences.
6. To support all those steps that lead to the human and professional enrichment of its partners
and of the society in general.
Country Spain
Organisation founded 1988
EUFEPS Member Society 2000
Number of members 196
Postal address Dept. Farmacia y Tecnologia Farmaceutica, Facultad de Farmacia, Universidad de Santiago de
Tel
Compostela, ES-15782-Santiago de Compostela, Spain
+34 981563100
Fax
Email
Website
President (January 1, 2011)
Secretary (January 1, 2011)
Activities 2011-2012
Annual conferences 2011-
2012
National meeting2011-2012
Official journal
+34 981547148
presidente@sefig.org
jmirache@unav.es
secretario@sefig.org
http://www.sefig.org/EN/
Juan Manuel Irache Garreta
Carmen Álvarez Lorenz
Co-sponsor the 4
International Exhibition for Pharmaceutical, Biopharmaceutical and Laboratory
Technology Providers, February 15–17, 2011, Zaragoza ES
Partner Organisation in the 3rd SciFair, June 13–17, 2011, Prague CZ
Co-sponsor of 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical
Technology, March 19–22, 2012, Istanbul TR
X Congress of SEFIG, February 2–4, 2011, Madrid ES
th Annual conferences 2011-
2012
National meeting2011-2012
Official journal
International Exhibition for Pharmaceutical, Biopharmaceutical and Laboratory
Technology Providers, February 15–17, 2011, Zaragoza ES
Partner Organisation in the 3rd SciFair, June 13–17, 2011, Prague CZ
Co-sponsor of 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical
Technology, March 19–22, 2012, Istanbul TR
X Congress of SEFIG, February 2–4, 2011, Madrid ES
21

Swedish
Swedish
Academy
Academy
of
of
Pharmaceutical
Pharmaceutical
Sciences
Sciences
– SAPS
– SAPS
Mission Mission The The Swedish Academy of of Pharmaceutical Sciences Sciences is is a a non-profit non-profit organisation organisation with with the the purpose purpose of
promoting of promoting a high a high professional standard standard within within the the field field of of pharmaceuticals. APS should also
work
for work favorable for favorable development development and usage and usage of pharmaceuticals, of pharmaceuticals, for the for the public public as as well well as as for for the the individual.
In individual. this regard, In this APS regard, favors APS the favors knowledge- the knowledge- and competence and competence development development within the within pharmaceutical
the
field. pharmaceutical field.
Country Sweden
Organisation founded 1778
EUFEPS Member Society 1991
Number of of members 6000
Postal address Box 1136, SE-111 81 StockholmSweden
Tel Tel +46 8 7235000
Fax Fax
Email
Website Website
President President (January (January 1, 1, 2011)
Secretary
Secretary
(January
(January
1,
1,
2011)
2011)
Activities 2011-2012
Activities 2011-2012
Annual conferences 2011-
Annual conferences 2011-
2012
2012
National meeting2011-2012
National meeting2011-2012
Official journal
Official journal
+46 8 205511
info@apotekarsocieteten.se
andreas.furangen@apotekarsocieteten.se
www.swepharm.se
Dr Dr Eva Eva Sjökvist Saers
Dr
Dr
Agneta
Agneta
Larhed
Larhed
Läkemedelskongressen (Annual Meeting), November 7-9, 2011, Stockholm SE
Läkemedelskongressen (Annual Meeting), November 7-9, 2011, Stockholm SE
e-lexir
e-lexir
Swiss Society of Pharmaceutical Sciences – SGPhW
Swiss Society of Pharmaceutical Sciences – SGPhW
Mission The society promotes as a principal goal Pharmaceutical Sciences inSwitzerland. For this
Mission purpose The society the society promotes has as assumed a principal the goal function Pharmaceutical of an academy Sciences pursuing inSwitzerland. the following mission: For this purpose
Unifying the society and has coaching assumed the national the function and regional of an academy societies pursuing linked to the following discipline mission: of
Pharmaceutical Unifying and coaching Sciences. the national and regional societies linked to the discipline of Pharmaceutical
Promotion Sciences. of national and internationalscientific contacts and of cooperations with otherscientific
societies Promotion and of academies. national and internationalscientific contacts and of cooperations with otherscientific
Public societies promotion and academies. of Pharmaceutical Sciences.
Promotion Public promotion of the communication of Pharmaceutical of eminent Sciences. pharmaceutical findings and realisations in science,
research, Promotion development, of the communication industry, health of eminent care and pharmaceutical public society. findings and realisations in science,
To research, award distinguished development, persons industry, for health their merits care and in Pharmaceutical public society. Science.
Country Switzerland To award distinguished persons for their merits in Pharmaceutical Science.
Country Organisation founded 1993 Switzerland
Organisation EUFEPS Member founded Society 1998 1993
EUFEPS
Number
Member
of members
Society
117
1998
Number
Postal address
of members
General
117
secretary: Philippe Tschopp, Pharmatrans Sanaq AG, Birsigstrasse 79, CH-4011 Basel,
Switzerland
Postal address General secretary: Philippe Tschopp, Pharmatrans Sanaq AG, Birsigstrasse 79, CH-4011 Basel,
Tel +41 61 2259000
Switzerland
Fax +41 61 2259001
Tel +41 61 2259000
Email sgphw@sgphw.ch
Fax
hans.leuenberger@unibas.ch
+41 61 2259001
Email
Website www.sgphw.ch
sgphw@sgphw.ch
President (January 1, 2011) Prof.
hans.leuenberger@unibas.ch
Dr. Hans Leuenberger
Website Secretary (January 1, 2011) Dr. www.sgphw.ch
Benoîte Kaeser
President Activities (January 2011-20121, 2011) Monthly Prof. Dr. PharmaLunchs Hans Leuenberger (see www.sgphw.ch)
Secretary Annual conferences (January 1, 2011- 2011) Swiss Dr. Benoîte Pharma Kaeser Science Day (see www.sgphw.ch)
Activities 2012 2011-2012 Monthly PharmaLunchs (see www.sgphw.ch)
Annual National conferences meeting2011-2012 2011- Swiss Pharma Science Day Day (see (see www.sgphw.ch)
2012 Official journal Swiss Pharma
National meeting2011-2012 Swiss Pharma Science Day (see www.sgphw.ch)
Official journal Swiss Pharma
22

Turkish Pharmaceutical Technology Scientists' Association – TÜFTAD – TÜFTAD
Mission
Mission
Country
Country
Organisation
Organisation
founded
founded
EUFEPS
EUFEPS
Member
Member
Society
Society
Number
Number
of
of
members
members
Postal Postal address address
Tel Tel
Fax Fax
Email
To provide a dynamic national and international forum for the exchange of knowledge among
To provide a dynamic national and international forum for the exchange of knowledge among
scientists, pharmaceutical industry members and regulatory authorities to enhance their
scientists, pharmaceutical industry members and regulatory authorities to enhance their
contributions to health care and pharmaceutics in Turkey. This Association offers timely scientific
contributions to health care and pharmaceutics in Turkey. This Association offers timely scientific
programs, opportunities for networking and professional development.
programs, opportunities for networking and professional development.
Turkey
Turkey
1991
1991
1991
1991
400
400
Hacettepe University, Faculty Faculty of of Pharmacy, Pharmacy, Department Department of of Pharmaceutical Pharmaceutical Technology, Technology, TR-06100 TR-06100
Sıhhıye AnkaraTurkey
+90 312 3051241
+90 312 3100906
scalis@hacettepe.edu.tr
secretariat@tuftad.org.tr
hincal@tr.net
Website www.tuftad.org.tr/
President (January 1, 2011) Prof. Dr. A. Atilla Hincal
Secretary (January 1, 2011) 2011) Prof. Prof. Dr. Sema ÇALIŞ
Activities 2011-2012 2011-2012
Annual conferences conferences 2011-
2012
National meeting2011-2012
TUFTAD TUFTAD Sessions Sessions in PharmSciFair Meeting, June 13–17, 2011, Prague CZ CZ
Official journal TUFTAD News
23

5. Individual Memberships Representatives to Council
The body of Individual Members is represented by delegates to the Council. The delegates
are elected biennially by written ballot 4 months prior to the Council to serve for a term of
two years. A delegate may serve for a maximum consecutive period of four years. Current
delegates are:
Professor Ole J. Bjerrum
University of Copenhagen, Copenhagen, Denmark
Email ojb@farma.ku.dk
Dr Natasa Jovanovic
BioConnection, Oss, The Netherlands
Email natasakomal@yahoo.com
Professor Amin Rostami
University of Manchester, Manchester, United Kingdom
Email amin.rostami@manchester.ac.uk
Dr Sven Stegemann
Capsugel, Bornem, Belgium
Email sven.stegemann@pfizer.com
24

Effective as of September 24, 2006
1 Objectives of the Federation
6. The Statutes of EUFEPS
The European Federation for Pharmaceutical Sciences (hereinafter referred to as the
Federation) is a voluntary association of pharmaceutical scientists, established to advance
research in the pharmaceutical sciences in Europe. This can be achieved by promoting cooperation
between national, regional and European societies or associations which aim at
the advancement of pharmaceutical sciences, and by promoting cooperation between and
with other pharmaceutical organisations and between individual pharmaceutical scientists.
The Federation seeks to achieve its objectives by the following means:
A To facilitate the exchange of scientific information between European pharma
ceutical scientists by
• organising a European Pharmaceutical (Pharm) Sciences (Sci) Congress or
Fair, at regular intervals and in different European countries;
• organising specialised meetings on relevant topics of multidisciplinary aspects
of drug research;
• encouraging the organisation of joint meetings between member societies;
publication of a European Journal of Pharmaceutical Sciences.
B To collect and disseminate information on the activities of the member societies,
including the production of a calendar of events.
C To enhance the recognition of the pharmaceutical sciences and to contribute to
public policies relevant to the pharmaceutical sciences and drug-related issues
at the European level.
D To encourage high standards of undergraduate, graduate and postgraduate
education and training in the pharmaceutical sciences and to encourage
exchange of relevant scientific information as well as exchange of staff and
students of teaching and research institutions between the different European
countries.
2 Membership and Administration
A. Categories of Membership:
• Member Societies; these are societies, which aim at the advancement of
pharmaceutical sciences and are established in one (or more) of the Euro
pean countries;
• Member Institutions; these are universities and research institutions, which
engage in pharmaceutical sciences and are established in one (or more)
of the European countries;
• Individual Members; these are individuals who support the objectives of
the Federation.
25

B. The membership terminates:
• if a Member Society or Member Institution is dissolved;
• by notification of withdrawal in writing to the secretariat of the
Federation at least 3 months before the end of a year;
• if the Member does not pay the annual dues.
C. The affairs of the Federation shall be conducted by a Council through an Execu
tive Committee.
D. The Council comprises representatives from each Member Society of the
Federation, together with the delegate/s of Member Institutions, the delegate/s
of Individual Members and the members of the Executive Committee.
Member Societies shall nominate before the 1st of January of each year who
will be their representatives for the coming year.
Member Societies with up to 250 members will have one vote at Council, those
with 251-1000 members two votes, those with 1001-3000 members three votes,
and those with above 3000 members four votes. The number of delegates rep
resenting a Member Society at Council will depend on how many votes that are
given to a single delegate. As applicable, this is left to each of the Member
Societies to decide upon.
The body of Member Institutions shall agree among themselves on delegate/s
to the Council. The contingent of Members Institutions will have one vote for
one of ten fee-paying Member Institutions, and one additional representative
for each additional one to ten fee-paying Member Institutions. All appointed
delegates may attend the Council. Names of delegate/s should be provided
4 months prior to Council.
The Fédération Internationale Pharmaceutique (F.I.P.) shall have observer
status in the Council. At the discretion of the President, other organisations may
be invited to send an observer.
E. Among the specific duties of the Council shall be:
• to accept Member Societies of the Federation on the basis of the
bylaws presented;
• to propose names for candidates of the Executive Committee, to be
received at least 3 months before a Council meeting;
• to elect the members of the Executive Committee;
• to ratify changes in the Statutes and other regulations of the
Federation as proposed by the Executive Committee or Council itself;
• to establish committees for specific policy purposes;
• to propose items to be discussed in Council to the Executive Commit
tee. Such proposals from individual Council members should reach
the Executive Director no later than three months prior to the Council
meeting.
26

F. There shall be one regular meeting of the Council each year. Additional
meetings may be held at the recommendation of the majority of the Executive
Committee or at least 30% of the Council members. The Federation shall not
be held responsible for the costs involved for Council members to attend
any Council meeting.
G. Except when explicitly stated otherwise in these Statutes, any matter to be
decided by the Council shall be on the basis of a simple majority vote of those
present and voting at a meeting of the Council.
H. The Executive Committee is composed of eight members, plus the immediate
Past President. The Executive Committee consists of: the Past-President, the
President, the President-Elect, the Treasurer and five Ordinary Members.
Each member of the Executive Committee shall be nominated by the
Council and elected by secret ballot at a meeting of the Council. Each
member is elected for a term of two years and may be re-elected for a
maximum of two successive terms. No more than two members of
the Executive Committee may originate from the same country.
The Past-President shall serve as a co-opted member with full voting
rights for a period of up to two years.
The Executive Director (see Section K, below) is an ex officio member of
this Committee, without voting rights.
I. The Executive Committee meets as often as it deems necessary for
the interest of the Federation. The Federation will to the extent possible
assist in bearing the costs involved to attend meetings of the Exective
Committee. The Executive Committee shall make decisions on the
basis of majority vote of those members present (not less than three) at a
meeting. In case of a draw, the President casts the deciding vote.
Interim vacancies on the Executive Committee may be filled by the
President after consultation with the other members of the Executive
Committee. The appointment is subject to approval at the next meeting
of the Council. The individual so appointed shall serve for the unexpired
term(s).
The Executive Committee may establish committees for specific activity
purposes.
J. The President shall be responsible for coordinating the activities and
affairs of the Federation and shall normally represent the Federation. The
President shall call and chair the meetings of the Executive Committee
and of the Council. The Vice-President assists the President in his or her
activities and may deputise for the President whenever necessary.
27

K. The Executive Director shall
• be appointed by the Executive Committee;
• keep a record of all members of the Federation;
• keep a minute book of the transactions of the Federation;
• keep the records of all meetings of the Council and the
Executive Committee;
• distribute the agenda for the meetings of the Council and the
Executive Committee at least one month prior to such meet-
ings and shall distribute the minutes of the meetings not later
than three months after the meetings;
• collect and distribute information relevant for the objectives of
the Federation from and to the members of the Federation.
• keep a record of all financial transactions of the Federation;
• be responsible for the collection of all dues and other financial
income;
• pay all obligations and debts.
A major deviation from the budget will require the approval of the
Executive Committee before the expenditure is made.
The Financial Account of the Secretary-General/Treasurer shall be
audited annually by a legally authorised auditor. The approval of the
Financial Account by the Council will relieve the Executive Commit-
tee and auditor from all subsequent financial responsibility.
L. The Treasurer, together with the Executive Director, shall:
• undertake efforts to increase the financial resources of the
Federation;
• render annually a complete Financial Account and submit a
proposed budget to the Executive Committee for approval by
Council.
A major deviation from the budget will require the approval of
the Executive Committee before the expenditure is made.
The Financial Account of the Treasurer shall be audited annually by
a legally authorised auditor. The approval of the Financial Account
by the Council will relieve the Executive Committee and auditor
from all subsequent financial responsibility.
M. EUFEPS operating procedures will be defined by a set of Internal
Operating Procedures, produced by the Executive Committee.
28

3 Duties of the Member Societies
4 Meetings
5 Finances
The Member Societies shall:
A. Support the objectives of the Federation
B. Pay their annual dues; such payment shall be made before the 1st of
February each year. The annual dues will be set by the Council each
year.
C. Submit on a regular basis relevant information concerning their own
activities to the Executive Director.
D. Publicise on a regular basis the activities of the Federation as received
from the Executive Director, including distribution of the News-letter to
individual members of the Member Society.
A. The Federation shall organise a European Congress of Pharmaceutical
Sciences normally every two years. The venues of these
congresses will be selected by the Executive Committee and require
approval by the Council.
B. The Federation may organise meetings on relevant topics of
multidisciplinary aspects of drug research.
C. Joint meetings between member societies, as well as other relevant
meetings, may be organised under the auspices of the Federation.
This requires the approval of the Executive Committee.
Finances of the Federation shall be obtained from membership dues and donations, as
well as from other sources approved by the Executive Committee. The Treasurer, together
with the Executive Director, shall prepare an annual budget in Euro to be approved by the
Council in the year prior to the budget year. The fiscal year of the Federation shall coincide
with the calendar year.
6 Amendments to the Statutes
Amendments to the Statutes shall only be made by the Council. Prepared amendments
must be sent to the Executive Director at least three months before the Council meeting
at which they are to be considered and must be endorsed by at least five members of the
Council. The Executive Director shall transmit the proposed amendments to Council members
at least one month before the Council meeting. A proposed amendment shall be considered
adopted upon receiving a three-fifth (3/5) majority of votes cast.
In any case of conflict between these Statutes and other rules or regulations adopted by
the Federation, these Statutes shall prevail. All such apparent conflicts shall be resolved
by the Council whose decisions shall be binding on all interested parties.
7 Legal Representations
The President is the legal representative of the Federation in its dealings with other organisations.
The President may authorise the President-Elect or Executive Director to represent
him or her in such dealings.
29

7. Executive Committee 2010–2011
EUFEPS Role & Sciences Affairs & General Policy & Conference Planning
Clive G. Wilson (2009-2011)
President 2010-2011
Professor and JP Todd Chair of Pharmaceutics,
Strathclyde Institute of Pharmacy & Biomedical Sciences,
University of Strathclyde, Glasgow, United Kingdom
Network Liaison BioAvailability and BioPharmaceutics
Pharmaceutical Sciences Fair and Exhibition (PharmSciFair)
Finance & Funding
Alain Cuiné (2009-2011)
Vice-President 2010-2011
Director of R&D for Becton Dickinson, Grenoble, France
Lennart Dencker (2009-2011)
Treasurer 2010-2011
Professor in Toxicology and Vice-Chairman of the
Faculties of Medicine and Pharmacy at the University of
Uppsala, Sweden
Network Liaison Environment and Pharmaceuticals
Awards and Prizes & EUFEPS Senate
Daan J.A. Crommelin
Past-President 2009-2011
Professor of Pharmaceutics, Utrecht University, and
Scientific Director, Dutch Top Institute Pharma, Leiden,
The Netherlands
c.g.wilson@strath.ac.uk
Membership Development & Industry Education and Training
Buket Aksu (2010-2012)
Corporate Relations Director, Santa Farma, Istanbul &
EGE University, Ìzmir, Turkey
Network Liaison Quality by Design (QbD) and Process
Analytical Technology and Underpinning Sciences (PAT)
30
alain_cuine@europe.bd.com
lennart.dencker@farmbio.uu.se
daan.crommelin@tipharma.com
baksu@santafarma.com.tr

Regulatory Science and Affairs
Rogério Gaspar (2009-2011)
Full Professor of Pharmaceutics, University of Lisbon,
Portugal
Network Liaison Regulatory Science
Academia Education and Training & Communications
Ulrike Holzgrabe (2009-2011)
Professor of Pharmaceutical Chemistry, University
of Würzburg, Würzburg, Germany
Committee Liaison Education and Training
Conference Planning and PharmSciFair Program
Milena Jadrijevic-Mladar Takac (2010-2012)
Professor of Medicinal Chemistry and Drug
Biochemistry, Faculty of Pharmacy and Biochemistry,
University of Zagreb, Croatia
Industrial Research Relations
Eva-Maria Muchitsch (2009-2011)
Director of Global Preclinical R&D, Baxter, Vienna,
Austria
Network Liaison Safety Sciences
CEO & Office & EJPS & Students Relations
Hans H. Linden
Executive Director, EUFEPS, Stockholm, Sweden
31
rgaspar@ff.ul.pt
u.holzgrabe@
pharmazie.uni-wuerzburg.de
mladar@pharma.hr
eva_muchitsch@baxter.com
hans.linden@eufeps.org

8. Advisory Committees
Committee on Industrial Research Relations (CIRR)
One important and clear objective of EUFEPS is to interact with the pharmaceutical industry,
thereby contributing to strengthening the pharmaceutical sciences and scientists in enhancing
innovative drug research and development in Europe.
CIRR was established as think-tank in the early history of EUFEPS. It plays an important
role in identifying timely and strategic topics for EUFEPS congresses, conferences and
workshops, and it discusses education and training needs as well. The New Safe Medicines
Faster project (NSMF) to improve drug development, initiated in the late nineties and
forerunner of the today’s Innovative Medicines Initiative (IMI), was also a product of CIRR.
Committee on Pharmaceutical Policies (CPP)
This Committee was installed early as well, to help to establish regular contacts and scientific
exchange in the regulatory field and create fora for discussion of relevant pharmaceutical
issues between authorities, industry, academia and other interested parties. The Committee
also provided input for several meeting programmes.
The roles of this Committee are today seen to by the Conference Planning Committees,
Network Steering Committees and the Executive Committee.
Committee on Academic Research Relations (CARR)
CARR was established ten years ago to see to interests on the academic side. The major
task of CARR was to analyse current status of academic research in the pharmaceutical
sciences in Europe and to make a proposal on how to foster the impact of academic fundamental
research in the discovery of new medicines.
The outcome of the work of CARR includes an extensive position paper on the current
status and future opportunities as to contributions of academic research to drug discovery,
published in the European Journal of Pharmaceutical Sciences.
Committee on Training and Education (CTE)
Rapidly changing demands in newly emerging science and technique in pharmaceutical
research and development call for new and improved training and education. The CTE was
established to identify such needs and also to address the considerable heterogeneity of
pharmaceutical sciences training and education across Europe.
Top-ten needs have been identified, discussed and published, and some courses initiated.
CTE has also, for example, engaged in the EUFEPS workshops on safety sciences education
and training, which needs are now seen to in the IMI Project on a European Modular
Education and Training Programme in Safety Sciences for Medicines.
32

Committee on Awards and Prices (CAP)
CAP manages the EUFEPS Awards Programme, chaired by the EUFEPS Past-President,
normally.
The Awards include the annual New Safe Medicines Faster Award, sponsored
by SANOFI, and the also annual Best Paper Award, sponsored by
Elsevier, for article in the European Journal of Pharmaceutical Sciences, plus the
biennial Giorgio Segré Prize, which is given in partnership with the Segré Family. Until 2004,
there was also a Young Investigator's Award for best poster at the EUFEPS Congress.
Committee Contact Points
To approach any of the current EUFEPS Committees (CAP, CIRR and CTE) as well as e.g.
Conference Programme Committees, contact the EUFEPS Secretariat, which will provide
contact information of the Committee Chair and/or Secretary.
33

9. EUFEPS Networks
Scope and aim
This Network was initiated by the EUFEPS Committee on Industrial Research Relations
(CIRR) and established to develop and implement educational programmes to meet the
training needs of scientists working in the field of safety sciences, primarily, and to provide
input for the New Safe and Innovative Medicines initiatives, all to help out of the attrition
dilemma. To achieve this, it actively engaged with stakeholders in enhancing and coordinating
a multi-disciplinary, holistic approach in the development of new medicines through
education and continuous training of scientists, capable of contributing to the innovative and
continual development of new medicines. Brainstorm and planning workshops have been
organised, and many are actively involved in the current IMI Project on safety sciences education
and training for medicines research and development.
Contact Point
Network
Safety Sciences
European Federation for Pharmaceutical Sciences
Hans H. Linden hans.linden@eufeps.org
Network
QbD and PAT Sciences
European Federation for Pharmaceutical Sciences
www.eufeps.org/PATnetwork.html
Scope and aim
This Network is developing a forum for academic, industrial and regulatory professionals in
the various scientific fields underpinning Quality by Design (QbD) and Process Analytical
Technology (PAT), sharing and discussing findings in cutting edge research and establishing
effective and innovative collaboration, the EuPAT conference series being a new platform.
It also contributes to education and training in the field as well as to foster hands-on implementation
of systems approaches and emerging technology in pharmaceutical production
processes. Promoting and supporting collaborative research projects established from interacademic,
academic-industrial and public-private partnerships is an additional important objective,
ultimately leading to innovation and better process understanding.
Contact Point
Thomas de Beer thomas.debeer@ugent.be
34

Network
Bioavailability and Biopharmaceutics
European Federation for Pharmaceutical Sciences
Scope and aim
The initiation of this Network appeared to be a natural progression of the EUFEPS vision
that biopharmaceutics forms the bedrock of many of the activities of the contributing societies.
Its activities have provided many important opportunities to assist legislature in defining
a harmonised approach across Europe. For example, proposed changes in European
Guidelines in bioavailability and bioequivalence have prompted the scientific community to
engage in a more comprehensive communication with regulatory scientists and to stimulate
exchange between both groups. In particular, efforts focus on scientific questions, which
arise from poorly resolved areas and to provide a focal point from which best practice can
be developed. There is now a platform for discussion for all interested scientists. Several
conferences and decision fora have been organised, and more will follow.
Contact point
Henning Blume henning.blume@socratec-pharma.de
Network
PharmacoGenetics
and PharmacoGenomics Research
European Federation for Pharmaceutical Sciences
www.epr-network.org
Scope and aim
Pharmacogenetics and pharmacogenomics (PGX) are emerging disciplines that focus on
genetic determinants of drug response at the levels of single genes or the entire human
genome, respectively. The network is the voice of the European science community in
pharmacogenetics and pharmacogenomics, with the following objectives. The Network provides
a platform for experts for gathering and disseminating knowledge, determining PGXstrategies;
for collaboration between academic institutions and industry; for mechanisms of
set up and exchange of databases; and for gatherings and promotion of knowledge about
pharmacogenetics and genomics in Europe. Objectives also include to serve as a knowledge-bank
for EU research programme calls, and to engage in education and training, particularly,
PHD students.
Contact Point
Anke-Hilse Maitland-van der Zee a.h.maitland@uu.nl
35

Network
Environment and Pharmaceuticals
European Federation for Pharmaceutical Sciences
Scope and Aim
Pharmaceuticals are indispensable for a high quality of life. Their use however also has an
environmental downside that needs to be handled. In recent years, a huge amount of data
has been collected, demonstrating the widespread of a variety of active drug ingredients in
the aquatic environment and sporadically even in drinking water. Being only insufficiently
eliminated in the conventional sewage treatment plants, there is growing evidence that the
substances and their metabolites have adverse effects on aquatic and in some cases terrestrial
organisms on both the individual and population level. How to adequately address
these issues? The Network has been initiated to address scientific achievements and discuss
various issues on exposure of pharmaceuticals to the environment, including attempts
towards global harmonisation.
Contact Point
Lennart Dencker lennart.dencker@farmbio.uu.se
Network
Food-Drug Synergies
European Federation for Pharmaceutical Sciences
Scope and aim
This Network initiative is new. The idea is to assemble the industry-academia-regulatory
triangle to work on topics which cross between food science and pharmaceutical sciences.
Topics would be, for example: Personalised nutrition and personalised medicine; special
needs (the sick, children, the elderly); sharing technology to evaluate product performance;
best practice to be communicated to public bodies; encouraging liaison across Europe to
create enterprise; and to explore new neutraceutical concepts.
Contact point
David Featherston DFE@biopeople.ku.dk
36

Network
NanoMedicine
European Federation for Pharmaceutical Sciences
Scope and aim
This Network is also new. Broadly, nanomedicine has been defined as therapeutic and/
or diagnostic systems capable of comprehensive monitoring, control, construction, repair,
defence and improvement of all human biological systems, working from the molecular
level using engineered devices and nanostructures, ultimately to achieve medical benefit.
Nanoscale includes active components or objects in the size ranging from one nanometre to
hundreds of nanometres. Naturally, this Network should focus on pharmaceutical and biomedical
sciences and the diagnostics and therapeutic aspects of nanomedicine, primarily in
cooperation with related nanotechnology fields such as optics, bioinformatics to achieve a
wide range platform for pharmaceutical researchers in this field.
Contact point
Erem Bilensoy eremino@hacettepe.edu.tr
Network
Regulatory Science
European Federation for Pharmaceutical Sciences
Scope and aim
This initiative is an additional Network option for, primarily, academic, industrial and regulatory
professionals in the various scientific fields to engage in brainstorming meetings, workshops
and discussions on strategic goals and key issues in translational research covered
by the pharmaceutical sciences. It would foster collaboration and contribute to implementation
of high quality basic and applied science, promote joint activities and engage in education
and training.
Contact point
Rogério Gaspar rgaspar@ff.ul.pt
37

10. Awards and Prizes
EUFEPS is, since 1998, presenting a number of Awards. Below is information on them,
along with the laureates.
The Giorgio Segré Prize
In 1998, EUFEPS established, in partnership with the Segré family, a special biennial
award for young investigators showing distinction in the field of PK and PD, to honour the
memory of the late Professor Giorgio Segré of the University of Siena, Italy. The Giorgio
Segré Prize was presented for the first time in 1998.
Laureates
Year Laureate
1998 Mats Karlsson
University of Uppsala, Sweden
2000 Wojchiech Krzyzanski
State University of New York at Buffalo, Buffalo NY
USA
2002 Oscar E Della Pasqua
University of Leiden, The Netherlands, and Glaxo-
SmithKline Research & Development, Greenford,
United Kingdom
2004 Inaki Troconiz
University of Navarra, Spain
2006 Niclas Jonsson
University of Uppsala, Sweden
2008 Lena Friberg
University of Uppsala, Sweden
2010 Jürgen Bulitta
State University of New York at Buffalo, Buffalo NY
USA
The Best Paper Award
The Best Paper Award, sponsored by Elsevier, is given to the author/s of the best paper
selected among those published in the European Journal of Pharmaceutical Sciences in
the year before the Award is presented. The European Journal of Pharmaceutical Sciences
is the Official Scientific Journal of EUFEPS, published by Elsevier. The Best Paper
Award was presented for the first time in 2002.
38

Laureates
Year Authors Article Published
2002 P.J. Gaillard, L.H.
Voorwinden, J.L.
Nielsen, A. Ivanov,
R. Atsumi, H. Engman,
C. Ringbom, A.G. de
Boer and D.D. Breimer
2004 G. Bäckström, J.
Taipalensuu,
H. Melhus, H.
Brändström,
A-C. Svensson, P. ArPtursson
and
A. Kindmark
2004 G.L. Perlovich, S.V.
Kurkov and
A. Bauer-Brandl
2005 G.W. Bos, J.J.L.
Jacobs,
J.W. Koten, S. Van
Tomme,
T. Veldhuis, C.F. van
Nostrum,
W. Den Otter and W.E.
Hennink
2006 M. Boustta, T. Etrych,
L. Leclercq and M. Vert
2007 J.H. Proost, L. Beljaars,
P. Olinga, P.J. Swart,
M.E. Kuipers, C. Reker-
Smit,
G.M.M. Groothius and
D.K.F. Meijer
2008 M. Norrman, F.
Hubáleka and
Schluckebier
2009 C. Fella, G.F. Walker,
M. Ogris and E. Wagner
2011 X. Shi, Y. Wang, R.R.
Varshney, L.R. Yihong
Gong and D-A. Wang
Establishment and functional characterization
of an in vitro model of the
blood-brain barrier, comprising a coculture
of brain capillary endothelial
cells and astrocytes
Genetic variation in the ATP-binding
Cassette Transporter gene ABCG2
(BCRP) in a Swedish population
Thermodynamics of solutions II.
Flurbiprofen and diflunisal as models
for studying solvation of drug substances
In situ crosslinked biodegradable hydrogels
loaded with IL-2 are effective
tools for local IL-2 therapy
Polyelectrolyte complex formation
and stability when mixing polyanions:
and polycations in salted media
A model study related to the case of
body fluids
Prediction of the pharmacokinetics of
succinylated human serum albumin
in man from in vivo disposition data
in animals and in vitro liver slice
incubations
Structural characterization of insulin
NPH formulations
Amine-reactive pyridylhydrazonebased
PEG reagents for pH-reversible
PEI polyplex shielding
Microsphere-based drug releasing
scaffolds for inducing osteogenesis
of human mesenchymal stem cells
in vitro
39
2001, 12, 215-
222
2003, 18, 359-
364
2003, 18, 423-
432
2004, 21, 561-
567
2005, 25, 281-
288
2006, 27, 123-
132
2007, 30, 414-
423
2008, 34, 309-
320
2010, 39, 59-67

The New Safe Medicines Faster Award
The New Safe Medicines Faster (NSMF) Award, sponsored by Sanofi, was established by
EUFEPS in 2002 to, every year, honour an individual scientist – or a team of scientists –
for outstanding contributions to innovation and advancement of new methodology or technology,
primarily, which has significantly contributed to shorten or make the drug development
process more efficient. The NSMF award was presented for the first time in 2003.
Laureates
Year Laureate
2003 Mats Bergström, Anders Grahnén and Bengt Långström
(Uppsala, Sweden)
2004 Geoffrey T. Tucker and Amin Rostami (Sheffield, United
Kingdom)
2005 Per Artursson (Uppsala, Sweden) and Manfred Kansy
(Basel, Switzerland)
2006 Meindert Danhof (Leiden, The Netherlands)
2007 Peter York (Bradford, United Kingdom), Staffan Folestad
(Moelndal, Sweden), Hans Leuenberger (Basel, Switzerland),
and Jouko Kalervo Yliruusi (Helsinki, Finland)
2008 Hans Lennernäs (Uppsala, Sweden)
2009 Malcolm Rowland (Manchester, United Kingdom)
2010 Hans H. Lindén (Stockholm, Sweden)
40

11. European Pharmaceutical Scientist Prize
The European Pharmaceutical Scientist Prize was created on the occasion of the First
PharmSciFair, which took place in 2005 in Nice, France. The Prize is intended to recognise
significant contributions by a European researcher in any domain of the pharmaceutical
sciences, such as: drug modelling, medicinal chemistry, gene therapy, pharmacology,
pharmacokinetics, drug metabolism, toxicology, pharmaceutical formulation, drug delivery,
pharmaceutical physical chemistry, new in-vitro/in-vivo models, etc., i.e. scientific domains
and disciplines relevant for drug discovery, development, processing and usage. The intention
is not to recognise a life devoted to science, but rather a discovery, which can be
considered as a decisive breakthrough in drug discovery and development.
The most prestigious European research centres are invited to nominate one or more
candidate(s) in one or more of the above-mentioned domains. These centres are: Karolinska
Institute (Sweden), Istituto di Recerche Farmacologiche “Mario Negri” (Italy), Fonds
National de la Recherche Scientifique (Belgium), FIGON (The Netherlands) and Centre
National de la Recherche Scientifique (France), as well as the EUFEPS Member Societies
and other scientific societies and associations participating in the organisation of the Pharm-
SciFair.
Laureates
Year Laureate
2005 Professor Pierre Potier,
Paris, France
2009 Professor Michael Karas,
Frankfurt, Germany
2011 Professor Patrick Couvreur,
Paris, France
A simple biological test (tubulin test) allowing
identification and selection of new anti-cancer
agents, leading to the development of Navelbine
and Taxotere.
Outstanding achievements in mass spectrometry,
related to the analysis of biomolecules by laserassisted
desorption ionization, more specifically
known as Matrix Assisted Laser Desorption
Ionization (MALDI).
First biodegradable nanoparticles for human use,
representing a real breakthrough in the field of
advanced drug delivery, e.g. opening new ways for
highly efficient and significantly improved drug
administration.
41

12. The Pharmaceutical Sciences Fair and Exhibition
PharmSciFair
The Pharmaceutical Sciences Fair and Exhibition – PharmSciFair – is a unique event in
Europe, co-organised by EUFEPS and a number of Partner Organisations. They are Member
Societies of EUFEPS, Sister Organisations, Learned Societies, and Special Interest
Networks and Institutions. The first PharmSciFair, in June 2005, in Nice, France, was attended
by over 1200 delegates. It pioneered this new platform, which allows the best and
newest European pharmaceutical achievements to be presented, and provides an excellent
spirit of collaboration between academia, the regulatory field and industry.
A second PharmSciFair and Exhibition was held in June 2009 in Nice, France, with a lot of
students among the attendees and a young scientist meeting, partly on its own and partly in
the PharmSciFair. The 3rd Pharmaceutical Sciences Fair and Exhibition was held in June
2011 and, for the first time, in Prague, Czech Republic. It was co-organised, as previously,
by EUFEPS and a broad partner representation of 30 national and international organisations
and networks in pharmaceutical sciences, around the common theme: Pharmaceutical
Sciences for the Future of Medicines. In Prague, after the Welcome Reception, the scientific
programme comprised over forty Parallel Sessions, focusing on topics of the pharmaceutical
sciences in Europe, a Plenary Session and Panorama Sessions for overview, Young
Scientist Sessions, and a EUFEPS 20 th Anniversary Session and Reception.
The PharmSciFair is unique because it encompasses all aspects of pharmaceutical
sciences from discovery tools, over drug delivery in the body and drug processing, to
medicines usage. EUFEPS is convinced of the need to carry the pharmaceutical sciences
forward in this kind of global event; it should be the ‘Olympia’ of pharmaceutical
sciences, enabling all involved to think and to consult together and to share experiences,
different approaches, perspectives and sensitivities among the different players in
pharmaceutical sciences as represented by delegates from the academic, industrial and
regulatory domains. Building on the strengths of each and every actor, it ensures a consolidated
movement towards common goals and targets and creates synergy within the
array of different disciplines, all having the objective to better serve the health of populations.
The pharmaceutical science, as a multi-faceted concept, is reflected at this event,
which is wide-ranging in terms of scientific content, activities and participating parties.
Furthermore, EUFEPS wants to see a powerhouse in Europe, able to match other
international organisations at the equivalent level. Partnership of equals can only occur
if there is a strong, well organised interaction between national, regional and international
organisations, which are of relevance to pharmaceutical sciences. Instruments such as
PharmSciFair are needed to introduce partners, foster future interactions and generate a
European ideal. This combination of the diverse learned societies and networks of interest
and focus groups, associated with the pharmaceutical sciences in Europe into one assembly,
shows the combined strength of European pharmaceutical sciences in a way, which will
gain recognition globally.
42

Slovenian Pharmaceutical Society and
University of Ljubljana, Faculty of Pharmacy
are organizing the
th
4 BBBB - Bled International
Conference on Pharmaceutical
Sciences
Second Announcement
New Trends in Drug Discovery,
Delivery Systems and Laboratory Diagnostics
Bled, Slovenia, 29 th September – 1 st October 2011
www.bbbb-eufeps.org
Announcement – April 2011
Continuous Innovation in
Process Analytics & Control
May 9-10 • 2012 • NH Hotel Ghent Belfort • Ghent • Belgium
Invitation to Join EuPAT 5
The topic of EuPAT 5 – Continuous Innovation
in Process Analytics & Control – underlines the
importance of bringing innovation into pharmaceutical
manufacturing based on QbD and PAT
sciences. Building quality into drug products
should commence during the early phases of
research and development and sustain during the
product and process life cycle. Consideration and
implementation of the quality requirements for
new medicines should facilitate effective process
development and robust large-scale manufacture.
Advanced process analytics should therefore
play a crucial role in design, analysis, and control
of manufacturing processes based on timely
in-process measurements for integrated system
approaches, innovative developments and cutting
edge scientific advances.
This is to invite you for the fifth pan-European
Science Conference on QbD and PAT Sciences,
building on the successes of the EuPAT conference
series that started in 2006. EuPAT 5 will be held on
May 9-10, 2012, in Ghent, Belgium, and organised
back-to-back to a training day on “continuous
pharmaceutical manufacturing of solid dosage
forms”, to be held on May 8, 2012, at the Faculty
of Pharmaceutical Sciences from the University of
Ghent. The attendees of EuPAT 5 are welcome to
register to the pre-conference day and vice versa.
www.eufeps.org
Session Topics of EuPAT5
• Continuous pharmaceutical processing
• PAT in bio-active pharmaceutical processing
• Advanced process sensors for control
• Process modeling for in-depth understanding
and control
• Material characterization and understanding at
molecular level in (bio)process environment
Invited Speakers at EuPAT 5
Dr. Marcel de Matas, AstraZeneca, Macclesfield,
United Kingdom
Professor Wuqiang Yang, University of
Manchester, Manchester, United Kingdom
Professor Johannes Khinast, Technical University
of Graz, Graz, Austria
Professor Krist Gernaey, Technical University of
Denmark, Copenhagen, Denmark
Professor Reiner Luttmann, Hamburg University
of Applied Sciences, Hamburg, Germany
Professor Anna de Juan Capdevila, University of
Barcelona, Barcelona, Spain
The programme will be continuously updated on
the conference website.
43
Drug Absorption,
Transport and Delivery (WCDATD):
Responding to Challenging Situations
October 1-3 • 2012 • Edinburgh • Scotland • United Kingdom
Invitation
We invite you to start planning to
participate in the 5th World Conference
on Drug Absorption, Transport and
Delivery, to be held on October 1-3,
2012 in Edinburgh, Scotland, United
Kingdom. This international event will
take place immediately before the FIP
Centennial World Congress in Amsterdam,
The Netherlands. The programme of the
WCDATD 2012 is being developed around
progress, issues and challenges in all aspects
of drug absorption, transport and delivery
crucial to drug development and improved
drug usage. Previous Conferences in this
series were held in 2001 (Denmark), 2003
(USA), 2005 (Spain), and 2007 (Japan).
Scope and Aim
WCDATD 2012 will focus on understanding
of drug absorption mechanisms,
including the role of transporters, and
5 th World Conference on
www.eufeps.org
opportunities and constraints in the design
of formulations within a biopharmaceutical
context. Using new imaging, simulation
and measurement tools that integrate
knowledge from laboratory to clinic, the
optimal management of drug therapy in
complex patients and disease areas will be
considered together with implications for
harmonising drug product regulation. New
developments in drug design and delivery
technologies, including omics and material
sciences, and the concurrent evolution of
regulatory principles for the approval of
biosimilars offer exciting research areas
for both academic and industrial scientists.
The intent will be to assemble cutting
edge knowledge to consider and debate
contemporary challenges in drug usage,
including the treatment of patients at the
extremes of age and the impact of the disease
process on effective and safe delivery of
active pharmaceutical compounds.

14. EUFEPS in EU Projects
Since establishing (more than 10 years ago) and running the New Safe Medicines Faster
initiative (NSMF), EUFEPS has, obviously, been in leading and supporting roles and positions
of a number of EU funded projects within the European Commission Framework
Programmes for Research and Technological Development. Current projects stem from the
first and second rounds of calls of the Innovative Medicines Initiative (IMI) Joint Undertaking
(JU), which is a highest-level Public-Private Partnership (PPP) in Europe. Four of them, the
first round of calls ones, are focussing on education and training needs and how to fill them,
not the least in the pharmaceutical industry but also in the regulatory area an academic
world.
EUFEPS is consortium member and represented in the executive committee of the project
on European Modular Education and Training Programme in Safety Sciences for Medicines
(www.safescimet.eu). EUFEPS is leader of the Work Package on new and emerging
education and training needs in safety sciences and sustainability of the new programme.
SafeSciMET develops and delivers a pan-European education and training programme on
drug safety that emphasises integrative and translational aspects, from pre-clinical phases
to clinical ones, lacking largely in today’s educational programmes.
EUFEPS is consortium member and also liaised with the executive board of the project on
New and Harmonised Education and Training in Pharmaceutical Medicine in Europe (www.
pharmatrain.eu). EUFEPS contributes actively to three of its work packages – one on strategy,
one on new member state needs and involvement in the education and training programme,
and one on course quality. PharmaTrain aims at fostering the overall understanding
and competence for successful execution of integrated drug development and life-cycle
management of medicines.
EUFEPS is in the External Advisory Board and Strategic Coordination Board of the European
Medicines Research Training Network project (www.emtrain.eu). EUFEPS participates,
moreover, in the work of two of its teams or working parties. One of them should deliver
outcomes of a “gap analysis”, and the other one has started looking into continuing professional
development (CPD) or life-long learning (LLL) for those in medicines research, development,
processing and usage. EMTRAIN should establish a sustainable, pan-European
platform for education and training, covering the whole life-cycle of medicines research.
EUFEPS is liaised with the project on European Education and Training Programme in
Pharmacovigilance and Pharmacoepidemiology (www.eu2p.eu), through two IMI Cross
Project Task Forces. The first one of them focuses on communication of the IMI Education
and Training, lead by EUFEPS, and the other one is tasked to map out and implement
“Bologna” agreements and European higher education quality criteria for quality in the IMI
Education and Training. Eu2P addresses training needs and offers a range of qualification
level courses (certificate, master and PhD) and allows part or full time study by those in employment
as well as graduate students.
Finally, EUFEPS accepted an advisory role in the project on Drug Disease Model Resources
(www.ddmore.eu). It is a project from the IMI second round of calls.
For EUFEPS earlier involvement, including in the New Safe Faster Medicines (NSMF) initiative,
see the EUFEPS Online at www.eufeps.org
44

A EUFEPS Senate is being established.
15. EUFEPS Senate
Strategic discussions and decisions in the EUFEPS Executive Committee and Council lead
to a recommendation that an academy or group of renowned scientists be established in
Europe. If so, it would be a “EUFEPS Senate” or evolutionary think-tank for further scientific
developments, covering the pharmaceutical sciences as “the science of the drug”, preferably.
This would, to some extent, be broader than the traditional understanding of the field.
Maybe, there would be networking and educational roles as well. Having concluded that
such a body, a well-organised advisory group of senior leaders or elders in the science,
would be beneficial as sounding board and pool of experience to EUFEPS and its membership,
further steps were taken.
The first and inaugural meeting of the EUFEPS Senate was held in June 2009 in Nice,
France (at the 2 nd PharmSciFair), the second meeting in April 2010 in Vienna, Austria, and
the third one in November 2010 in New Orleans, USA (at the 4 th Pharmaceutical Sciences
World Conference). The fourth meeting was held in June 2011 in Prague, Czech Republic
(at the 3 rd PharmSciFair).
The EUFEPS Senate comprises 16 members, currently, many of them having played leading
roles not only as scientists, including in education and training, but also in EUFEPS.
Professors Douwe D. Breimer (Leiden, The Netherlands), and Christian R. Noe (Vienna,
Austria) are Chair and Secretary of it.
45

16. EUFEPS on the Global Scene
Since its inception the EUFEPS leadership has realised that a strong European presence
on the global scene would be a benefit to the EUFEPS membership; ‘the European voice
should be heard’. That is why, over the years, EUFEPS played an active role on the global
pharmaceutical sciences ‘scene’. In the following text only interactions of EUFEPS with
international organisations and national organisations outside Europe are mentioned. The
intention is not to give an exhaustive overview. It should be seen as a sampling of EUFEPS
activities in a global perspective and EUFEPS willingness to engage in answering global
questions.
FIP
In the EUFEPS statutes a special mentioning is made to the International Pharmaceutical
Federation (FIP). This international platform for pharmacy practice and pharmaceutical sciences
is mentioned is an observer to the EUFEPS Council meeting. EUFEPS has played
an active and stimulating role in the scientific wing of the FIP (Board of Pharmaceutical Sciences,
BPS). Even more so, EUFEPS joined FIP as Member Organisation in 2008 and by
this became the first Member Organisation of FIP/BPS with a world regional (Europe) coverage,
instead of a national basis. EUFEPS and FIP worked together on different occasions,
including in organising joint conferences. A prime example is the Pharmaceutical Sciences
World Conference (PSWC) series. Since the first PSWC in 2000 in San Francisco, CA USA,
EUFEPS has fully supported this FIP led initiative, where pharmaceutical scientist from all
over the world meet. The follow up PSWC conferences (Tokyo, 2004), in particular Amsterdam
(2007) and New Orleans (2010), all enjoyed European programmatic input through
EUFEPS.
AAPS, ACCP, ISSX, APSTJ and JSSX
Several other organisations worldwide collaborate on a regular or temporary basis with
EUFEPS. Among those are the American Association of Pharmaceutical Scientists (AAPS),
the American College of Clinical Pharmacology (ACCP), and the International Society for
the Study of Xenobiotics (ISSX). Over the last 20 years co-sponsored conferences were
run on a regular basis. Examples are meetings in the EUFEPS Basel Conference Series,
the Groundbreaking Workshop on ‘Assuring Quality and Performance of Sustained and
Controlled Release Parenterals’ also in Basel, and the World Conference on Drug Absorption
Transport and Delivery (WCDATD), by EUFEPS in 2001 in Copenhagen and in 2005 in
Barcelona – and aiming for Edinburgh in 2012. In this context the longstanding interactions
and collaborations with the Academy of Pharmaceutical Sciences and Technology of Japan
(APSTJ), the Japanese Society for the Study of Xenobiotics (JSSX), and the, newly established,
Asian Federation for Pharmaceutical Sciences (AFPS) must also be mentioned.
ISPE
The International Society for Pharmaceutical Engineering (ISPE) has been EUFEPS’ partner
for a number of years in the field of Process Analytical Technology (PAT) and Quality by
Design (QbD). ISPE Nordic and ISPE Europe cosponsored a number of successful conferences
set up by the EUFEPS Network in this field.
46

The European Pharmacopoeia and the USP
A link between EUFEPS and the European Pharmacopoeia (within the European Directorate
for Quality of Medicines and Health Care) is a logical one. But, EUFEPS has a longstanding
relationship with the Unites States Pharmacopoeia (USP) as well, as it contributed
to stakeholder fora organised by USP. EUFEPS is also engaged in discussion on how to
establish global pharmacopoeia meetings.
DUPHAT
EUFEPS contributes, since about ten years, to the programme of the Annual Dubai International
Pharmaceuticals & Technologies Conference & Exhibition (DUPHAT), by recommending
(European) speakers and leaders for plenary sessions and workshops, and by co-sponsoring
it. It is held in the beginning of March, every year, in Dubai, United Arab Emirates.
47

17. Sponsorship Recognition
The core funding of EUFEPS is based on annual membership fees. The major part is provided
by the EUFEPS Member Societies, the fee of which is related to the size of the Member
Society. Currently, there are 24 Member Societies of EUFEPS, in 24 countries, including
Israel and Turkey. In addition there are around 500 Individual Members of EUFEPS as well
as 15 Member Institutions, comprising universities and research institutes.
“Meetings and events”, meaning congresses, conferences, workshops and courses etc. is
an additional source of income of EUFEPS, in many cases covering not only direct expenses
and the administration and management of them, but also some of the development
costs for future activities, including important and crucial meetings not bearing their
own financial burden. In addition, EUFEPS initiated and participated (and still does) in EU
funded projects, also covering their own costs and time spent, after approved application
and reimbursements.
Since 2007, a number of major European pharmaceutical companies provided significant
sustained sponsorship for EUFEPS, in three-year cycles or year by year. This is gratefully
acknowledged. It helped to, for example, keep and continuously run the permanent
secretariat of EUFEPS, located in Stockholm, Sweden. Sustained sponsors were/are:
AstraZeneca, Bayer Healthcare, GlaxoSmithKline, Novartis and Pfizer. In addition, many
companies sponsored EUFEPS events, over the years, including those organised by
EUFEPS Networks.
For the future, even broader support of EUFEPS will be sought to build longer term financial
stability – more members (societies, individuals and institutes), as well as small, medium
and big companies, all for new significant initiatives and to better serve the pharmaceutical
scientist community, e.g. towards a framework for continuing professional development
(CPD).
48

18. Executive Committee membership 1991–2011
18. Executive Committee membership 1991–2011
\
Past-
Secretary
President Vice President
Treasurer
Member Member Member Member Member
President
General
E. Mutschler D.D. Breimer None P. Sensi S. Agurell K. Nicolics P. Rossignol
E. Mutschler D.D. Breimer None P. Sensi S. Agurell K. Nicolics P. Rossignol
E. Mutschler D.D. Breimer None P. Sensi S. Agurell Y. Michotte M. Rowland
D.D. Breimer M. Rowland E. Mutschler B. Lindeke B. Lindeke Y. Michotte F Pellerin
D.D. Breimer M. Rowland E. Mutschler B. Lindeke B. Lindeke Y. Michotte F. Pellerin
M Rowland A.Grahnén D.D. Breimer B. Lindeke B. Lindeke A.F. Fell F. Pellerin A.A. Hincal
M. Rowland A. Grahnén D.D. Breimer B. Lindeke B. Lindeke A.F. Fell M. Veillard A.A. Hincal
M. Rowland A. Grahnén D.D. Breimer B. Lindeke B. Lindeke A.F. Fell M. Veillard A.A. Hincal
1991-
1992
1992-
1993
1993-
1994
1994-
1995
1995-
1996
1996-
1997
1997-
1998
1998-
1999
Secretary
Past-
President Vice President
General Member Member Member Member Member Member
President
(Ex Officio)
M. Rowland A. Grahnén D.D. Breimer B. Lindeke D. Duchêne A.F. Fell M. Veillard A.A. Hincal B. Clement O.J. Bjerrum
D. Duchêne O.J. Bjerrum M. Rowland B. Lindeke A. Grahnén R. Paoletti M. Veillard A A.Hincal B. Clement H. de Jong
D. Duchêne O.J. Bjerrum M. Rowland H. H. Lindén F. Bühler R. Paoletti M. Veillard A A.Hincal B. Clement H. de Jong
1999-
2000
2000-
2001
2001-
2002
49
Secretary
Past-
President President-Elect
Treasurer General Member Member Member Member Member
President
(Ex Officio)
D. Duchêne O.J. Bjerrum None C. Bogentoft H. H. Lindén R. Paoletti C.R. Noe A. Mrhar B. Clement A. Demirdere
O.J. Bjerrum C.R. Noe D. Duchêne C. Bogentoft H. H. Lindén R. Paoletti T. Dingermann A. Mrhar C. Doherty A. Demirdere
O.J. Bjerrum C.R. Noe D. Duchêne P. From H. H. Lindén R. Paoletti T. Dingermann H. Köszegi-Szalai C. Doherty D.J.A. Crommelin
C.R. Noe D.J.A. Crommelin O.J. Bjerrum P. From H. H. Lindén R. Paoletti T. Dingermann H. Köszegi-Szalai C. Doherty P. Vuorela
C.R. Noe D.J.A. Crommelin O.J. Bjerrum P. From H. H. Lindén B. Aksu T. Dingermann H. Köszegi-Szalai C. Doherty P. Vuorela
D.J.A. Crommelin P. Vuorela C.R. Noe P. From H. H. Lindén B. Aksu U. Holzgrabe H. Köszegi-Szalai C. Doherty J.A. Guimarães Morais
D.J.A. Crommelin P. Vuorela C.R. Noe S. Stegemann H. H. Lindén B. Aksu U. Holzgrabe Vacant C. Doherty J.A. Guimarães Morais
C.G. Wilson A. Cuine D.J.A. Crommelin L. Dencker H. H. Lindén B. Aksu U. Holzgrabe R.S. Gaspar
E-M.
J. Murrey
Muchitsch
E-M.
C.G. Wilson A. Cuine D.J.A. Crommelin L. Dencker H. H. Lindén B. Aksu U. Holzgrabe R.S. Gaspar
Muchitsch
M. Jadrijević-Mladar Takač
2002-
2003
2003-
2004
2004-
2005
2005-
2006
2006-
2007
2007-
2008
2008-
2009
2009-
2010
2010-
2011

Selection of articles
from the EUFEPS NewsLetter since 1991
EUFEPS First NewsLetter ...................................................................................................................... I
The Inaugural Council Meeting in Strasbourg ....................................................................................... II
1st European Congress of Pharmaceutical Sciences .......................................................................... III
Dear Members, successful first EUFEPS Congress ............................................................................IV
The Future of Pharmaceutical Sciences................................................................................................V
European Journal of Pharmaceutical Sciences ....................................................................................VI
EUFEPS – the Right Federation at the Right Time .............................................................................VII
Research Training in the Pharmaceutical Sciences in Europe ...........................................................VIII
EUFEPS Strategic Plan for 1994–1998.................................................................................................X
On EUFEPS Progress ..........................................................................................................................XI
Visions and Realisations – New President takes Stock .....................................................................XIII
The Influence of Pharmaceutical Sciences on the International Harmonisation Activities ................. XV
Biopharmaceutical Classification System (BCS) for Oral Immediate-release Drug Products .......... XVII
Strategic events ................................................................................................................................. XIX
EUFEPS forges links with FDA, EMEA and EU ................................................................................ XX
EUFEPS Permanent Secretariat established .................................................................................... XXI
New Safe Medicines Faster - A Proposal for a Key Action
within the European Union’s 6th Framework Programme ................................................................ XXII
Workshop Report - New Safe Medicines Faster .............................................................................XXIV
Decennial Milestone ........................................................................................................................XXVI
The European Federation for Pharmaceutical of Sciences - EUFEPS ..........................................XXVII
EUFEPS 10th anniversary - European Federation for Pharmaceutical Sciences ............................XXX
A need for Excellence in Pharmaceutical Sciences........................................................................XXXII
‘Safety Sciences’ – a way out of the attrition dilemma ..................................................................XXXIII
Pharmaceutical Sciences Fair ........................................................................................................XXXV
EUFEPS Vision on Training and Education ...................................................................................XXXVI
New Safe Medicines Faster Award 2003 .....................................................................................XXXVIII
Pharmaceutical Research Community Contributions
and Expectations in New European Union Countries....................................................................XXXIX
Importance of Research Linked with the EMEA ...................................................................................XL
Pharmaceutical Sciences: Towards a more Competitive Europe ......................................................XLII
The First PharmSciFair – a Highly Successful Event ...................................................................... XLIV
The Role of Learned Societies in Forming
a European Technology Platform for Innovative Medicines ..............................................................XLVI
The First BBBB Conference on Pharmaceutical Science,
a successful start to a new drug research conference in East Europe ..........................................XLVIII
New Safe Medicines Faster European Technology Platform/Strategic Research Agenda/
Innovative Medicines for Europe EU Joint Technology Initiative ........................................................... L
Public-Private Partnerships and ‘Le défi Americain’ revisited .............................................................. LII
How to develop academic drug research in Europe ...........................................................................LIV
15th Anniversary .................................................................................................................................LVI
Pharmaceutical Science in Europe. Part 1: Analysis ..........................................................................LIX
Pharmaceutical Science in Europe. Part 2: “Where to go” ................................................................LXII
“Changing of the Guard” – EUFEPS’ New President and Past President Share Views .................. LXIV
Birth of the EUFEPS BABP Network .............................................................................................. LXVII
Innovative Medicines Initiative (IMI) kick-off .................................................................................. LXVIII
EUFEPS Today ................................................................................................................................. LXX
“Times are changing and we change with time”
Reflections of the Past President and President at the turn of the year ........................................LXXIV
2nd PharmSciFair - Premier European Platform for Advancing Pharmaceutical Sciences ...........LXXVI
Update from the President............................................................................................................LXXVII
3rd PharmSciFair.........................................................................................................................LXXVIII
50

EUFEPS Newsletter, 1992, vol 1, issue 1
EUFEPS
First Newsletter
Ernst Mutschler, Professor
President of The European Federation for Pharmaceutical Sciences
Dear Members,
With this first Newsletter, which will
be followed by more on a regular basis
(three per year), the EUFEPS Executive
Committee would like to inform you of
our present and future activities and also
to ask you for your personal contributions.
We would like you, whenever possible, to
participate in the activities arranged by
EUFEPS, to inform us about your own
national organisation and its scientific
activities, to give us your suggestions as
well as your critical views, and to inform
other pharmaceutical scientists of our
organization and its goals. Only through
initiative and active cooperation between
the members can our federation develop
successfully and become the desired link
of international cooperation and scientific
exchange between scientists.
In this connection, I would like to
cordially invite you to participate in the
1st European Congress of Pharmaceutical
Sciences, which takes place on October
7–9, 1992 in Amsterdam. Our Dutch
colleagues have enthusiastically put
together an attractive program with
prominent speakers, and we are sure that
the participants will find the congress
interesting and worth attending.
Since the inaugural meeting in
Strasbourg, the Executive Committee
has taken a number of initiatives. The
Committee on Industrial Relations was
established and its first meeting was held
in Brussels. We expect this Committee
to generate an active exchange of ideas
between the universities and the research
based pharmaceutical industry.
The establishment of the European
Journal of Pharmaceutical Sciences –
the scientific journal of the Federation
– will be of special significance. Our
Scandinavian colleagues are in favour of
merging the Acta Pharmaceutica Nordica
with the new journal, which would create
a good opportunity for a successful start
for our journal.
I
The saying “The beginning is always
difficult” is also valid for a new scientific
organisation. But we have already made
considerable progress and we are confident
that the Federation will be successful.
Hoping to see you in Amsterdam!
Sincerely yours,
Ernst Mutschler

EUFEPS Newsletter, 1992, vol. 1, issue 1
The Inaugural
Council Meeting
in Strasbourg
Stig Aurell, Professor
EUFEPS Secretary-General
The Inaugural Council Meeting of the
Federation was held in Strasbourg on
September 21, 1991. Representatives
from 15 European member societies and
a number of observers and guests were
present.
Mr Björk, the President of the
Parliamentary Assembly of the Council
of Europe, opened the meeting. He
underlined the importance of joint efforts
by European countries to be able to
develop and compete effectively in the
future. He also emphasized the interest of
the Council in maintaining contacts with
the new Federation.
The proposed statutes were discussed,
revised and approved - the statutes will
be included in the next Newsletter. After
the formal constitution, an Executive
committee was elected. Professors Ernst
Mutschler as President, Douwe Breimer as
Vice-President, Stig Agurell as Secretary-
General, and Piero Sensi as Treasurer,
and Professors Karoly Nikolics and Paul
Rossignol (members).
The task of the Federation is to
advance research in the pharmaceutical
sciences in Europe through cooperation
between national, regional and other
societies. This will include a European
Congress of Pharmaceutical Sciences and
will contribute towards the recognition
of pharmaceutical sciences and to public
policy. To address these tasks it was
decided to establish several committees.
The Secretariat of the Federation will
be located at and sponsored by the Swedish
Academy of Pharmaceutical Sciences in
Stockholm for the coming three years.
II
A. Björk, The President of the Parliament-
ary Assembly of the European Council of
Europe opening the Council meeting.
The Executive Committee.
From left; D. Breimer, E. Mutschler,
S. Agurell, P. Sensi and P. Rossignol.

EUFEPS Newsletter, 1992, vol. 1, issue 1
1 st European Congress of
Pharmaceutical Sciences
Amsterdam • October 7–9 • 1992
Hans Junginger, Professor
President of the Organizing Scientific Committee
The first European Congress of
Pharmaceutical Sciences organized
by the Netherlands Association of
Pharma-ceutical Sciences will be held
in Amsterdam on October 7–9. The
program is finalized and also the technical
arrangements with respect to the congress
venue (the very modern and well equipped
RAI Congress Center) are coming along
fine.
The definite program, registration
forms, hotel reservation forms and call
for papers (poster presentation) will be
distributed by our member societies. The
deadline for submission of abstracts is July
1. The abstracts should be sent to: Prof. Or
H. E Junginger, Gorlaeus Laboratories, PO
Box 9502, NL 2300 RA Leiden, fax +31 71
274277. The size of the poster boards are
1 m high x 1.50 m wide. The registration
fees are Dfl 500 for senior scientists and
Dfl 200 for junior ones before June 1, and
Dfl 550 and Dfl 250 respectively, until
September 1. Onsite registration is Dfl
650 for senior participants and Dfl 350 for
students.
If you do not receive a program, please
contact the F.I.P Congress Department,
Alexanderstraat 11, NL-2514 JL The
Hague. Tel +31 70 3631925, fax +31 70
3659047.
You are all urged to publicize the
congress as much as possible and make
sure that interested persons receive
information of the definite program.
The congress starts with welcome
cocktails on Tuesday, October 6 at 16.00-
19.00 hrs in the Foyer of the Forum Zaal at
the RAI Congress Center.
You are cordially invited to attend!
III

EUFEPS Newsletter, 1992, vol. 1, issue 2
Dear Members,
successful first
EUFEPS Congress
Hans Junginger, Professor
President of the Organizing Scientific Committee
Following the establishment in 1991 of the
European Federation for Pharmaceutical
Sciences, one of the first aims of the Society
was to bring together pharmaceutical
scientists and to organize a truly scientific
congress in one of the member countries.
The Dutch Association for
Pharmaceutical Sciences is honoured to
arrange the First European Congress of
Pharmaceutical Sciences, to take place in
Amsterdam at the RAI-Congress Center,
during October 7–9, 1992.
As chairman of the Scientific
Committee, I am pleased to announce
that we succeeded in attracting 39 leading
scientists from primarily European
countries, and covering all pharmaceutical
disciplines, who will contribute to 12
symposia and present the results of their
latest research. Already two weeks before
the deadline for submitting the abstracts
for poster presentation, we had received
more than 100 abstracts. This clearly
indicates that the congress will, in fact,
be an accepted meeting place of scientists
from all over the world. I would therefore
like to encourage you, too, to participate in
the Congress.
Amsterdam is today a modem
metropolis which houses the dynamic
RAI Amsterdam Convention Center.
The Dutch capital has succeeded in
combining its contemporary character
with the unique historical atmosphere of
the 17th century inner city and its famous
system of canals. It is my sincere hope
IV
Hans Junginger, Professor
that all those attending the First European
Congress will be able to enjoy the exciting
dualism of this city, blending the serious
work of acquiring the latest information
and research results from all branches
of the pharmaceutical sciences with the
delightful experience of being captured by
the intimate allure of the streets, squares
and canals of this fascinating place.
What a superb environment in which
to attend a very important Congress, to
relax and to make new friends, and to
experience the charm of Amsterdam!
With best regards,

EUFEPS Newsletter, 1992, vol. 1, issue 3
The Future of
Pharmaceutical
Sciences
Douwe D. Breimer, Professor
EUFEPS Vice-President
Pharmaceutical sciences may traditionally
be regarded as conglomerate of various
disciplines, each of which deals with
a certain aspect of biologically active
molecules and each of which was
considered essential for the training and
education of pharmacist. In fact such
disciplines were defined as belonging to
pharmaceutical sciences because they
were undertaken in the context of a faculty
of a college or pharmacy, although some
flourished more in dependently in faculties
of medicine (e.g. pharmacology) or natural
sciences (e.g. biochemistry). Research
was mostly of a monodisciplinary nature
and strongest in fields like pharmaceutics
and pharmaceutical technology,
pharmaceutical chemistry, pharmacognosy
and drug analysis. In the 60s and 70s,
biopharmaceutics, pharmacokinetics and
drug metabolism began to flower and
the development of specific and sensitive
analytical methodology made it possible for
pharmaceutical sciences to become more
involved in biological experimentation,
including in vivo studies in laboratory
animals and man. New fields of interest
developed, borders flanking the biomedical
sciences were crossed.
However, despite the fact that these
new areas of research have given a new
impetus to pharmaceutical sciences and
have contributed to a better recognition
of pharmaceutical research in general,
the newer fields still tend to develop in a
monodisciplinary way.
The major challenges in
pharmaceutical research today are not
associated with one discipline only,
but with several at the same time. This
requires multidisciplinary approaches,
as illustrated by a few examples, all of
which constitute major objectives of drug
research:
• new drug molecule design based on
cloned receptors and molecular
graphics, in relation to mechanisms
and origins of disease;
• drug delivery system design, based
on physicochemical principles, and
with rates and time specifications
based on pharmacodynamic and
pharmacokinetic considerations;
• drug targeting, primarily based on
(patho) physiological, (patho)
biochemical and ilmmunological
principles and only secondarily on
principles derived from pharmaceutical
technology;
• application of products originating
from biotechnology (proteins and other
macromolecules), by non-parenteral
routes of administration based on the
principles of membrane biochemistry
and cell biology;
• individualization and, thereby,
optimization of drug therapy
based on new methodologies in
characterizing metabolizing enzyme
activities (deficiencies) in vivo and
new methodologies in quantifying and
monitoring pharmacological effects;
• assessment and prediction of drug
(xenobiotic) toxicity and adverse
reactions based on insight into
(molecular) mechanisms of drug
toxicity, e.g. as related to drug
metabolism.
All these subjects require integrated
approaches, both at the molecular level
and at the higher organizational levels of
living organisms, with the ultimate goal
of unifying all information towards the
in vivo human situation. Such approaches
are all at the interface between chemical/
physical and biological/biomedical
sciences. It is this unifying and
V
Douwe D. Breimer, Professor
integrating concept that holds the future
of pharmaceutical sciences. Whenever
monodisciplinary considerations continue
to prevail, the risk of disintegration is
near at hand. The synergistic additional
value of being part of a conglomerate of
interacting disciplines should be utilized
and fully explored. This will give rise
to most important implications for drug
discovery, drug delivery, and improved
and more rational drug therapy.
It is in this spirit that EUFEPS
will organize its biannual European
Congresses of Pharmaceutical Sciences,
as was illustrated just recently by the first
Congress in Amsterdam.

EUFEPS Newsletter, 1993, vol. 2, issue 1
European Journal
of Pharmaceutical
Sciences
Ernst Mutschler, Professor
EUFEPS President
At the time of the foundation of the
European Federation for Pharmaceutical
Sciences (EUFEPS) in Strasbourg in
1991, its Executive Committee and
Council considered the creation of an
internationally well-accepted journal of
high scientific standing to be one of the
Federation’s most important goals. The
first issue of the European Journal of
Pharmaceutical Sciences, which appeared
in March 1993, illustrates that the initial
step toward achieving this objective has
been taken. What, then is the intention
of such a new journal? Certainly it is
not just to publish yet another journal in
addition to the already existing journals,
but rather the ideal of providing a
European platform for the publication of
exciting and outstanding pharmaceutical
scientific results and to facilitate and
exchange information between European
pharmaceutical scientists with colleagues
elsewhere in the world. We would like
to express our sincere gratitude to our
colleagues, Prof. Dr. H.E. Junginger and
Prof. Dr. G.J. Mulder in Leiden for their
willingness to serve as Editors in chief
of the journal. The same applies to all the
members of the editorial board.
Without a doubt, 1993 will be a year in
VI
Ernst Mutschler, Professor
which the European community will move
more closely together. Hopefully, this will
also hold true for its scientific community
and the first issue of the European Journal
of Pharmaceutical Sciences reflects this
development. The journal will also serve
to underline the Federation’s main aim,
which is to strengthen the pharmaceutical
sciences in Europe, to support innovative
drug research and to promote advanced
pan-European pharmaceutical education.

EUFEPS Newsletter, 1993, vol. 2, issue 3
EUFEPS
– the Right Federation
at the Right Time
Ernst Mutschler, Professor
EUFEPS President
Two years ago - in September 1991 - the
European Federation for Pharmaceutical
Sciences was founded. A number of
questions now need to be answered.
What, from the aims laid down in the
statutes, has been achieved during this
time? What is left to do? Where are the
problems and what is the current status
of the Federation? Which developments
can be expected in the future?
More member associations have joined,
so EUFEPS now has 20 member societies
with altogether more than 16.000
members. In addition, 15 pharmaceutical
companies have joined EUFEPS as
supportive members despite the severe
difficulties European companies have met
during the year.
The First European Congress of
Pharmaceutical Sciences took place in
Amsterdam in October 1992, organized
by the Netherlands Association of
Pharmaceutical Sciences, undoubtedly a
good start for EUFEPS. -- At the end of
September 1994, the Second European
Congress will take place in Berlin,
organized by the German Pharmaceutical
Society. The scientific program for this
is almost finalized. Apart from the main
programme, joint symposia on topics
of great interest will be held including
subjects such as Alzheimer’s disease and
on alternatives to experiments on animals.
From this congress we expect another step
forward and even stronger ties to be forged
between the family of pharmaceutical
scientists.
Further scientific meetings on specific
topics are in preparation such as “Proper
Use of Experimental Animals” and
“Tumor Targeting”.
After intensive discussions and
negotiations with Elsevier, the introduction
of the European Journal of Pharmaceutical
Sciences, and thus one main aim of
EUFEPS, was achieved. With Prof.
Junginger and Prof. Mulder as editors-inchief
the first issue was published in March
this year. Particularly important was the
decision to set an annual subscription fee
of Dfl. 100 for individual members which
is very cheap. In this context it ought to
be mentioned that the introduction of the
Journal was only made possible by the fact
that both Swedish, Norwegian, Danish
and Finnish colleagues ceased publication
of their own national journals: this shows
true European spirit! We hope that the new
Journal will have a good future and we
would like to see innovative contributions
from as many different countries as
possible in order to ensure that our Journal
becomes the product we envisaged.
The EUFEPS Newsletter, published
three times a year, has become an
important voice for the Federation. In
addition to the Committee on Congresses
and Symposia and the Committee on
Indus trial Relations, the Committee on
Pharmaceutical Policies was created
with renowned members of regulatory
bodies as well as universities with Prof.
Henning Blume (Germany) as chairman.
The main objectives of this Committee
are to set up regular contacts with
authorities in the EC member states and
to contribute to the current international
harmonization processes. Contacts with
other internationally operating scientific
organizations like AAPS, the EFMC,
Eurotox and ISSX were also established.
An organization like EUFEPS
cannot exist without financial resources.
Since we deliberately kept the fees for
the member societies at a very low level,
projects conducted by EUFEPS are not
possible without additional financial
VII
Ernst Mutschler, Professor
contributions. The main burden of this
is carried by the Swedish Academy of
Pharmaceutical Sciences, which places
50.000 DEM at EUFEPS’ disposal each
year and takes care of the administration
of the Federation. Without the dedicated
work of Stig Agurell, Bjorn Lindeke,
Ingegerd Kalles and Anita Ljung, an
active EUFEPS would simply not exist!
At present, our main problem is that
the exchange of information between the
member societies of the Federation and
their input in general is not as great as we
had expected. However, this is rather the
rule than the exception for international
organizations. We will relentlessly pursue
our efforts to encourage members to
participate in the activities of EUFEPS to a
greater extent. It also seems important that
EUFEPS participates in the discussions
surrounding the harmonization of
pharmaceutical curriculum in the
different European countries, a difficult
and momentous task.
Two years of EUFEPS! On the
whole, the slogan “EUFEPS - The Right
Federation at The Right Time” seems to be
justified. Nothing is perfect, this certainly
holds true for EUFEPS as well. But the
first two years were positive. Due to the
economic recession, political changes and
the curb on expenditure of state controlled
health services, drug research was
hampered and the pharmaceutical sciences
are facing tougher times than ever before.
It is now more important than ever that the
importance of drug research for the well
being of public health standards is made
clear, both on a national and international
level. By concentrating resources and
intensively perusing this goal further
improvement can be achieved.

EUFEPS Newsletter, 1994, vol. 3, issue 2
Research Training
in the Pharmaceutical
Sciences in Europe
Douwe D. Breimer, Professor
EUFEPS Vice-President and Director of Research of the Leiden-Amsterdam, Center
for Drug Research
In the previous issue of This Newsletter,
Prof. Stig Agurell, EUFEPS’ General
Secretary, re viewed the major problems
and challenges that the pharmaceutical
industry is currently facing worldwide.
Cost containment and foreseeable reduced
return on investments is affecting the
industry severely and reorganizations are
being implemented in many companies,
also in Europe. Yet, the future of this
industry will remain highly dependent on
its innovative capabilities and, therefore,
very much on its cur rent and future
“human capital”, i.e. on highly competent
and creative scientists. Hence the quality of
undergraduate and graduate training in the
pharmaceutical sciences, and in particular
with respect to the development of research
skills, is a most relevant topic to consider.
Before doing that more specifically, I
would like to emphasize three issues for
background consideration.
1. For Europe, the pharmaceutical
industry is the high-tech sector par
excellence.
In most, if not all, European countries most
economic growth must originate from
new products and services. These must be
innovative in order to be competitive and
therefore the combination of high quality
fundamental, strategic and applied research
will have to be a major driving force for the
future economy of Europe. In this respect,
the pharmaceutical industry will remain a
most important sector, because it still has
a relatively strong current position, it is
strongly R&D oriented (it is the “highesttech”
sector of all industries in terms of
R&D expense in % of cash flow), it adds
very high value to its products and it is
relatively clean from an environmental
perspective. These properties should
make for Europe; our politicians should
realize this and therefore stimulate rather
than discourage further investments in
this field of industrial activity.
2. The opportunities for
pharmaceutical scientists to
discover and develop new
medicines have never been greater.
This is a free translation from the Guest-
Editorial that Dr P.J. Brown (the Editor of
SCRIP) wrote in the EUFEPS Newsletter
in 1993. His observation is related to
the enormous impact that progress in
molecular biology and biotechnology
has had on the identification of new
therapeutic targets and the design and
production of novel molecules. He adds,
however, that the real challenge is to
discover new products which also provide
cost-benefit for the patient and the payer,
i.e. if, for example, a novel high-priced
biotech product does not deliver superior
treatment to a (generic) alternative, it will
not find a place in to day’s sensitive health
care market place. The current turmoil in
the industry is a partial reflection of this
tension between the supply of (novel)
medicines and what society is willing
to pay for them. To overcome this, a
reorientation to wards research objectives
and areas of therapeutic priority is needed.
In addition it is necessary that the drug
development process becomes more
efficient and more effective, i.e. innovative
strategies are needed to bring a new drug
product to the market at lower cost and in
a shorter time.
3. The turnover of science is
considerably higher than the
turnover of scientists.
This is true for almost any field of natural
science and implies that in order to keep up
to date and even be at the forefront all the
VIII
Douwe D. Breimer, Professor
time, high investments in human capital
are constantly needed. For companies,
this may not be feasible financially, except
if a very high degree of specialization is
pursued in a very limited therapeutic
area. Therefore Dr J. Drews (R&D
President of Hoffmann-La Roche) has
suggested in a paper in PhaQ11. Tech. Int.
in 1990 that more often than in the past,
manufacturers have to look for partners
who can offer skills and results which are
complementary to their own. Only the
formation of functional links with other
groups can produce the broad scope of
scientific opportunities that is needed
to obtain a sufficiently large number of
intelligent options for the development
of novel drugs. Hence, the integration
of research groups into networks of
international scientific cooperation should
be pursued between different industries
and also with high quality university
groups. This is a call for multidisciplinary
approaches and strategic alliances between
various institutes. And this is indeed what
is currently happening on a large scale, as
may be read in SCRIP.
The three issues discussed should have
a major impact on the research training
of pharmaceutical scientists in Europe,
which is a primary responsibility of our
universities. In order to remain highly
innovative, the pharmaceutical industry
must be able to recruit sufficient numbers
of excellent young scientists. These should
include highly specialized persons in
some of the basic sciences (molecular
biologists, immunologists, geneticists etc),
and also those that have a basic training
in all aspects and disciplines relevant
for drug discovery and development
(pharmaceutical scientists). They should
already be confronted with and engaged
in one or two experimental research

subjects during their under graduate
training in order that motivation and
suitability for a research career (Ph.D.
training) can be evaluated at the time
of graduation. Preferably such training
should be undertaken in a high quality
and stimulating re search environment and
include a training period abroad, either
at another university or in an industrial
research institute. Internationalization,
mobility, flexibility, interdisciplinarity in
basic research competence are key words
in this respect. Subsequent graduate studies
and research should be undertaken by the
best qualified students and should lead to
independent and creative researchers at the
time of obtaining this Doctor’s degree. In
the Newsletter of the Academia Europaea
(November 1993) it is outlined by the
Swedish Minister for Education and Science
that this country will invest heavily during
the coming years in education and research
in an international context and that the
number of doctoral exams in Sweden will
have to be doubled by the year 2000. This
is surely also in the interest of the (Swedish)
pharmaceutical industry and should serve
as an excellent example for other European
countries to follow.
An important question is to what
extent our universities, and in particular its
faculties of pharmacy and pharmaceutical
sciences in Europe, are willing and
capable of accommodating the future
needs of innovation in drug research
and development. There is, in my view,
no doubt that the overall willingness is
there, but that there are in many places
also major obstacles to engage in high
quality re search and therefore also in
the research training of excellent young
pharmaceutical scientists. These obstacles
include the fact that in most faculties or
institutes the orientation centres primarily
on the training of pharmacists rather than
pharmaceutical scientists. In only a few
countries are undergraduate programmes
offered which may also effectively lead
to a research career as described above.
Furthermore, in many instances pharmacy
programmes are heavily taught rather
than research oriented; this is partially
caused by large numbers of students
and/or by lack of resources for research
with no competitive basis for successful
application for external grants. Also
the organizational structure in terms of
monodisciplinarity is an inhibiting factor
in developing cross-disciplinary re search
programmes, as is the lack of participation
in international research networks.
In order to improve this current
unsatisfactory situation it is necessary
to remind our selves of some of the
conditions which are required to perform
high quality research. A major issue
in this respect is the development and
implementation of an effective research
strategy which should exhibit most of the
following characteristics:
• the establishment and creation of a
stimulating and creative environment
through building research around
excellent and motivated scientists;
• the abandonment of hierarchical
levels, i.e. much autonomy for
individual scientists;
• appreciation of individual scientist’s
initiatives (self expression), within the
con text of the overall research mission
of an institute or a faculty;
• encouragement of working in
multidisciplinary teams;
• emphasis on research output through
publications in first class peer reviewed
international journals and through
patent applications;
• effective decision making on research
orientation, budget allocation and
incentives.
Once this research strategy is agreed
upon, an effective organizational structure
will be required for its implementation. In
this respect, an important development
in Europe is the creation of so-called
“research schools”. These are defined as
university based re search institutes of
international standing which provide the
structural environment for high quality
research training. The reasons for the
establishment of such “schools” are:
• improved quality of research training
in a multidisciplinary environment
(combined undergraduate and graduate
research programmes with great
emphasis on highly qualified Ph.D.’ s;
• enhanced efficiency of the use of
research resources;
• matching human resources for research
to science policy priorities, i.e. taking
serious account of the research needs in
the public sector (e.g. the pharma-
ceutical industry);
• enhancement of international
collaboration and exchange of staff and
students.
Such research schools may have a “local”
character, i.e. be established within a single
IX
university that contains all necessary
disciplines. More often, however, it will
have a “network” character with several
departments of different universities and
complementary expertise collaborating.
In my own country, the government is
strongly stimulating the establishment of
re search schools. The Royal Netherlands
Academy of Arts and Sciences has
been given the responsibility to review
applications for such· a recognition. High
quality research and graduate teaching,
as well as an organizational structure as
outlined above, belong to the most important
recognition criteria with preferably
more than one university participating
in a school. Two such schools have been
established for the pharmaceutical sciences:
in 1992, the Leiden-Amsterdam Center for
Drug Research (LACDR), comprising the
Center for Bio-Pharmaceutical Sciences at
Leiden University and the Department of
Pharmacochemistry of the Yrije Universiteit
in Amsterdam and in 1994 the Groningen-
Utrecht Institute for Drug Exploration
(GUI DE), that consists of the faculties of
pharmacy of the University of Groningen
and that of Utrecht. LACDR is further
Europeanized in ULLA, a consortium
for postgraduate research training in the
pharmaceutical sciences together with
the Faculties of Pharmacy in Uppsala and
London. There is currently a committee of
EU Member States investigating the need
for similar developments in other European
countries. For the pharmaceutical sciences
and the training of pharmaceutical
scientists, this should represent an important
development towards meeting the needs of
the pharmaceutical industry in Europe in
the future.
One could think of different
organizational models to accommodate
this, but most of the basic elements
indicated in this Editorial should be
implemented in order to make such an
organization successful.
Most likely, new organizational
structures are needed for the
pharmaceutical sciences in Europe in
order to improve the quality of research
training. Such structures could still
be closely associated with Faculties of
Pharmacy, but their mission should be
clearly differentiated from the training of
pharmacists and focus on pharmaceutical
sciences. In my view, this is a prerequisite
guaranteeing that the three issues as
discussed are fully met and appreciated
through university industry partnerships.

EUFEPS Newsletter, 1994, vol. 3, issue 3
EUFEPS Strategic
Plan for 1994–1998
Douwe D. Breimer, Professor
EUFEPS President
On the occasion of the Congress the
EUFEPS Council met and one of the major
items on the agenda was the Strategic Plan
for 1994 –1998 prepared by the Executive
Committee. With some amendments, the
Plan was approved and in this Editorial
some of its main features are summarised.
Mission of EUFEPS
The mission of the European Federation
for Pharmaceutical Sciences (EUFEPS) is
to support and advance the pharmaceutical
sciences and innovative drug resarch in
Europe and to represent scientific interests
and scientists within academia, industry
and government and other private and
public institutions engaged in drug
research and development, drug regulation
and drug policy making.
Short-term overall Objectives
a To seek coherence of the pharmaceutical
sciences in Europe by
promoting co -operation between
national, regional and European
societies or associations which aim to
advance pharmaceutical sciences with
EUFEPS recognised as the leading and
coordinating organisation.
b To promote cooperation with
other European and international
pharmaceutical organizations and
federations with EUFEPS recognised
as an “equal merit” organisation.
c To provide individual pharmaceutical
scientists in Europe with a platform
to exchange information and to meet
and support their individual scientific
interests in the multi-disciplinary
environment of drug research and
related activities.
d To make the European Journal of
Pharmaceutical Sciences the leading
European journal on the subject.
e To enhance the recognition of the
pharmaceutical sciences and to
contribute appropriately to public
policy relevant to drug research and
development, drug regulation and drug
utilisation, with EUFEPS as the
primary voicing organisation at the
European level.
Intermediate to long-term
Objectives and Visions
a Assuming that the short-term
objectives of EUFEPS will be met
and recognising that research in the
pharmaceutical sciences will further
internationalise and that further
integration of several relevant issues
related to drug research and
development, drug regulation and
utilisation will take place at the
European level, it is envisaged that
EUFEPS will become the premier
organisation for the advancement
of pharmaceutical sciences and of
pharmaceutical scientists in Europe.
b EUFEPS will be a recognised authority
and collective resource on pharma-
ceutical science issues and will play a
proactive role in public issues affecting
drug re search and development, drug
regulation and utilisation. EUFEPS
will have a primary focus on
advancement in science and the
contribution of such to benefit/risk
considerations of drug therapy for
society as a whole.
c EUFEPS will be international in scope
and have strong links (affiliations)
with likewise minded scientific
societies worldwide. It will play a
leading role in organising joint
meetings with closely allied
associations in Europe and elsewhere
through its own offices.
X
In direct connection with these objectives,
the following topics (among others) have
been agreed for priority decision making
and actions:
1 Further develop and professionalise the
EUFEPS Secretariat, ultimately
leading to the appointment of a paid
(initially part time) Executive Director.
Since the establishment of EUFEPS,
all secretarial activities have been
undertaken through the Swedish
Academy of Pharmaceutical Sciences
in Stockholm. Prof. Stig Agurell
was the EUFEPS Secretary-General
from 1990–1994, and Prof. Bjorn
Lindeke was newly elected in this
office. Strengthening of the financial
basis of EUFEPS will, in particular,
be a condition to make the entire
organization, and the Secretariate,
more self-sufficient.
2 Active membership recruitment should
be pursued with respect to member
organizations (several countries are
still note represented) and supportive
members (only a limited number of
pharmaceutical companies currently
fulfil this category). In addition, the
Council has accepted the proposal
to make membership of EUFEPS of
individual persons also possible, on the
condition that a recruitment strategy
be developed in close consultation
with the member organisation(s) in a
particular country.
3 Two EUFEPS Committees will
propose and develop activities to
strengthen the recognition and position
of the Federation, i.e. the Committee
on Industrial Relations, and the
Committee on Pharmaceutical Policies.
There was clearly a very positive spirit
towards these actions to further develop
and strengthen EUFEPS’ position. The
newly elected Executive Committee
intends to become very active in
implementing the Strategic Plan within
the time frame indicated.

EUFEPS Newsletter, 1995, vol. 4, issue 3
On EUFEPS Progress
Douwe D. Breimer, Professor
EUFEPS President
It is important that EUFEPS’
membership be kept up-to-date as to
what progress the Federation is making.
In 1994 at the Council meeting in
Berlin, the EUFEPS Strategic Plan for
1994–1998 was adopted in which clear
short-term and intermediate to longterm
objectives were defined, as well as
priority activities to reach these. In the
November 1994 issue of our Newsletter,
a summary of this Strategic Plan was
provided. In this President’s Report I will
briefly cover topics that have been high
on the Agenda of the EUFEPS Executive
Committee and which also reflect items
discussed at the latest EUFEPS Council
meeting held in Leuven, September 16,
1995.
Membership
At this moment 22 organisations
originating from 19 countries are members
of EUFEPS. The latest application was
accepted in Leuven, from the “Societe
Française des Sciences et Techniques
Pharmaceutiques (SFSTP)” in Paris,
whereas an applica tion by a Spanish
organisation is pending. Recruit ment of
corporate members is an ongoing process
and there are now 16 in this category. The
pharma ceutical industry is going through
a tremendous pro cess of reorganisaiton
and it is quite difficult to draw their
attention to scientific organisations at this
time. Personal contacts within the industry
are extremely valuable to convince
company executives of the importance of
organisations like EUFEPS. During the
summer of 1995 a first effort was made
to recruit individual members, a new
membership category approved of by the
Council in 1994. At the time this report is
being written, I am pleased to report that
nearly 100 persons have joined EUFEPS
as individual members. As soon as their
number exceeds 100 a representative of
this membership category will be elected
for representation on the EUFEPS Council.
Several individual members are located
outside Europe and it is mostly through
personal contacts with the members of
the Executive Committee of EUFEPS
that they have become convinced that
it is important to support our young and
ambitious European organisation.
Meetings
“It is important to meet” was the Editorial
title that Malcolm Rowland (Vice-
President of EUFEPS) wrote in the March
1995 issue of this Newsletter. I will not
repeat all of what he emphasised, except to
again stress that an essential mechanism
of achieving EUFEPS’ objectives is
through the organisation and sponsorship
of meetings. Strong commitment from our
members is needed to make such meetings
a suc cess. We are now leading up to the
3rd European Congress of Pharmaceutical
Sciences in Edin burgh (September 15–17,
1996), and from the 2nd Announcement,
it can be derived that the programme
committee has put together symposia
on topics that are of high current interest
and relevance in the pharmaceutical
sciences. Very near is the 2nd EU FEPS
Nuremberg Conference (December 8–9,
1995) on “Quality and Interchangeability
of Topical Products for Local Action”. It
is our intention to organise a conference
each year at the beginning of December
in Nurem berg on a highly specialised
topic that should be of great interest to the
pharmaceutical industry as well.
EUFEPS was very recently given
high recognition at the First Central
European Symposium on Pharma ceutical
Technology, held in Bled, Slovenia.
XI
I was there to represent the Federation and
to stress that EUFEPS is very interested to
be associated with such regional initiatives
and activities.
In his Editorial, Malcolm Rowland
has also indicated that EUFEPS is
actively seeking links with other related
European and inter national scientific
organisations. This had led to definitive
plans for meetings jointly orga nised with
EUROTOX and ISSX in 1997. BIO-
International ‘96, organised by FIP and
co-sponsored by EUFEPS and others will
take place in Tokyo, Japan, in April 1996.
Discussions are ongoing with the
American Association of Pharmaceutical
Scientists (AAPS) to see what collaboration
with them is possible in terms of meeting
and course or ganisation, as well as other
activities. I will represent EUFEPS at the
meeting of the AAPS Executive Council in
Miami during their Annual Meeting. On
this occasion further discussions will also
take place with FIP, AAPS and Japanese
representative on the feasibility of jointly
organising the First Millennial World
Congress of Pharmaceutical Sciences in
the year 2000.
Executive Committee’s strong belief
that it is in the interest of it membership
to build up strong links with other
organisations in order to join forces rather
than duplicate activities and meeting.
EUFEPS Working Committees
Two working committees have been
put into place, primarily to advise the
Executive Committee on specific issues
and activities. One is the Committee
on Industrial Relations (CIR), chaired
by Prof. J. Vessman, Astra Hässle,
Mölndal, Sweden, and the other one is the
Committee on Pharmaceutical Policies
(CPP), chaired by Professor H. Blume,

Frankfurt. CIR consists of a core group of
3 members and an advisory group of 14
members, all originating from different
European pharmaceutical industries. The
Committee met in Leuven for a full day
on September 16, and will shortly come
up with recommendations as to how
EUFEPS could become more important
to the pharmaceutical industry in general
and in particular to the pharmaceutical
scientists employed by industry. CPP is
still in the process of establishing itself,
and has been requested to advice on
which policy issues EUFEPS should be
actively engaged in, in terms of voicing
views and opinions. I should like to seize
this opportunity to thank the members of
the committees for their very important
contributions to EUFEPS, at a time when
the Federation is not able to financially
compensate for the expenses that these
committee member are incurring in travel
ling to the meetings, etc. EUFEPS has
to draw very strongly on dedicated and
motivated individual scientist to make
progress and it is encouraging to find this
spirit among European colleagues.
EUFEPS Publications
This Newsletter will remain cornerstone
for communication with our members.
From 1996 onwards, it will appear at
a frequency of four issues per year
and EUFEPS members are invited to
contribute by voicing opinion on relevant
topics within the pharmaceutical sciences.
The EUFEPS Executive Committee will
continue to report on important activities,
meetings, information on member and
related organisations. It is still a handicap
that News letter distribution has to go
through the secretariats of member
organisations, which - for understandable
reasons - sometimes causes considerable
delay before a Newsletter actually
reaches the individual member of that
organisation. On the other hand, EUFEPS’
own individual members will receive the
newsletter through direct mail from the
EUFEPS Secretariat in Stockholm.
The European Journal of
Pharmaceutical Sciences (EJPS) is the flag
ship scientific journal of our Federation.
The journal has grown steadily over
the past few years but could still benefit
from improved commitment by top
pharmaceutical scientists in Europe in
terms of submitting high quality papers.
It is encouraging that several of the new
individual member of EUFEPS have taken
a personal subscription to the journal. The
journal could also achieve a higher profile
by realising a closer association with
congresses and symposia organised by
EUFEPS, and the Executive Committee is
working on this. ln any case, the abstract of
all invited paper and free communications
of the Congress in Edinburgh will
be published in a Supplement of the
journal. Furthermore, efforts are being
made to integrate other existing regional
pharmaceutical journal into EJPS. We
strongly believe that it is in the interest of
our membership to decrease the number
of exiting journals in the pharmaceutical
sciences within Europe. It is anticipated
that within one or two years the frequency
of appearance of EJPS will double, i.e.
will go from bimonthly to monthly.
Secretariat and Finances
EUFEPS is still heavily dependent on the
strong and generous support provided by
the Swedish Academy of Pharmaceutical
Sciences, for which we are extremely
grateful. However, it is the clear ambition
XII
of the Executive Committee to pursue
financial independence in the coming
year, a has been pelled out in EUFEPS’
Strategic Plan. First steps have been taken
in the context of the budget for 1996, in
which a decreased contribution by our
Swedish colleague is foreseen, how ever,
compensated by increased income from
EUFEPS’ member hips and activities.
In due course, we aim to appoint an
(initially part time) Executive Director of
the Federation to further professionalise
and enhance our activities. For the time
being, I should very much like to thank
Björn Lindeke, Hans H. Lindén and Anita
Ljung at the Secretariat in Stock holm for
their ongoing and very dedicated support
of EUFEPS!

EUFEPS Newsletter, 1996, vol. 5, issue 4
Visions and Realisations
– New President takes
Stock
Malcolm Rowland, Professor
EUFEPS President
Every successful organisation needs a vision
and a strategic plan of action, both of which
must be subjected to periodic review with
adjustment or refinement, as appropriate.
EUFEPS has embodied these precepts in
a document entitled ‘Towards the Strategic
Plan 1994–1998’ which was approved by
Council at its third annual meeting, in 1994.
At this mid way point thought it would be
useful to share with you to what extent the
objectives of our fledgling organisation,
established in 1991, have been met, and what
still needs to be done or amended. I have done
this by listing below, for you, the original
objectives for the 4-year period followed by
a review of each in terms of achievements
to date, together with some future plans.
Overall, we have achieved much, but there
is still much more to do.
Objective 1
To seek coherence of the pharmaceutical
sciences in Europe by promoting
cooperation between national, regional
and European Societies or associations
which aim at the advancement
of pharmaceutical sciences with
EUFEPS recognised as the leading and
coordinating organisation.
We are certainly well on our way to
meeting this objective. For example, since
September 1994, EUFEPS has increased
it number of national Member Societies
from 20 in 18 European Countries to 24
in 20 countries; held successful European
Congresses in Berlin (1994) and the recent
one in Edinburgh; held the first (1994),
and second (1995) EUFEPS Nuremberg
Conference on Tumour Targeting, and
Topical Products for Local Action,
respectively, followed by the most recent
in 1996; and sponsored or patronised
six Regional or European meetings. We
also increased the number of issue of the
newsletter from 3 to 4 a year. And, we have
much more in store for the future, including
the 4th International Conference on Drug
Absorption, in Edinburgh (June 1997), to
run under the a uspices of EUFEPS; the
4th European Congress on Pharmaceutical
Sciences, planned for 1998 in Milan, Italy,
a well as the 4th (1997) and 5th (1998)
Nuremberg Conference. Furthermore,
by 1998 we would hope to have national
Member Societies in essentially all
European countries.
Objective 2
To promote cooperation with other
European and international, broadly
pharmaceutical organisations and
federations, with EUFEPS recognised
a an “equal merit” organisation.
Here again, effort to meet this objective
are bearing fruit, partly in the form of
jointly organised activities. Examples are
the forthcoming EUFEPS/lSSX meeting
in Gothenburg (July 1997) and the recent
Symposium on Excipients, held at the 3rd
European Congress, in conjunction with
the International Pharmaceutical Excipient
Conference. Our sister organisation in
north America, the American Association
of Pharmaceutical Scientists (AAPS),
with which we had a successful oneday
Workshop on Cell Line and Tissue
Cultures at the 3rd European Congress,
and we look forward to an increasing
collaboration between AAPS and our
elves. In addition, we offer observer
status at Council to many European and
International societies and enjoy reciprocal
arrangements with them. The future
portends even greater collaboration - a
XIII
particular landmark being the Millenium
World Congress on Pharmaceutical
Sciences in 2000, organised by the FIP
- Board of Pharmaceutical Sciences, at
which EUFEPS, AAPS and the Japanese
Pharmaceutical Sciences will be major
regional players.
Objective 3
To provide individual pharmaceutical
scien tists in Europe with a platform
to exchange information, and to meet
and support their individual scientific
interests in the multidis ciplinary
environment of drug research and
related activities.
The growing number of participants
at the increasing number of EUFEPS
organised and sponsored meetings is a
clear expression of success in meeting this
objective. Another measure of success
is the growing number of Individual
Members, a category introduced in 1994.
But much has still to be done here, and
we are looking at such developments as
the use of the Internet to communicate
directly with our members
Objective 4
To make the European Journal of
Pharma ceutical Sciences (EJPS)
the leading Europe an Journal on the
subject.
Now in its 4th year, subcriptions to EJPS,
our official journal, have grown steadily.
Ho wever, it is fair to say that EJPS has
achieved modest succes to date. Its success
would be much greater if each and every
member of EUFEPS subscribed to EJPS
and submitted their best manuscripts to it.
Help us to meet our aspirations for EJPS!

Objective 5
To enhance the recognition of the
pharma ceutical sciences and to
contribute appropria tely to public
policy relevant to drug research and
development, drug regulation and
drug utilization, with EUFEPS as the
primary voi cing organisation at the
European level.
This is a tough objective to meet, but we are
making headway through the activities of
the Committee on Pharmaceutical Policy,
which organise some of the Nuremberg
Con ferences. One positive step has been
our con tact with various European bodies,
such as the EMEA in London, making
those aware of our contribution to debates
on scientific issues and policy pertinent to
the European pharma ceutical arena.
Although not explicitlytated in the
1994–1998 strategic document, implicitly
training and education in research,
interfacing with industry, and finance
are central to the suc cess of EUFEPS.
Training was identified by the Committee
of Industrial Relationships (CIR) as an
urgent and critical need that we must
address seriously in the coming years, in
partnership with industry and academia.
Here our Corporate Membership, which
continues to gro, We do, however, need
to make even more extensive contacts and
have among our membership a greater
number of industrial pharmaceutical
scientists.
Finally,
underpinning all our activities is sound
finance, without which we cannot continue.
Since its inception, with limited resource,
EUFEPS has been financially dependent
on the gene rosity and foresightedness of
the Swedish Academy of Pharmaceutical
Sciences. While gratefully received and
acknowledged, the strategy has been to
continually diminish this dependency
such that by 1998 EUFEPS will be
financially independent. With a string of
successful meetings, rising membership
and increasing subscription to EJPS, I am
confi dent that we will meet this objective
on time, so enabling us to look forward
with confidence to an ever successful
future. I sincerely hope that you share my
enthusiasm and optimism for the future
of EUFEPS. With your help, together we
cannot fail.
XIV

EUFEPS Newsletter, 1997, vol. 6, issue 1
The Influence of
Pharmaceutical Sciences
on the International
Harmonisation Activities
A. Atilla Hincal, Professor
EUFEPS Executive Committee Member and Director of Postgraduate Institute for
Medicine and Health Sciences, Hacellepe University, Ankara, Turkey
“The advantage of a technically based
conference such as this one, is that
the real experts can express the true
scientific needs and the regulators can
benefit from the clear unbiased views of
the international experts.
Martin Bangemann, Ph.D., Brussels /
ICH 1991”
Quality, Safety and Efficacy
It is noted that the scientific and
technological developments which have
speeded up after the 1960s have had great
reflections in different fields of industry,
and even greater and speedier reflections
in the pharmaceutical industry due to the
fact that the industry is based on research.
After 1976 the European community
accepted quality, safety and efficacy
as the basic criteria to be sought for the
registration of pharmaceutical products.
This issue is also accepted and required
by other nations in the world. The basic
reason for this event being placed in the
legal practice is the need to protect public
health. It is natural for a scientific evaluation
entailing quality, safety and efficacy to
be the basic of regulatory procedure,
necessary for a drug to be brought on to the
market. If the universality of the scientific,
humane and ethical regulations brought
about for clinical research by the Helsinki
Declaration is considered, the necessity for
harmonisation of the criteria sought for the
registration of drugs in different countries
can be better understood. Thus scientific
research better focused and directed
towards innovative research, in which the
needs of the patient are directly considered
and the resources more efficiently used,
rather than defensive research. According
to scientific research and developments,
while the number of drugs for treatment
increased starting from the 1960s until
the 1980s, it could be considered that
scientifically three main factors played a
role in the decrease of new drugs starting
from the 1980s. These are:
(i) The fact that the tests required for
pharmaceutical research became very
complex
(ii) The realisation that fewer new
drugs would be able to fulfil
regulatory demands
(iii) The fact that more specific criteria
were set for selecting potential
substances by the pharmaceutical
companies conducting the research.
Common Scientific Criteria
It has been noted, not only by the
pharmaceutical companies conducting
research and undertaking the development
of drugs, but also by other related groups,
that these problems have a universality.
An important point that needs to be
considered is the fact that, according to a
study undertaken in the SA approximately
14.2 years and US 360 M (according to
1990 U value) are spent during the R&D
and supply-to-usage stages preceding
the appearance of a pharmaceuticals on
the market. On the other hand it cannot
even be considered, that the medical
authorities in a country do not pay heed to
the demands of the patients and relatives
awaiting the new drugs with high hopes.
In order to solve the multifaceted problems
of drug registration, faced by those
companies that apply for pharmaceutical
registrations, the EU, USA and Japan
decided to instigate a study to set common
scientific criteria to guide the companies
in the regulatory procedures they have to
undertake. This subject is in the interest
of those countries, which develop the
majority of drugs and have a developed
and well functioning health care system,
XV
A. Atilla Hincal, Professor
as well as other countries whose citizens
have a natural right to obtain new
pharmaceuticals. The intention at this
point was to achieve uniform rules within
the scope of scientific criteria accepted in
international regulations, for the study,
evaluation and registration of new drugs
obtained through scientific research, and
that have been presented, or are to be
presented, for public use to serve public
health. Doesn’t this situation once again
illustrate the fact that science is universal
and that pharmaceutical sciences have
developed substantially?
Conference on International
Harmonisation
As stated above the European Union (EU)
had started the process of harmonisation
in the field of pharmaceuticals among
the European countries. The USA claims
to have research in this field dating back
over a period of time. When the USA and
Japan associated themselves with the EU
in 1991, the first tripartite International
Conference on Harmonisation of
Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH)
took place in Brussels. The guidelines
to be prepared at these conferences
were established and intense work was
undertaken for their preparation and
realisation. The work undertaken has
been extensively discussed in the three
ICH conferences held biannually. These
were: ICH 1 Brussels - 1991, ICH 2
Orlando - 1993 and ICH 3 Yokohama
- 1995. Even though these conferences
seem like tripartite harmonisation, from
the beginning the developments were
followed by other countries with keen
interest. Today, it should be noted that
several other countries have made plans to
utilise the scientific criteria to be set, and

that they have reached the conclusion that
great benefit can be derived from ICH.
The ICH meetings take place between
the regulatory and the industrial groups
and those organisations representing
them. But the infrastructure of these
conferences is based on the total scientific
knowledge of the participating regulatory
and industrial experts and academics,
together with R&D findings of clinics
and research centres through the years.
The ICH meetings within the frame work
of science aim at setting and presenting
the regulations within certain limitations.
These should be based on international
and scientific rules. By completion of
inform action and documentation for
presentation to the legal authorities, they
enable rapid supply of pharmaceuticals
to the market and the patient. One should
not lose this perspective in the light of the
volume of data derived from the research
and development of drugs.
Guidelines Produced
The first of the economic problems facing
the research- based pharmaceutical
companies when they develop a new
drug, is the speedy delivery of drugs to
patients and to markets in more countries.
New scientific therapies, approaches
and technologies, on the one hand, have
increased the importance and the impact
of the results and, on the other hand,
have strengthened the relations and the
interaction between scientific R&D
organisations and regulatory authorities.
The fast and linear increase noted in
scientific research, and results in the
second half of the 20th century in
pharmaceutical and medical sciences,
have deemed it imperative that drugs
be speedily dispersed for the health of
the people to other countries besides its
country of origin. Thus when economic
reservations of the companies were
added to the humane, ethical, legal and
medical necessities the harmonisation
activities were brought about. These
tripartite activities between the EU, USA
and Japan are an indispensable step for
strengthening the right to live healthily, by
all the people in the world. There are also
benefits for the world economy, and the
efficient utilisation of human, animal and
substance resources will be achieved with
concomitant increase of quality of life.
For the Benefit of Patients
With the sophistication of technology in the
second half of the 20th century, it is a fact
that the safety standards have increased
the expense of research and development.
But this fact makes it economically
necessary for those companies in vesting
largely in pharmaceutical R&D to expand
their markets to cover the world, instead of
only their own countries. For this reason,
the basic aims of harmonisation are to
set common criteria for the scientific
evaluation of new drugs, to pre vent
unnecessary procedures and duplication
as resulting from different approaches and
methods, to overcome the differing ha bits
and subjectivity of institutions and those
circumstances arising from the customs
and tradition of different countries. In
every ICH meeting for the setting of these
judgement criteria the starting point is
the question. “Is this for the benefit of the
XVI
patient?” With this approach it is going
to be possible for the good quality, safety
and efficacy of drugs to be assured, the
clinical research to be con ducted with
international standards and to harmonise
the work undertaken with advanced
scientific research. A point that should
not be overlooked is that harmonisation
activities undertaken within the scope of
scientific criteria can yield permanent and
realistic benefits, by contrast with work
undertaken with no regard to scientific
criteria.
Effective Pharmaceutical Sciences
The biggest achievement of the ICH has
been that, even though in name it is an
officially tripartite meeting from 1991
up to this day, a harmonisation accepted
internationally, through scientific research
based on detailed work on every level
has been achieved with the participation
of many other countries. Since the talks
held at the conference do not only en tail
the development and the registration of
new drugs in a narrow sense, but also
entail subjects such as informed consent,
protection of patients rights in clinical
research and the use of electronic media
in regulatory communications, which
are all technical subjects based on truths
of science itself, this is a sign that the
harmonisation activities have a broad range
and every chance of being successful.
Doesn’t it warm your heart to see that
pharmaceutical sciences are effective and
a leader with such a universal approach in
the application of human health issues?

EUFEPS Newsletter, 1997, vol. 6, issue 3
Biopharmaceutical
Classification System (BCS)
for Oral Immediate-release
Drug Products
Anders Grahnen, Assoc. Professor
EUFEPS Vice–President and Quintiles AB
A biopharmaceutical classification
system (BCS) for immediate release
(IR) drug products has recently been
proposed (I) and is under consideration
by regulatory authorities. The new
classification system is a result of basic
research into the mechanistics of drug
absorption. Advances in physiology,
molecular biology and pharmacokinetics
have revealed crucial new information
regarding physiological mechanisms
involved in the absorption process.
Although drug absorption has been
investigated for more than four decades,
predictive models (such as the pH-
partition hypothesis) for absorption
have so far been of limited value due
to the complexity of the physiological/
physiochemical events involved in the
intestinal absorption process of drugs.
Theoretical considerations of the
BCS
Drug dissolution is a prerequisite to drug
absorption and clinical response for most
drugs given orally. Amidon and co-workers
have developed a microscopic approach
to drug absorption and demonstrated
a good correlation between the extent
of drug absorption and the intestinal
membrane permeability in both animals
and man (1). In addition they developed
a drug dissolution and absorption model
for water insoluble drugs that limits to
the previous microscopic results under
appropriate conditions. These models
show that the key parameters controlling
drug absorption are three dimensionless
numbers: Absorption number (An);
Dissolution number (Dn); Dose number
(Do); representing the fundamental
processes of membrane permeation, drug
dissolution and dose respectively.
The rate of absorption from the
intestinal lumen (assuming no luminal
reactions) at any time is:
Absorption rate = ʃʃ A P eff C lumen dA
(double integral is over the entire gastrointestinal surface)
where A is available intestinal surface area.
P eff is the effective membrane permeability
and C lumen is the drug concentration at the
membrane (intestinal) surface.
The total mass (M) of drug absorbed
at time t is thus:
M(t) / Dose = ʃ ʃʃ 0
t
P C dAdt
A eff lumen
These relations are general since the
surface can be of any arbitrary shape
and the concentration at the lumen and
permeability can have any dependence
on position and time. It is thus important
to point out that P eff is both position
dependent and time dependent.
Based on these general mass balance
equations, it follows that: If two drug
products, containing the same drug,
have the same concentration time profile
at the intestinal membrane surface then
XVII
Anders Grahnen, Assoc. Professor
they will have the same rate and extent
of absorption. In addition, if two drug
products have the same in vivo dissolution
profile under all luminal conditions they
will have the same rate and extent of drug
absorption. Furthermore, the relationship
between in vivo drug dissolution and
the luminal concentration as well as the
relations hip between in vivo dissolution
and in vitro dissolution become crucial for
the prediction of absorption.
As shown above, membrane
permeability and solubility are the
primary determinant for predicting drug
absorption in man. Pioneer work of
Lennernäs and co-workers utilizing a multi
channel tube system with double balloons
has enabled segmental perfusion of the
gastrointestinal tract (preferably jejunum)
in man (2). Through this experimental
technique it is possible to determine the
effective membrane permeability (P err )
in man for any type of drug including
carrier mediated transported compounds
(using scaling factors) throughout the
entire gastrointestinal channel (including
the rectum). The experimental procedure
has been validated and extensively tested.

The procedure is safe and of relative ease
for experimental subjects. Furthermore,
it is possible to predict human in
vivo permeability using preclinical
permeability models, such as perfusion
of the rat jejunum, the Caco-2 model and
excised intestinal segments using the
Using chamber. Through a collaborative
academic-regulatory project*, P err in man
for a number of drugs have now been
determined (2). As shown in Figure 1,
there is a good (non-linear) relationship
between extent of intestinal absorption in
man (as determined by pharmacokinetics)
and in vivo membrane permeability.
Permeability-Solubility
Classification
The BCS divide drugs into 4 different
classes based on their solubility and
permeability (Table 1).
Class 1. High Solubility-High
Permeability Drugs.
These drugs are well absorbed (although
systemic availability may be low due
to first-pass metabolism) and the rate
limiting step is drug dissolution or gastric
emptying if dissolution is very rapid. The
dissolution profile must be well defined
and reproducible to insure bioavailability.
A dissolution specification for IR drugs
of 85 % dissolved in

EUFEPS Newsletter, 1997, vol. 6, issue 4
Strategic events
Malcolm Rowland Professor
EUFEPS President and University of Manchester, United Kingdom
In some ways it seems but a moment, and
in others an age, but it is one year since
I took over the presidency of EUFEPS.
Then, I wrote an editorial on the visions
and realisations of EUFEPS in the
December 1996 issue of the Newsletter.
One year on seems an appropriate time
to reflect on what we have achieved and
express some views on the future.
Permanent secretariat
Perhaps the most important strategic event
over the last year has been the establishment
of a permanent home for the secretariat,
who have been doing an outstanding job
with limited resources available. But,
you might say, the secretariat is housed
already within the premises of the Swedish
Academy of Pharmaceutical Sciences.
That is true, but it was a temporary
arrangement through the kind generosity
of the Swedish Pharmaceutical Society,
which has provided space and financial
assistance. So I am now delighted to report
that, at the recent meeting in Istanbul,
Council approved the proposal from the
Executive Committee that the secretariat
be permanently housed within the current
premises in Stockholm, and thank the
Swedish Pharmaceutical Society for
making this possible. Every organisation
needs an efficient, well-resourced and stable
secretariat to implement its policies and
undertake its day-to-day functions. Now
having secured the base, the secretariat
needs to be enhanced to adequately serve
the increasing activities of EUFEPS.
Graduate student meeting
Another important development at Council,
was the support of an initiative from the
German Pharmaceutical Society for the
establishment of a European Meeting of
Graduate Students in the Pharmaceutical
Sciences, the first of which to take place,
in English, in Frankfurt, February 20–22,
1998. Previously a successful national
meeting, the intention is that it become
European but its success depends heavily
on research students from other countries
attending and becoming actively involved.
Training of high quality researchers
with the necessary skills and knowledge
to meet the future challenges in the
pharmaceutical sciences is paramount.
This subject has been one of the important
activities of the Committee of Industrial
Relations, (CIR) which is helping to define
and identify the needs through various
means, including questionnaires. And, this
given its importance, training will command
increasing attention within EUFEPS in the
coming years. CIR serves as an excellent
example of what a group of committed,
motivated and enthusiastic individuals can
accomplish, and EUFEPS will follow this
example and establish a number of additional
committees to deal with such matters as
conferences, membership, and awards.
Major scientific meetings
To establish itself as a major regional
organisation in the pharmaceutical
sciences EUFEPS has, in addition to
its usual successful biennial European
Congress in Pharmaceutical Sciences, the
next to be in Milan, September 11–13 1998,
which I encourage you to attend, run more
specialised meetings often in collaboration
with other organisations. Examples have
been the recent successful meetings on
Drug Absorption (Edinburgh) and Drug
Metabolism (Gothenburg), together with the
Edinburgh Drug Absorption Foundation
and ISSX, respectively. Another example
is the forth coming meeting in Jerusalem,
April 25–29, 1999, organised together with
the European Congress in Biopharmacy
XIX
and Pharmacokinetics, around the central
theme “Mechanistically-based Drug
Discovery and Development: Integrating
the Biological Revolution”. As part of our
strategic plan we have also successfully
sought sponsorship of some of our meetings
from our sister organisation within the USA,
AAPS, and from the FDA and EMEA,
an example being the next Nuremberg
meeting, this 27–29 November, on “Drug-
Drug and Drug-Food Interactions” - For
those of you that attended the recent AAPS
meeting in Boston you will have noticed in
the program the joint EUFEPS-AAPS short
course on cell-lines and tissue cultures,
which was first successfully run in our
1996 Edinburgh Congress. We intend to
undertake more such and other activities
with AAPS.
Flagship journal
The editorship of the European Journal
of Pharmaceutical Sciences, our flagship
journal, will move its base from the
Netherlands to Uppsala, Sweden, by early
1998. The existing editors, Professors H.
Junginger and G. Mulder, who have done
an extremely important job of giving EJPS
its initial push, will pass on the baton to
Professor P. Artursson and his colleagues
to move it further. However, EJPS will only
become the highly successful journal that
we would all like to see if you submit your
best papers to it. We are also of the opinion
that there are too many journals dealing with
the pharmaceutical sciences within Europe
and there is need for further consolidation.
Increasing membership
Finally, a note on membership which has
remained relatively static over the past
year. We now have Member Societies
from most countries within Europe and we
are hopeful that the remaining countries
in which there is a strong presence of
pharmaceutical sciences will join us
during the coming years. We also feel
strongly about our Individual Members,
as they identify personally with the aims
and aspirations of EUFEPS. We intend
to increase this sector of our membership
over the next few years, as well as that
of our Corporate Members, which has
grown, but has room to grow still further.
In closing
Through this Newsletter, it remains for
me to wish all of you a successful year. I
look forward to either seeing you at one of
our meetings, or reading about you m the
Newsletter, or preferably both.

EUFEPS Newsletter, 1998, vol. 7, issue 1
EUFEPS forges links
with FDA, EMEA
and EU
Malcolm Rowland, Professor
EUFEPS President and University of Manchester, United Kingdom
Although, developments within EUFEPS
have never been slow, recently the pace
has quickened by several notches. In the
space of just three short months, major
strategic developments involving the USA
Food and Drug Administration (FDA),
European Medicines Evaluation Agency
(EMEA) and European Union (EU) have
occurred that puts EUFEPS well on
its planned course of being recognised
as the umbrella platform for the
pharmaceutical sciences within Europe.
In all these developments neutrality in all
but science is the key to acceptance and
success.
Natural neutral umbrella
In the bringing of pharmaceuticals to
the marketplace, regulatory approval
is mandatory. To meet their statutory
obligations, regulatory authorities publish
guidelines to facilitate the rational
development of safe, effective, and reliable
medicines. At the same time, major strides
are being made to harmonise guidelines
across continents, as part of the recognised
globalisation of drug development. It is in
this arena that EUFEPS is playing an ever
increasing pivotal role. This is reflected
by the FDA’s Division of Pharmaceutical
Sciences, of the Center for Drug Evaluation
and Research (CDER), decision to
recognise EUFEPS as the natural neutral
umbrella platform within Europe, to
bring together interested organisations
and persons from academia, industry
and government to explore issues within
the pharmaceutical sciences relevant to
the development of such guidelines. To
further this collaboration Dr Larry Lesko,
Head, Clinical Pharmacology within
CEDR, has been appointed as the FDA-
EUFEPS Federal Liaison Officer (see
article p..), whilst fittingly Prof. Henning
Blume, has been appointed EUFEPS-
FDA Liaison Officer. Henning is chair
of the Committee on Pharmaceutical
Policy, which among its activities deals
with guideline issues and developments.
Discussions along similar lines as with the
FDA are also taking place with Professor
Rolf Bass of the EMEA. Staff from both
the FDA and EMEA strongly participated
in the recent 4th EUFEPS Nuremberg
Conference on Drug-Drug and Drug-
Food Interactions, not only giving lectures
but were also actively involved in many of
the discussions.
Hot tandem meetings
One tangible example of EUFEPS’s
pivotal role in advancing drug
development science is its next (5th)
Nuremberg Conference on the hot topic
of ‘Optimising Drug Development: Fast
Tracking into Human’, which is being
sponsored by the FDA, EMEA, AAPS
and EACPT. This will run in tandem
with a meeting on the same theme in
Washington, organised by AAPS, and
sponsored by FDA, ASCPT, AACP, as
well as EUFEPS. The intention is to put
out a co-ordinated discussion document to
facilitate guideline developments across
both continents, in this important phase of
drug evaluation and selection.
Links to EU
On a separate front, members of both
EUFEPS Executive Committee and
Committee on Industrial Relations had
fruitful discussions with various EU
representatives in Brussels to explore
developments and opportunities in
education and training at the postgraduate
and research level. These discussions were
aimed at improving the skill base in the
pharmaceutical sciences within Europe.
XX
Malcolm Rowland, Professor
Also discussed were research themes
of the 5th Framework Programme for
research and Technological Development
(1998-2002) relevant to the pharmaceutical
sciences. This important meeting was
facilitated by Dr Maj-Inger Nilsson,
Swedish Research EU Liaison Officer,
who is an Individual Member of EUFEPS.
And, because of the importance that
EUFEPS places on these developments,
Maj-Inger has now been appointed
EUFEPS-EU Liaison Officer (see article
p...). We wish both Henning and Maj-Inger
every success in their new roles within
EUFEPS.
Mutual interest and concern
Finally, links are also being established
with EFPIA (European Federation of
Pharmaceutical Industry Association),
which has an interest in ensuring a vital
and successful pharmaceutical industry
within Europe. Once again the areas
of mutual interest and concern are the
education and training of pharmaceutical
scientists.
We are looking forward to fruitful
collaborations with all these organisations
to meet the challenges and opportunities
that lie ahead.

EUFEPS Newsletter, 1999, vol. 8, issue 2
EUFEPS Permanent
Secretariat established
On February 20, 1999, the permanent
Secretariat of EUFEPS was officially
opened in the premises of the Swedish
Pharmaceutical Society in Stockholm,
Sweden. Members of the Executive
Committee, as well as of the Board of
the Swedish Pharmaceutical Society/
Academy of Pharmaceutical Sciences
attended the inaugural reception and
opening ceremony. The opening was
held in conjunction with the February
Executive Committee Meeting in
Stockholm.
Increased activity
As is well-know to the readers of this
Newsletter, EUFEPS was founded in
1991 in Strasbourg, France, by a number
of national societies and associations
for pharmaceutical sciences in Europe,
one of which is the Swedish Academy of
Pharmaceutical Sciences (SAPS) within
the Swedish Pharmaceutical Society. Since
then, the number of Member Societies of
EUFEPS has grown substantially, and
additional forms of membership have also
been established. Currently, EUFEPS
links 25 Member Societies in 22 European
countries. In addition, there is approx.
480 Individual Members, as well as 25
Corporate Members of EUFEPS.
From the inauguration of EUFEPS,
the Swedish Academy of Pharmaceutical
Sciences have been providing secretarial
assistance for EUFEPS. As the
activities of EUFEPS have increased,
the administrative and managerial
requirements on the Secretariat have
also increased. To meet these needs, a
permanent secretariat has been sought
for, and, in 1997 (?), the EUFEPS
Council accepted an offer by SAPS that
the EUFEPS Secretariat be permanently
established in its premises in Stockholm.
Mutual happiness
Against this background, the EUFEPS
President, Professor Malcolm Rowland,
at the opening ceremony, said that he, on
behalf of EUFEPS, is very pleased that
there is from now on EUFEPS Secretariat
physically established. In addition,
substantial, financial support, for a period
of two years, is provided by the Academy.
Perhaps, this will also challenge other
Member Societies of EUFEPS to increase
their support.
The President of the Swedish
Pharmaceutical Society/Academy of
Pharmaceutical Sciences, Professor Conny
Bogentoft, said that he as well is very
pleased with this solution. International
co-operation and collaboration are of
utmost importance for the development
of new drugs. Without extensive research,
there would not be many new effective
medicines, if any. Also, most of the
medicines produced are developed for
the international market. Collaboration
between national regulatory agencies
is growing, and a European one was
recently created. Drug companies in one
country merge with drug companies
in other countries. In other words,
internationalisation and globalisation
seem to be inevitable, and, in this
perspective, it is a matter of course that the
Swedish Pharmaceutical Society, through
the Academy of Pharmaceutical Sciences,
firmly supports EUFEPS and its efforts to
advance the pharmaceutical sciences and
innovative drug research in Europe.
Modern facilities
Three suitable, newly and nicely
renovated, rooms have been reserved for
the EUFEPS Secretariat, closely located
in the same building and on the same
floor as the Scientific Secretariat of SAPS.
XXI
From left to right, Björn Lindeke,
Anders Grahnén, Malcolm Rowland,
A. Atilla Hinchal, Dowe D. Breimer,
Michelle Veilard and Tony Fell.
Equipment includes up-to-date computer
work-stations, telephone, fax, printer,
copy machine etc.
Current staff
Currently, the Executive Director of
the Swedish Pharmaceutical Society,
Professor Björn Lindeke, is elected
Secretary-General/Treasurer of EUFEPS.
In the EUFEPS Secretariat, three
individuals are heavily involved in the
day-to-day service of EUFEPS. They
are Jenny Hagberg, Hans H. Linden, and
Anita Ljung.

EUFEPS Newsletter, 1999, vol. 8, issue 3
New Safe Medicines Faster
A Proposal for a Key Action
within the European Union’s
6 th Framework Programme
Ole J. Bjerrum, Professor
Chair EUFEPS/CIR Task Force on EU Framework Programme
The budgets of European RTD
Framework Programmes have steadily
increased over the years. They now
count for approx. 5% of public spending
on research in Europe. Every 4th
year, a new Framework Programme,
including various key actions and
generic activities, is launched. Through
a bottom up process it should theoretical
be possible to influence the contents of
future framework programmes. The issue
of getting impact is very complex and
involves many players - including you.
Important measures
To get involved in the future EU RTD
Framework programmes the following
exercises are needed as a minimum:
• a well defined, thoroughly described
research area covering many European
stakeholders
• a plan and the commitment to carry it
through
• a presentation of the proposal to the
Commission
• further substantiation and refinement
of the proposal through discussion
at specially arranged workshops and
conferences in an interactive play with
the Commission
• heavy support from all the stakeholders
at the EU member state level to
convince their respective governmental
bodies including their research
ministers about the value of the
proposal.
The EUFEPS Committee on Industrial
Relations (CIR) have decided to bring the
pharmaceutical sciences in focus to EU’s 6th
Framework Programme 2003–2007, under
the title “New Safe Medicines Faster”.
The rationale is the following: The
global competitiveness of the European
pharmaceutical industry is under threat.
Technology currently available for the
development of new medicines is unable
to match the pace of drug discovery and
design; and the ever-growing demand for
safety, efficacy and quality documentation
has increased the cost and time involved in
getting new medicines on the market thus
creating severe restrictions on industry’s
ability to create wealth and launch safe,
cost effective drugs for the treatment of
common and rare afflictions.
Clear objectives
The present proposal is based on three main
objectives: to develop new technologies
capable of more effective selection of
potential drug candidates for innovative
medicines while accommodating safety
demands; to use such technologies to
speed up the pharmaceutical development
and eliminating foreseeable bottlenecks,
created by the many drug candidates
now generated in the discovery phase.
Furthermore to cultivate a pan-European
interdisciplinary network on science and
training that bridges the gap between
industry and academia.
By breaking down the barriers put up
by the legislation of individual nations, and
initiating a new set of recognised European
standards, new medicines can be brought
onto the market faster and thereby cheaper
— thus benefiting European health care.
The key action
A key action is an excellent way of creating
consortia of research groups representing
all the specialist areas involved in
drug development — pharmacology,
toxicology, pharmaceutics, scale-up
processing, analytical chemistry and
clinical trials. A new and important
discipline, pharmacogenomics, will
XXII
also play a major role in the future when
determining the effect of specific drugs
on individual patients. In addition, the key
action should comprise clusters, centres
of excellence, programmes for specialist
training and dedicated support for small
and medium-sized enterprises.
Methodologies and technologies
Promoting and implementation of new
methodologies and technologies are a
major issue. Work on these aspects should
include as many of the pharmaceutical
sectors and EU member states as possible.
As a result, the new pharmaceutical
methods, techniques, tools and procedures
that emerge will more easily obtain broad
international approval and, at the same
time, represent the most competitive
solutions for increasing the speed, cutting
the cost and improving the quality of
drug development. The new front-line
methodologies often derive from basic
sciences, such as molecular genetics,
biomedicine, bioengineering and
information technology. Also techniques
related to robotics and miniaturisation in
pharmacology and pharmaceutics and
structure activity relations in absorption,
distribution, metabolism and excretion
studies and toxicology will contribute to
faster, more efficient drug development, as
can the auxiliary disciplines of analytical
and processing chemistry.
Education and training
A highly qualified work force is also
important. PhD and post-graduate
students trained in up-to-date technologies
and research areas will help to close the
current gap between academia and the
needs of industry. The present deficiencies
are thought to be due to the small size of
individual faculties, a lack of academic

and industrial integration and inadequate
post-doctoral programmes. But, through
training and mobility measures, the key
action provides a basis for solving these
problems by combining top level university
research with front-line technology in
areas where there is little or no training in
Europe today.
Concerted effort
Thus a concerted effort put forward by the
key action “New Safe Medicines Faster”
has clear benefits that speak loudly in
favour of its inclusion in the EU’s 6th
Framework Programme. By crossing
the divide between individual fields of
research and development, industry
and academia and transforming drug
development into an integrated process,
the European pharmaceutical industry
will be better equipped to tackle the health
and employment challenges of the future.
First step taken
The first version of the Proposal has been
approved by the EUFEPS’ Executive
Committee, and copies of it were
submitted to the DG XII of the European
Commission, and to EFPIA, to get their
early comments and support. In the year
to come, the collaboration on this with
EFPIA will be expanded, as well as
with others, to improve the proposal and
solidify the arguments with data and facts.
Furthermore, the scientific content of the
work programme of the key action should
be worked out. To support this process,
dedicated workshops will be arranged.
Additional involvement welcome
Support of this Proposal is needed
XXIII
also from you as member of the local
pharmaceutical research communities at
universities, industries, and hospitals. Only
you can convince research councils and
research administration bodies in relevant
ministries of your country about the value
of this Proposal. Please bear in mind that it
is your Minister in the European Council
who in the very end decides the fate of this
initiative.
The full text of the EUFEPS/CIR
Proposal can be obtained from the
EUFEPS Secretariat, and CIR will
welcome any comment to the Proposal
itself, or to this Editorial, through the
EUFEPS Secretariat.

EUFEPS Newsletter, 2000, vol. 9, issue 3
March 15–16 ● 2000 ● Hotel Le Plaza ● Brussels
Workshop Report
New Safe Medicines
Faster
Ole J. Bjerrum, Professor
Chair Workshop
This Workshop was organised with
the ultimate goal of increasing safety,
efficacy, speed and process capacity for
the downstream development of new safe
drugs. Representatives from academia,
industry and regulatory authorities
made a thorough analysis of the key
requirements to achieve this aim. The
outcome will be presented in a report
to the European Commission, as follow
up on the EUFEPS proposal of July 1,
1999, regarding the key action: New Safe
Medicines Faster for the forthcoming
EU’s 6th Framework Programme
for Research and Technological
Development.
Organisation
An organising committee with
representatives from EUFEPS, EFPIA
(European Federation of Pharmaceutical
Industries and Associations), regulatory
authorities, academia and industries stood
behind the Workshop, cf. box.
Organising Committee:
Prof. G. Alderborn, Uppsala, SE
(Academia)
Prof. O. J. Bjerrum, Bagsværd, DK
(Novo Nordisk)
Prof. C.-M. Lehr, Saarbrücken, DE
(Academia)
Mr H.H. Lindén, Stockholm, SE
(EUFEPS)
Assoc. Prof. M.-I. Nilsson, Brussels, BE
(Pharmacia & Upjohn)
Dr J. Reden, Brussels, BE (EFPIA)
Dr J. Renneberg, Copenhagen, DK
(Regulatory)
Prof. J. Vessman, Mölndal, SE
(AstraZeneca)
The Workshop had obtained support from
the EU as an accompanying measure under
Quality of Life in the 5th RTD Framework
programme. Additional sponsoring for
the Workshop, including for the reception
and the dinner, was obtained from
AstraZeneca (UK), Farmindustria (Italy),
Novo Nordisk (Denmark), Organon
(the Netherlands), Pharmacia & Upjohn
(Belgium) and Servier (France).
Workshop participation took place
only after invitation, since the organisers
wanted to focus on the needs of the pharma
industry achieved through a true bottomup
process covering as many European
companies as possible. Out of a total of
approx. 115 Workshop participants, 75
came from the pharmaceutical industry,
including CROs (representing 36
companies), 24 academia (20 universities
and schools of pharmacy), and five
regulators (four European agencies). Also,
a number of officials and civil servants of
the European Commission attended. The
Organising Committee is very pleased with
this outcome, including with the number
of scientific fields that were represented
by these delegates, although clinical
pharmacology was underrepresented in
the Workshop.
Workshop structure
To work with a reasonable number of
participants seven discussion for a were
created. The drug development process
was divided into four sessions covering
1. “How to select candidate drugs faster”
covering discovery and selection; 2.
“How to bring candidate drugs faster into
human” enclosing the preclinical aspects;
3. “How to bring candidate drugs into
full-scale production” containing upscaling
and analytical chemistry and 4.
“How to bring drugs faster to regulatory
acceptance” comprising clinical trials and
regulatory demands. The special aspects
XXIV
Ole J. Bjerrum, Professor
of biopharmaceuticals were covered in
session five. “How to bring new biotech
molecules into deliverable products”.
The importance and expected impact of
information technology (IT) were included
in Workshop group 6: “How will IT be
utilised to speed-up the drug development
process?” Finally a fresh look was taken
on the process per se in the session “How
to reshape the drug development process
from the beginning”.
Day 1. Opening and Lectures
The Workshop was opened at 1 p.m.
by the President of EUFEPS, Professor
Malcolm Rowland and by the Director
of the Quality of Life Programme at the
Research Directorate of the European
Commission, Mr Bruno Hansen. On
behalf of Commissioner Busquin the
latter welcomed the initiative and stressed
the importance of being in contact with
the users of future programmes at an early
stage.
To set the scene distinguished lecturers
for each of the seven sessions were
invited: Professor Trevor M. Jones, the
Association of the British Pharmaceutical
Industry, London in very fine fettle, gave
the background for the current trends of
the pharmaceutical industries. He pointed
out that the developmental time after some
years of reduction again shows increases.
This put against the ever-increasing cost
call for faster drug development, which
he foresaw as the challenge of the 21st
century.
Dr Frank Fildes, AstraZeneca,
Macclesfield also fit for fight, emphasised
that “more candidates faster are not enough
- the quality of the candidates is the key”.
The winners should be picked earlier by
predicting attributes with better data,
earlier attrition and anticipating wasted

clinical trials. He also argued for a smooth
discovery-development transition.
Professor Staffan Folestad,
AstraZeneca, Mölndal underlined the
necessity of having a seamless process
development with the right analytical tools
at hand as real time direct measurements
at line/in line (better pharmametrics).
Further he saw a future in simulation and
modelling of processes.
Dr Brian White-Guay, Merck Sharp
& Dohme (Europe) Inc., Brussels,
focused on the regulatory process as
a bottleneck and suggested various
improvements regarding modifications
of the requirements, the efficiency, the
transparency and quality standards.
Professor Fritz Bühler, European
Centre for Pharmaceutical Medicine,
Basel advocated for a holistic approach
involving European consortia: universitypharma
industry-regulators together with
data collection and analysis networks.
For the clinical trials surrogate endpoints
and biomarker validation were of outmost
importance.
Dr Alistair Shearin, PriceWaterhouse
Coopers, London, also stressed the
current imbalance due to the long and
costly developmental phase. Further
he showed the power of the IT solution
if implemented throughout the drug
developmental process. Also he foresaw
how simulation based on public databases
of clinical data could reduce development
time.
Professor Daan Crommelin, Utrecht
University underlined that better drug
delivery was a big issue for biotech
products and he promoted the importance
of other delivery routes than injection for
pharmaceutical proteins.
Day 2. The Workshop Sessions
Since faster drug development calls for
• New Strategy, *Research and
innovation,
• New techniques, methodologies and
processes,
• Strengthened academic research and
training, and
• Flexible regulatory authorities, each
Workshop Session was asked to deliver
input regarding these aspects.
The seven parallel groups worked
enthusiastically under the chairmanship of
the invited lecturers and after three hours
of hard work all groups delivered very
useful material. Through the rapporteurs
(the Organising committee members
supplemented with Professor S. Frøkjær,
Copenhagen and Professor A. Grahnén,
Stockholm) the material was presented in
plenum by well-structured overheads and
the contents were further elucidated and
discussed.
The results
As an overall conclusion it was considered
realistic to believe that the New Safe
Medicines Faster proposal could form
the basis for a new key action in the
forthcoming 6th FP because drug
development has
• Well-defined deliverables to the
citizens,
• Interfaces to many scientific areas,
• Bottlenecks to be addressed,
• The need for pan-European
collaboration,
• Job generation potential,
• Room for starts-up and small and
medium size enterprises (SMEs) and
• Links to topics of the former
programmes.
Besides this a wealth of concrete
research topics to the key action was
identified and brought forward. These
lists of topics, methodologies and
techniques will in the coming months be
further substantiated and discussed in
subgroups and networks created during
the Workshop. After final editing by the
organising committee it will be delivered
as a report to the Commission before
summer holidays.
The general conclusions
• The key action New Safe Medicines
Faster fulfils a real need
• High front load implies down-stream
bottlenecks
• Joint effort with Regulatory is needed -
right from the beginning
• IT: integration is necessary for the
truncation of the process
• The importance of training and
education is equally important to
research
• Centre of Excellence, public databanks
and databases are needed
• The initiative has become concrete and
shows already impact.
XXV
Future actions
In the closing session Professor Ole J.
Bjerrum described the future actions
necessary to drive the proposal to
a successful completion. First of all
continuous support is needed from all
members organised under the EUFEPS
umbrella. Therefore in case you - as the
reader of this - also want to contribute to
the initiative your help is most appreciated.
Join EUFEPS’ New Safe Medicines
Faster mailing list and get involved in the
description of the wanted research topics
and/or be active as opinion leader and
ambassador for the proposal.
Conclusion
The Workshop laid a good foundation
for the future work on promoting the key
action New Safe Medicines Faster within
EU’s 6th Framework Programme. Only
through a massive EU funding it will
be possible to create platforms where
the necessary collaboration between
regulatory, academia and industry can
take place to introduce the so much needed
changes in drug development process.
Please remember that without such a
conversion the high frontload of new drug
candidates cannot reach its ultimate target
- the patients.
Let the final words at the Workshop
also be your motto: “Plan and act as the
New Safe Medicines Faster program is
real, and your dreams come true”.

EUFEPS Newsletter, 2001, vol. 10, issue 4
Decennial Milestone
The Decennial Anniversary of EUFEPS
is a milestone in the rather short history
of EUFEPS. It was celebrated, in the
European Parliament in Strasbourg,
France, with a “Decennial Conference
on Optimising Drug Development” and
an Anniversary Ceremony, on Friday,
September 21, 2001. Ten years earlier,
EUFEPS had been inaugurated in
Strasbourg.
At the end of the Decennial
Conference, the EUFEPS President
Professor Dominique Duchêne opened
the Anniversary Ceremony by welcoming
all, including two of the three “founding
fathers” of EUFEPS, Professor Stig
Agurell and Professor Ernst Mutschler,
with their wives, as well as Dr. Bruno
Hansen, representing the European
Commission. The third “founding father”,
Professor Douwe D. Breimer was unable
to attend the Friday Ceremony, but he
arrived later in Strasbourg.
In the Anniversary Address, Professor
Duchêne referred to the establishment and
mission of EUFEPS and discussed what
could and should be done, in the future.
After this, Dr. Hansen presented the role
and current activities of the European
Commission to strengthen and expand
European research, including in the health
related field. He also acknowledged the
significant contributions by EUFEPS
for the next European Framework
Programme for Research and
Technological Development (FP6), and
he looked forward to future collaboration
on science and research with EUFEPS.
Professor Ole J. Bjerrum reported on the
to date encouraging outcome of – and
future plans for – the EUFEPS New Safe
Medicines Faster initiative (NSFM).
In the Anniversary Ceremony, the
“founding fathers” of EUFEPS, and
their impressive contributions to the
development of EUFEPS, were duly
recognised. Professors Agurell, Breimer
and Mutschler were awarded a Decennial
Anniversary Medal, the symbolic of
which was explained by Professor Björn
Lindeke, Secretary-General and Treasurer
of EUFEPS. Executive Committee
members were also awarded a diploma,
with the same symbol, acknowledging
their leadership and hard work to proceed
along the lines early established and
to expand the activities of EUFEPS.
Professor Breimer received the Medal at
the Council and Anniversary Dinner, on
Saturday evening.
After closing the Ceremony,
conference delegates, guests, Council
Members and EUFEPS officials got a
chance to remember the past, exchange
views on the present and plan for the
future, while mingling and enjoying the
Anniversary Cocktail, also in the facilities
of the European Parliament.
XXVI

XXVII

XXVIII

XXIX

EUFEPS Newsletter, 2001, vol. 10, issue 4
EUFEPS 10 th anniversary
European Federation
for Pharmaceutical
Sciences
Dominique Duchêne, Professor
EUFEPS President
Ten years ago here in Strasbourg,
EUFEPS was founded in the presence
of Anders Björck, the President of the
Parliamentary Assembly of the Council
of Europe.
This was the accomplishment of a
challenge launched by 3 scientists, 3
great Europeans: Stig Agurell, Douwe
Breimer and Ernst Mutschler. They
recognized the need for an independent
European scientific body to promote the
European pharmaceutical sciences at the
highest international level, with a simple
objective: to serve and advance excellence
in pharmaceutical sciences and innovative
drug research. In their task, they were
strongly and financially supported by the
Swedish Pharmaceutical Society.
The scientific potential of Europe
is known, but too often isolated and not
well enough organized and co-ordinated.
The task of EUFEPS is to contribute to
the reversal of such a situation. This can
be achieved by a fruitful international
competition in which Europe has to
participate as full partner, not for the
egotistical contentment of scientists, but
for the benefit of health.
From the scientific standpoint, as
well as from the political one, Europe is
characterized by its diversity. This is both
a strength and a weakness. It is a strength,
because diversity can generate scientific
ideas in profusion. But it is a weakness,
because it is energy- and time-consuming.
EUFEPS has to co-ordinate this inherent
diversity without destroying it. What can
be done by EUFEPS?
Members
On Saturday 21 September 1991, 16
societies representing 15 countries from
all over Europe (north to south, east to
west) constituted the founding members.
The societies were from: Austria, Croatia,
Czechoslovakia, Denmark, Finland,
France, Germany, Greece, Hungary, Italy,
Poland, Sweden, The Netherlands, Turkey
and the United Kingdom.
Today, the number of our member
societies has increased significantly to 25
societies representing 23 countries and
approximately 25,000 members.
The objective of EUFEPS, as a
European federation, is to have member
societies from all the European countries,
and to represent all the pharmaceutical
sciences. This is not easy to achieve, for
several reasons:
First, the reason why a scientific
society should become member of
EUFEPS is not clear to some of them, who
wonder what could be their benefit from
membership. In fact, there is no benefit,
except the satisfaction of participating in a
European task, for those who want. But, if
they do, both scientists and the citizens of
Europe will benefit.
We are aware of the difficulties some
European societies may have to pay
their subscription whatever our effort
in adapting the membership fees to the
country and the number of members of
the societies.
It is also difficult to have member
societies representing the different
pharmaceutical sciences because of the
great diversity of the European societies.
Some are national pharmaceutical
societies. They represent all the different
aspects of pharmacy: community
pharmacy, hospital, industry, academia,
etc. Some other member societies represent
a well-defined pharmaceutical science.
To have fruitful collaborations with our
member societies, we need to know
precisely their best scientific domain.
XXX
Dominique Duchêne, Professor
At the beginning of the year we sent
them a questionnaire, a matrix in which
appeared, on one side, the pharmaceutical
disciplines (academic approach), and, on
the other side, the processes (industrial
approach). We asked our member societies
to locate themselves on this matrix, but
unfortunately, probably due to insufficient
explanation from our part, the answers
were not as precise as expected.
Other European Organisations
There also exist European federations of
different pharmaceutical sciences, such as:
EACPT (European Association of Clinical
Pharmacology and Therapeutics), EFMC
(European Federation for Medicinal
Chemistry), Eurotox, ESBP (European
Society of Biopharmacy), EFPIA
(European Federation of Pharmaceutical
Industry Associations), etc. with which
we already have contacts. Some of them
would like to co-operate closely with
EUFEPS, and we have or are preparing
letters of understanding. In the near future,
we will probably be obliged to create a
new type of membership to give them the
possibility of becoming true members of
EUFEPS.
We also have individual members,
approximately 500. With them, with the
scientists recommended by our member
societies, we expect to create a virtual
school of excellence.
Roles of EUFEPS
The different memberships of EUFEPS
should not represent a kind of private club
for scientists, but a powerful group capable
of serving and advancing excellence in
pharmaceutical sciences and innovative
drug research.
One of the roles of EUFEPS is to
encourage the organization of scientific

events, more especially when they
result from a co-operation between
different EUFEPS member societies or
any scientific societies, or when they
are organized at a regional level. These
conditions can ensure the dissemination
(and progress) of science and prevent too
confidential an aspect.
EUFEPS also has the possibility
of organizing scientific events by itself,
but EUFEPS does not want to compete
or to overlap with its member societies.
This is the reason why, up to now, most
of the symposia we have organized have
been process-oriented and belonged to a
series ‘Optimising Drug Development’.
The theme and the programme of these
symposia have, in many cases, been
proposed by the EUFEPS Committee for
Industrial Relations.
However, EUFEPS needs to
strengthen its co-operation with academia.
This is why the Committee for Academic
Relations was recently created, and will
propose a new series of symposia ‘New
Trends in….’ which will contribute to the
dissemination of the most recent scientific
results.
An example of the type of
collaboration we would like to establish
with our members, for the benefit of the
pharmaceutical sciences, is the Fair of
Pharmaceutical Sciences we intend to
hold most probably in June 2005 in Nice,
France. This fair will be characterized
by the fact that at the same period, in the
same place our member societies and all
the European scientific societies involved
in drug development will be invited to
hold jointly, their most scientific meeting,
on the platform of EUFEPS. There will be
two or three-day conferences with parallel
sessions, as well as one-day symposia.
We are expecting several thousand
participants and we feel that exhibitors
will be interested in joining this event.
For our current member societies, this
project will be detailed at our Council,
on Saturday afternoon. In any event, they
will be contacted in the coming weeks or
months to build this project with us and to
participate in its success.
These different symposia, conferences
and fairs, cannot be restricted to European
scientists and participants. The contacts
we have had at the inter-continental level
with ISSX, AAPS (American Association
of Pharmaceutical Scientists), APST Japan
(Academy of Pharmaceutical Sciences and
Technology), CRS (Controlled Release
Society), and FDA, greatly facilitate the
organization of very high-level meetings.
At the world level, we are holding
discussions with the FIP (Fédération
Internationale Pharmaceutique). Our main
objective is to become their necessary
partner for the scientific events they will
organize in Europe and more especially
the 3rd Pharmaceutical Sciences World
Congress, which will take place in Europe
in 2007, after San Francisco in 2000 and
Kyoto in 2004.
The dissemination of knowledge must
not take place only between scientists from
different domains and countries, but also
between generations: the role of EUFEPS
in training and education has been pointed
out from the very beginning of EUFEPS.
It is not the role of EUFEPS to teach
pharmacy, but it is the role of EUFEPS to
give post-docs, pharmacists and engineers
high-level training in the most advanced
domains. Our Committee for Education
and Training is discussing 3 training
sessions, hopefully to take place next year,
on bio-informatics, high-throughput drug
metabolism, and combinatorial chemistry.
In the future, the school of excellence,
we have progressively organized will
contribute to this activity.
I said that it is not the role of EUFEPS
to teach pharmacy, but it can be the role
of EUFEPS to discuss the content and
the structure of this teaching. This is the
reason why we answered the request of
EAFP (European Association of Faculties
of Pharmacy) and EPSA (European
Federation of Pharmacy Students
Associations) and decided to have oneand-a-half
days of discussions and
exchange with them in spring 2002.
The dissemination of knowledge
must not be done exclusively by meetings,
whatever their nature, because they are not
only costly, but they necessitate travel, and
time. Another possibility is constituted
by scientific publications. From its very
beginning, EUFEPS decided to have a
scientific journal: the European Journal
of Pharmaceutical Sciences, published by
Elsevier. The successive editors-in-chief
(Hans Junginger, Per Artursson, and Arto
XXXI
Urtti) strongly contributed to its present
success. For the future, we can imagine
another kind of publication: a book series
edited by EUFEPS together with members
of our virtual school of excellence. Such a
series should constitute a reference library
for the pharmaceutical sciences.
The adequate development of a
Federation, such as EUFEPS, and the
recognition of its efficiency requires a
special activity: lobbying…
We have done it, at the level of the
European Commission, and this has
been one of our best successes. Thanks
to Ole Bjerrum and through a workshop
we organized about two years ago
in Brussels, we are promoting a new
concept: New Safe Medicines Faster. It
is a research proposal to strengthen the
European competitiveness in innovation,
development and use of new and better
drugs. It also necessitates the creation of
stronger links between industry, hospitals
and regulatory authorities, for the benefit of
European citizens. The means of reaching
such a goal is to have more efficient use
of modern technology. We are very proud
to tell you that New Safe Medicines
Faster already constitutes a topic of the
6th European Research and Technical
Development Framework Programme,
and that we received congratulations from
the Commission.
Collaboration important
In conclusion, and taking advantage of the
presence of Director Bruno Hansen from
the Life Sciences General Direction at
the European Commission, who is living
proof of the interest of the Commission
in innovative activities, I want to insist on
the fact that EUFEPS will not fail in its
mission: promote and advance excellence
in the pharmaceutical sciences.
EUFEPS will refuse to consider
European diversity as a drawback, but it
will take advantage of this diversity and
use it through close collaboration with its
societies concerned with the progress of
the pharmaceutical sciences in Europe.
Such collaboration requires a
permanent dialogue between EUFEPS
and its members and I encourage you
to criticize, suggest, construct and win
altogether.

EUFEPS Newsletter, 2002, vol. 11, issue 3
A need for Excellence
in Pharmaceutical
Sciences
Ole J. Bjerrum, Professor
EUFEPS Vice-President
The scene
At the present time, the pharmaceutical
sciences in Europe are both under
pressure and increasingly supported.
This paradox derives from the rapid
changes that our society is going through
technologically and structurally. Until
now, the main body of the pharmaceutical
sciences has been taught in Schools or
Faculties of Pharmacy within universities.
However, many of the classical roles of
the individual practising pharmacist are
diminishing while other roles are actually
increasing e.g. due to polypharmacy
and the evolution in the preventive use
of drugs. In many European countries,
the industry’s demand for pharmacists
is increasing leading to requests for new
topics in the educational curriculum. These
trends have put a squeeze on the present
structures of the pharmacy institutions.
Generally speaking, if the adaptations
required to meet the challenges of the
new developments and the needs of the
industry are not implemented, one may
fear that the present school structures in
many places will not survive.
The wrong response
Since the half-life of scientific and
technological advances is much shorter
than the half-life for turnover of academic
scientists, it is sometimes difficult for
the latter to keep pace with the changes
if not active in research. Falling back on
well-established privileges may delay the
process locally but overall it will not avoid
the need for adjustments in the longer
term.
The right response
It is much better to be open to the
current trends, before they finally result
in demands from politicians. The new
openings, which are structural as well as
economic, should be exploited proactively.
The essence is to have enough money to
be in a position to protect the key values of
the educational disciplines. The training
in the schools of pharmacy should be
potentiated with addition of new courses
e.g. (bio)technology and economics.
Also new curicula developed together
with schools in other European countries
should be considered as European Master
degrees. It is probable that the medicines
distribution system will undergo major
changes in the future, which ultimately
will result in a reduced need for the
classical dispensing role of the pharmacist.
To survive the pressure, it is important for
the pharmaceutical world to be strong. We
have to strive for excellence in all that we
do, including the sciences, which are our
foundations.
Where are the positive trends?
A major opportunity lies in reorientation
with the many new stakeholders involved
in discovery, development, production and
consumption of medicines. The economic
activity here increases every day and with
that the involvement of pharmacists. In
other words, the drug development process
as a whole represents an expanding market.
Note that under such conditions it is much
easier to become a significant player in the
market if so wished.
Where to get strength
Since the foremost dominating player
in this connection is the pharmaceutical
industry, the likeliest orientation is to their
needs, but don’t neglect the other players if
your scientific and organisational strengths
point in their direction. The future lies in
collaborative arrangements including the
XXXII
pharmaceutical industry and the medical
and health professional world. When the
concept of individualised therapies gains
momentum, closer relations to the clinical
arena are essential.
What is excellence?
Scientists are open to fair competition as it
is seen through the refereeing system for
articles in scientific journals, for example.
Thus the route to excellence for results and
“products” goes through comparison and
competition. To have enough space for
this, the national scene often is too narrow,
at least for many small countries. For this
reason, competition at the European level
is the rational next step in the process of
reaching for excellence.
How to reach excellence
If you want to reach excellence this can
happen through: 1. Competition for
national and supranational money (from
EU). 2. Potentiation of interdisciplinary
research. 3. Optimisation of your actual
critical mass, for example, through
mergers, alliances, collaborations, and
network creations. 4. Preferential research
carriers at universities. Just now, there is
no excuse for not trying these routes, as the
pharmaceutical sciences are stated topics
in the 6th EU Framework Programme
(FP6) starting in 2003. Remember when
the scientific topics are first defined,
money for all accompanying measures
linked to these topics is released. Some
of the many pharmacy institutions in
Europe have a tradition of international
collaboration but many keep back because
they don’t consider themselves to be
strong enough for partnering. Nothing is
more wrong. There is room for you if you
want. Look out for alliances, networks,
collaborations and consortia. Here it is

important to remember that collaboration
does not necessarily need to be with others
of your kind. By the involvement of other
stakeholders of the drug development
process i.e. disparate scientific disciplines,
start-up companies and established
industries, medical doctors and hospital
providers, medicinal agencies and other
authorities, you will be helped on your
way. The list of “Expressions of Interest”
for future EU applications, published
elsewhere in this issue, could function as
a first map for such networking.
EUFEPS role
Not all results and products can be
submitted for competition in a European
context and thereby be selected for
EUFEPS Newsletter, 2003, vol. 12, issue 1
excellence, for example for obtaining
financial support through FP6. For this
reason, the level of excellence has to be
defined in additional ways. Since EUFEPS
represents all the pharmaceutical sciences
in Europe it also represents the natural
platform for setting common European
denominators for excellence regarding
education, science and training, as well
as other issues of common interest for the
pharmaceutical scientific community as
a whole. Indeed this is part of EUFEPS
strategy for 2002–2006, which will be
presented at the Council meeting in
Stockholm on 20th October 2002.
‘Safety Sciences’
– a way out of the
attrition dilemma
EUFEPS Committee on Industrial Relations
The EUFEPS Committee on Industrial
Relations (CIR) produced this discussion
paper and presented it at a recent
meeting of the EUFEPS Executive
Committee, who wanted to see it
published. Moreover, the Committee
strongly supports the CIR in urging
you - from academia, industry and
regulatory - to read it and to open a
discussion on “safety sciences and the
attrition dilemma”. (Editor: why not in
this Newsletter? see below) Also, please
indicate your interest in participating in
forthcoming activities.
The CIR is a EUFEPS think-tank,
a proactive and sometimes provocative
group, meeting once or twice a year.
Primarily, it is there to strengthen the
industrial pharmaceutical sciences and
scientists.
The current state:
Steadily increasing investments and
fantastic numbers of screened molecules
as well as higher and higher numbers of
selected compounds for development
did not reverse the steady decline in the
number of drugs reaching the market
during the past years. There were only
16 NDA submissions across the pharmaindustry
in 2002 compared to 34 in 2001
and 32 in 2000. This may be one of the main
reasons why shareholders lose interest and
trust in our business. It looks like the low
hanging fruits in pharmaceutical R&D
have been harvested! The complexity of
our business makes a rapid turnaround in
drug development unlikely. The growing
number of new and unexplored drug
targets is accompanied by decreasing
knowledge of the safety aspects of
potential medicines and thus by higher
risks for investment.
We observe an increasing resistance
of our society voiced by regulatory
authorities to accept even theoretical
safety risks from drugs, which are not
life-saving. Thus, there is a need for early
XXXIII
Last words
Thus if you want excellence in
pharmaceutical sciences:
• European standards are in demand –
a strong EUFEPS is necessary.
• Exploit EUFEPS – the federation may
help you.
• Support EUFEPS – you are needed.
signal detection and risk management
before the costly clinical development
phases start. However, it would be too
easy to claim that increasing regulatory
demands are a major reason for the lack
of success of the pharma-industry. The
number of filings dropped actually before
authorities saw the dossiers.
Simplifying, one could state that, as
a long-term solution to the problem, top
management has little more in the toolbox
than the request for an increase of the
productivity goals for drug discovery.
All too often success of a Discovery
organization is limited to a high quantitative
output of new molecules without paying
attention to a sufficient sustainability of the
candidates. To arrange for the short-term
success that is important for shareholder
satisfaction, the obvious portfolio and
productivity gaps have often been bridged
in “big pharma” by acquisition of external
portfolios. This strategy buys time but
is not necessarily accompanied by a

paradigm shift regarding the quality of
internal productivity, which undoubtedly
will drive the mature portfolio in the 6 to
10 years to come.
We often hear that the remedy for
the present situation is seen in a decrease
of the attrition of early candidates. This
is the wrong direction! Before candidate
selection and prior to entering clinical
development, the attrition should be very
high. Thereafter of course, it must be
low or as close to zero as possible. If one
would follow logic then early attempts
to screen out molecules should focus on
the main causes of failure that we can
influence – if the principal stakeholders
accept a paradigm shift through very early
partnership. This partnership is still far
from optimal in most companies despite
the fact that safety issues are – after lack
of efficacy – the most important reason
for attrition. Knowing that pre-clinical
safety plays today a subordinate role in the
selection process of a drug candidate and
that Discovery’s efficacy models make
often a rather questionable prediction
of the desired efficacy in the human
target (disease) population, one cannot
be surprised about the result, i.e. high
attrition during those drug development
phases that start being very expensive, due
to lack of both safety and efficacy. Hence,
there is real urgency to partner between
Discovery and the scientists involved
in pre-clinical Drug Safety to improve
safety-related attrition at least.
Our industry cannot afford any
longer to start with safety evaluation
only once the candidates are selected,
knowing that many of them will fail rather
quickly thereafter due to safety issues.
Many of these compound deficiencies
could have been discovered prior to
candidate selection if enough API (Active
Pharmaceutical Ingredient) had been
available for a base set of experiments
looking at more than just acute toxicity,
genotoxicity and QT interval prolongation.
Examples include: photo-toxicity,
phospholipidosis, a reasonably short in
vivo study in a suitable rodent or small
non-rodent, the use of geneexpression and
metabonomics data as well as any other
pro-active data gathering that is tailored
to the needs of candidate selection and
to the development path of the future
drug, taking into account the indication,
target patient population with possible
specific hazards, etc. Most importantly,
experienced multi-disciplinary safety
experts will have to be an integral and
creative part of the project teams during
pre-candidate selection. Unfortunately,
preclinical safety people have in the past
not been viewed as creative contributors
to drug discovery. They rather have the
image of obstacles to productivity. As a
consequence, companies prefer investing
in increasing the number of discovery
scientists and new technologies promising
to fulfil the (short term) productivity
goals. This strategy has been in place now
for over ten years and companies get what
they reward for, i.e. high numbers of drug
candidates whereas overall productivity
in terms of successfully launched
innovative drugs still drops. So, in order
to progress logically one should strive
for a high safety-related attrition (of the
right molecules!) through a much earlier
(target identification!) more intense and
integrated partnership between Discovery
and preclinical as well as clinical safety
scientists (safety pharmacology, DMPK,
toxicology, clinical) with the goal to
increase the confidence in the safety of a
molecule, at the latest when it is selected
as a drug candidate. The solution cannot
be to simply shift the conventional safety
studies necessary for Phase I into the precandidate
selection phase. The solution
should rather be to use our grey matter
before we test the white powder in order
to come to a tailor made safety strategy for
every new molecule!
The future:
Today the profile of a pre-clinical safety
scientist has to go significantly beyond
the one of a traditional toxicologist. The
future safety scientist has to integrate
knowledge accumulated in all safety
relevant disciplines (primary & secondary
pharmacology, functional genomics,
safety pharmacology, ADME, physicochemistry,
clinical and toxicology with all
its special branches) to excel in modern risk
assessment and risk management. In order
to succeed in this ambitious endeavour,
there is an urgent need for improved,
XXXIV
enhanced and adapted academic training
in safety sciences, aiming at closing the
gap perceived in industry and regulatory
sciences. This gap becomes evident if
one tries to hire an experienced safety
scientist. Several university courses
such as veterinary medicine, pharmacy,
medicine and biology should provide
its students from the beginning with a
transparent avenue towards a future career
in multi-disciplinary ‘Safety Sciences’.
The latter must therefore become a visible
and attractive area of specialization.
How to proceed:
A rational approach for enhanced training
in safety sciences with a potential midterm
impact would be to seek input from
the interested parties (Academia, Industry
and Regulatory Agencies), during a
workshop focusing through case studies on
training needs in our university education
system. Such a gap analysis could then
serve to draft a post-graduate curriculum
for a safety scientist, identify already
existing elements for a tailored training
program and draft a staged approach to
meet the evident additional needs. An
increase in the quality of existing postgraduate
training and education could
have an impact relatively quickly, while a
real mid- to long-term improvement can
probably only be achieved, if the support
of European partners in the education
of future safety scientists can be gained
through the realization that there is a
true chance for a scientific career. This
career will have broad benefit not only
for the pharmaceutical industry, the
related regulatory agencies and eventually
the patient, but also for food, chemical
and cosmetic industries and agencies
protecting the environment from toxins,
to name the most obvious ones. Last but
not least a strong science driven safety
evaluation will serve the 3 R’s (Refinement,
Reduction and Replacement of animals). If
this rule is applied strictly then molecules
that do not merit development from a
safety point of view should not go beyond
initial pre-selection stages and will thus
not enter costly development phases that
require preparation by safety studies using
dogs and/or non-human primates.

EUFEPS Newsletter, 2003, vol. 12, issue 2
Pharmaceutical
Sciences Fair
Dominique Duchêne, Professor
EUFEPS President
Professor Dominique Duchêne
introduces a new EUFEPS initiative.
What is it?
This is a completely new concept
launched by EUFEPS: to gather together
the European Pharmaceutical Sciences
societies, associations and federations, for
the joint organization of a world event in
pharmaceutical sciences.
One year ago, the EUFEPS member
societies, as well as the major European
federations and organisations involved in
the promotion of specific pharmaceutical
sciences, were invited by EUFEPS to
cooperate in the organisation of a Fair of
Pharmaceutical Sciences. These societies
will be invited to organise or co-organise
scientific events. There will be congresses
with parallel sessions for several days and
symposia on well defined topics for one or
two days, combining invited prestigious
speakers with scientific contributions (oral
or posters). The partner societies will be
responsible for the scientific content of
their respective events. EUFEPS will set up
the platform and co-ordinate the different
activities. This proposal was enthusiastically
received by many of our member societies
and other European scientific organisations.
Who will participate? On what
topics?
Up to now, more than 50% of our member
societies (Austria, Belgium, Denmark,
Finland, France, Great Britain, Hungary,
Italy, Slovenia, Spain, Sweden, Switzerland,
The Netherlands, Turkey) indicated
their willingness to participate actively, as
well as ISSX, PEFRAS, IPEC, EFB/EAPB,
EPSA and the European Pharmacopoeia.
The different events, congresses or
symposia, will deal with: Pharmaceutical
Technology/Pharmaceutics, Excipients,
Drug Disposition/Metabolism/Safety,
Biotechnology, Proteomics, Biomarkers,
Bioanalysis, Medicinal Plants/Natural
Products, Regulatory Aspects of
Pharmaceutical Sciences. All this will fill
5 days and 6 parallel sessions, to which a
prestigious half-day opening session will
be added.
Beside this purely scientific aspect, all
our member societies and the European
pharmaceutical sciences organisations
are invited to introduce their society, their
members, their major objectives and their
activities through a stand.
Last but not least, an exhibition will
take place, open to all the partner companies
of drug research and development
activities: raw materials, apparatus for
physico-chemical evaluation, production
equipment, animal technologies, startup
companies, etc. About 100 to 150
exhibitors are expected.
Different social events will take place,
either global events for the whole Fair or
separate events for the partner societies
which are encouraged to organise cocktail
parties, in the same place on the same
evening.
Where and when will the Fair take
place?
For such an event a very attractive, wellequipped,
conference centre is essential.
This is the reason why the Nice Acropolis
Conference Centre was chosen for the
first Pharmaceutical Sciences Fair. The
Fair will take place in 2005, and more
precisely from June 12–17, which normally
corresponds to very pleasant weather on
the French Côte d’Azur.
We intend that the next Fair would be
held in 2008, in Vienna, and then regularly
every two years in different European
cities.
XXXV
Up to now, what has been done?
The partner societies are known. The
scientific programme is being set up. The
conference centre is already reserved with
rooms adapted to the different events. A
preliminary budget has been established.
The share of risk and benefit has been
defined. The Pharmaceutical Sciences
Fair has been definitively chosen as the
name of this event, with the abbreviation
of PharmSciFair.
The leading team has been nominated.
Currently, it consists of Dominique
Duchêne (EUFEPS, Chair), Hans H.
Lindén (EUFEPS), Bill Dawson (GB),
Elias Fattal/Philippe Arnaud (FR), Carlo
Fornara (IT), Véronique Préat (BE),
Bernard Rentier (EFB), Tom Sam (NL),
Nico Vermeulen (ISSX) and Pia Vuorela
(FIN).
Three plenary meetings of the partners
were already held (Nice, Brussels, Paris)
as well as three meetings of the leading
team (Brussels, Paris, Amsterdam). This
leading article constitutes the official
public launching of the Fair. The first
PharmSciFair circular will be mailed by
November 2003.

EUFEPS Newsletter, 2003, vol. 12, issue 3
EUFEPS Vision on
Training
and Education
Hans H. Lindén, MSc, Executive Director EUFEPS
Bernd Clement, Professor, Chair EUFEPS Committee on training and Education
(CTE)
Is there a role for EUFEPS? Yes, there
is. EUFEPS has made improvements in
the pharmaceutical sciences training and
education part of its strategy and started
new activities. In this article, Hans H.
Lindén, Executive Director of EUFEPS,
and Bernd Clement, Chair EUFEPS
Committee on Training and Education
(CTE), present the strategy and some
related issues.
Clear Mission
The mission of the European Federation
for Pharmaceutical Sciences, EUFEPS,
is to serve and advance excellence in the
pharmaceutical sciences and innovative
drug research in Europe. This includes
training and education, as well as
representing the interests of scientists
engaged in drug research and development,
drug regulation, drug utilisation, and drug
policy-making.
Agreed Strategy
Among the primary objectives of the
EUFEPS Strategic Plan 2002–2006
are active collaboration, cooperation
and coordination between all existing
players, leading to further advance of
the pharmaceutical sciences in Europe.
Without doubt, training and education of
those already in, and those considering
entering the field, are effective tools to
pave the way for further development.
In EUFEPS, postgraduate training and
education will have priority.
Widespread Support
Currently, the EUFEPS membership
includes 25 Member Societies in 24
European countries, and nearly 500
Individual Members. The total number
of individuals embraced, directly and
indirectly, is just over 18,000. They pay
individual, national and/ or federal fees to
support local, regional and global efforts
in their fields of interest.
Advanced Training Courses
Relevant (short) courses and programmes
to meet immediate (continuing/further)
training and education needs, particularly
in industry are not easily identified, or
not at all available in Europe 1 . Stimulated
by its Committee on Industrial Relations
(CIR), EUFEPS is moving towards a
virtual “School of Excellence in the
Pharmaceutical Sciences” in Europe. The
school is made up of advanced courses
and training programmes in key fields
and new disciplines. The EUFEPS role,
supported by CIR and the Committee on
Training and Education (CTE), is to define
specific training topics, engage experts
and organise the courses, including
‘hands-on’ sessions. Additionally,
EUFEPS will encourage the organisers of
relevant local or national training courses
to add international faculty and give
the courses in English, for a European
audience. The CTE has produced a set
of criteria for such “EUFEPS Training
Courses”; EUFEPS could contribute to
their organisation and publicity. In 2002,
three training courses were announced
and one of them, on High-throughput
Drug Metabolism/Disposition, was
successfully completed. This was in close
collaboration with the Amsterdam Free
University and the Leiden/Amsterdam
Centre for Drug Research (LACDR), both
in the Netherlands.
Experience of Training Courses to
Date
There has been a long road between
the ideas for each training course and
the circulation of the final programme.
XXXVI
Hans H. Lindén, MSc, Executive
Director EUFEPS
Specialists willing to help to set up
advanced training courses are busy people,
as is the additional faculty needed to make
the course truly European. The EUFEPS
Secretariat would need additional staff to
assist in the simultaneous development
of several training courses. Nevertheless,
EUFEPS intends to continue along
this avenue, encouraging increased
collaboration between current and new
institutes and centres of excellence.
So, developing additional postgraduate
training courses in pharmaceutical
sciences is in progress. For topics, date,
location and fee etc., consult the EUFEPS
Online (www.eufeps.org) and see
announcements circulated.
Course Database
EUFEPS also decided to start developing
a “database of post-graduate training
and education courses”, which will be
made accessible to its membership. A
couple of years ago Janne Tolstrup, who
was supported by a special task force,
designed a template for this database,
utilising MS Access. The Royal Danish
School of Pharmacy granted generous
funding. A substantial number of courses
and training programmes were listed.
Unfortunately, for a number of reasons, it
was not possible to complete the database
and make its contents available.
In 2003, a restart of the project was
budgeted; updating and completing
the database is in progress. Many more
postgraduate courses and programmes,
in all areas of pharmaceutical science and
available in Europe, have been identified
by searching the Internet and added to the
database, by the pharmaceutical institute
in Kiel, Germany.
Recently, EUFEPS learned that
the Young Pharmacists Group of the

International Pharmaceutical Federation
(FIP) is working on a database of
education. EUFEPS indicated that it
would be open to collaborate by e.g.
exchanging available information.
Pharmaceutical sciences courses are the
premier concern of EUFEPS. In FIP, there
is a much stronger professional pharmacy
theme. If there is overlap, it would not be
a big problem. Options to identify relevant
courses of interest just increase.
Specialist Training
There are several emerging new initiatives,
all over Europe, to start specialist training
in pharmaceutical sciences. EUFEPS
welcomes these, of course, as well as
strongly supports the idea of establishing
Master in Drug Development and Drug
Discovery programmes.
Since specialist training would take
more than one or two short courses,
during the summer or during the school
year, an orchestrated action by a number
of centres of excellence would be needed.
We require a visionary and able conductor,
or conducting team, who could make sure
that such an orchestra would perform
enjoyable music. Certainly, this is not
just an interest for future pharmaceutical
specialists. Europe will need them to
develop new, safe medicines for its own
citizens and other populations.
Quality ’starting materials’
To achieve a high standard for a product,
the quality of the “starting materials” is
crucial. Furthermore, the materials must
be handled well during the production
process. Obviously, there is a growing
concern in several European countries
about the quality of the undergraduate
pharmacy training. This concern seems
to be shared by European Pharmaceutical
Students’ Association (EPSA), who
recently initiated a scientific supplement
to their Newsletter.
In a recent article, the Executive
Director of the Swedish Pharmaceutical
Society/Academy of Pharmaceutical
Sciences, Prof. Björn Lindeke, discussed
(in Swedish) risks with establishing
new schools of pharmacy (in Sweden).
The challenge is to meet the required
numerical output for the pharmacy
profession 2 . Since the basic training is
the same for a professional pharmacist
and a scientific career, there may not be a
sufficient number of good quality students
and teachers to provide a solid base for a
career in the pharmaceutical sciences, he
argues. In other countries, there are strong
movements to reduce the scientific contents
of the curricula in schools of pharmacy, in
favour of professional pharmacy. If these
are trends, and they cannot be reversed,
the unique pharmaceutical sciences profile
may be in jeopardy.
Of course, one solution would be
for the students, who aim for a scientific
career, to leave their home country for a
school or a university where appropriate
training is provided. If there will be not
a sufficient number of quality schools
XXXVII
available in Europe to meet the industrial
drug research needs, Europe will also be
in jeopardy. Students, graduates and postgraduates
will go elsewhere, as will the
industry.
These issues are not explicitly
discussed in the current EUFEPS
Strategic Plan, for 2002–2006. With hard
information about the current situation,
such issues would certainly be considered
in the next Strategic Plan.
Other Regions
It is in the Strategic Plan 2002–2006
that EUFEPS should collaborate on
pharmaceutical sciences training both in
its own geographical region and in others.
The FIP Board of Pharmaceutical Sciences
(BPS) and the American and Japanese
pharmaceutical sciences organisations
are, for example, collaborating on thirdworld
programmes.
Perhaps, the global platform for
advancing the pharmaceutical sciences,
FIP BPS, will be the best level for
coordinating such efforts, jointly
supported by pharmaceutical associations
and federations of all regions.
1 Workshop Report: Future Training
Needs in Pharmaceutical Sciences; www.
eufeps.org
2 Lindeke, B.: Den blomstrande tid
som kom; Elixir (Apotekarsocietetens
medlemstidning) 2/2003

EUFEPS Newsletter, 2003, vol. 12, issue 4
New Safe Medicines
Faster Award 2003
Ole J. Bjerrum, Professor
This new EUFEPS Prize was first
awarded at the 1st EUFEPS Conference
on Optimising Drug Delivery and
Formulation: New Challenges in Drug
Delivery, on September 29, 2003, in
Versailles. The award given to the three
professors, Mats Bergström, Anders
Grahnén and Bengt Långström of
Uppsala University, for their contribution
to the microdosing concept.
The microdosing concept includes dosing
to man in the range of 1/100 – 1/1000th of
the normal dosage. A compound is labelled
with a radionuclide of high specificity
allowing measurement of its distribution
through sensitive techniques like
Positron Emission Tomography (PET) or
Accelerator Mass Spectrometry. The low
dose sets modest regulatory requirements
before actual testing. Microdosing
represents a new paradigm, since human
becomes a species for candidate selection.
In this way “First in Man” is brought
forward in time.
Thus, the invention is in full
accordance with the founding text (see
below):
Microdosing is a new innovation,
which has been experimentally proven. It
represents a precompetitive methodology
that has been accepted by regulatory
authorities. Through wider application,
it has the potential both to shorten and
to increase the capacity of the drug
development process significantly. This
means microdosing will contribute to a
more efficient drug development.
Further reading about the microdosing
concept can be found in Bergström M,
XXXVIII
A Grahnén, M Bergström, B Långström
and O. J. Bjerrum.
Grahnén A, Långström B. Positron
emission tomography: a new concept with
application in tracer and early clinical
drug development. Eur J Clin Pharmacol
(2003) 59: 357–366.
The founding text for the award runs as
follows: “To honour an individual – or team
– of scientists for outstanding contribution
to the innovation and advancement of
new methodology or technology which
significantly has contributed to shorten
or to make the drug development process
more efficient”.
The award, together with 3000
EURO, is sponsored by Aventis and the
nomination is done solely at the discretion
of the EUFEPS Committee on Awards
and Prizes (CAP).

EUFEPS Newsletter, 2004, vol. 13, issue 3
Pharmaceutical Research
Community Contributions
and Expectations in New
European Union Countries
Aleš Mrhar
Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
The 10 new European Union countries,
i.e. Czech Republic, Cyprus, Estonia,
Hungary, Latvia, Lithuania, Malta,
Poland, Slovak Republic and Slovenia,
have to solve the problem of the lag
in technological development of their
industries, when compared to the
15 countries of the former EU. The
promotion of new technologies in
production processes is a necessary
condition for restructuring of their
economies. This promotion, to be
successful, must be accompanied by
a modern educational and training
system providing professionals for
running research and development in
academia on one side and, on the other,
by the capability of industry to include
educated and trained people into their
environment.
EUFEPS has been recognized as
a powerful platform to promote
pharmaceutical sciences across united
Europe by integrating academic, industrial
and regulatory institutions to reach safe
and effective medicines faster. However,
the majority of these mechanisms have
been successfully established within 15
countries of the former EU but not between
them and new EU countries. For this
reason, EUFEPS must develop activities
to bridge this gap as soon as possible.
Although Slovenia may not be a
typical case when looking at the stage
of development of pharmaceutical
profession and sciences, because these
are rapidly growing fields in this country,
a survey of its institutions can illustrate
successfully the state of affairs in the new
EU countries:
- Slovenian pharmacies have developed
to a high level of professional work
in terms of dispensing and distributing the
drugs and providing the information on
proper use of drugs. The network is partly
privatized, partly state owned, with the
staff having mainly academic education
and trained continuously on national and
international courses. Modern concepts
such as pharmaceutical care, patient
counselling for prescriptions and OTC
drugs are in place. A high standard of
review has developed in this area with the
Slovenian Chamber of Pharmacy as a nongovernmental
institution, authorized with
the regulation of the quality of professional
service.
• Slovenian pharmaceutical companies
(Lek, Krka) grow progressively and
are able to compete with the
international companies (Lek recently
became a new member of Sandoz
group), predominantly in the value-
added generic segment. The two
companies are similar according to a
number of parameters:
employees, approximately 2500
each, one third with academic
education including a substantial
number of Masters and Doctoral
Degrees
turnover per year, approximately
500 million euros each, more than
two thirds exported, in considerable
part to EU, USA and Japanese
markets
allotment of more than 10% of total
earnings for research and
development activities.
• Slovenian academic educational
and research institutions (one faculty
of pharmacy, two medical faculties,
two faculties of chemistry, two
main research institutes with divisions
involved with pharmaceutical sciences)
are internationally recognized as part
of an advanced system, able to develop
XXXIX
Aleš Mrhar
and transfer up-to-date knowledge
and advanced technologies in many
directions, both as generator and user,
• Slovenian Agency for Medicinal
Products serves as the licensing
authority for drugs and medical
devices, playing its part in the
international harmonization process.
In its structures, a large number of the
experts from national pharmaceutical
and medical academic circles are
included.
The high level of pharmaceutical
profession and science in Slovenia
represents the basis for strong integration
of all institutions in international arenas,
in terms of organizing international
symposia, summer schools and workshops,
exchanging professors and scientists,
exchanging Ph.D. students, collaborating
with Slovene scientists who are affiliated
to foreign universities and companies, etc.
Without doubt, this statement holds good
for any of the 10 countries that joined EU
on 1st May 2004.
The main problem the pharmaceutical
professionals and scientists are facing
is that a majority of the 10 countries are
small and for this reason, viewed from
a global perspective, they are not freely
appreciated as places with considerable
potential in the fields of pharmaceutical
sciences and technologies. Consequently,
the results of their work, that are significant
in many fields, are not met with a wide
response, and the transfer of know-how is
still difficult.
What these countries need at the
moment is a settled access to institutions
(faculties, institutes, companies) where
first class educational and scientific
programmes are available to bring well
trained scientists and well educated

professionals into academia, industrial
enterprises and regulatory authorities.
The instruments to promote these
activities would be invitations, exchanges,
fellowships, information links via
Internet and library networks. Inclusion
of pharmaceutical research programmes
in the international collaboration projects
such as EU Frameworks, Socrates/
Erasmus and bilateral-twinning projects
within EU are welcome. This is a critical
item, particularly at the current period,
when these countries are adjusting their
activities to European Union criteria.
Free movement accompanied with free
employment of persons across EU,
EUFEPS Newsletter, 2005, vol. 14, issue 2
which should have been put into force
(but unfortunately was not) by the date
of accession of 10 countries to EU, is a
prerequisite for implementation of this
goal.
Furthermore, an assessment of
articles prepared by institutions in the new
countries engaged with pharmaceutical
sciences and published in international
peerreviewed literature should be
undertaken. Circumstances should
be set up to make these results much
more visible. Finally, the international
symposia organized by institutions of
these countries, such as Central European
Symposia on Pharmaceutical Technology
Importance of
Research Linked with
the EMEA
Malcolm Rowland, Professor Emeritus,
University of Manchester, United Kingdom
There is a vital service that the
EMEA can perform by researching,
or making available for research,
the large body of generic data it
holds. Such research would increase
the informativeness, efficiency, and
predictability of future clinical trials
to the benefit of the citizens of Europe,
and improve the competitiveness and
economic effectiveness of the European
pharmaceutical and biotechnology
industries, in the development of
innovative medicines for unmet medical
needs.
One of the perceived, and de facto,
primary functions of the EMEA is to
ensure that the citizens of the European
Union are provided with high quality,
effective medicines that are as safe as
reasonably possible. It achieves this
through a thorough evaluation process
of each submitted application for the
registration of a new medicinal product,
followed by a continuous monitoring of
the safety profile of registered medicines.
Dealing with this evaluation process is
time-consuming, occupying much of
limited resources of the EMEA. There
is, however, another important activity,
and it may be argued responsibility, that
the EMEA should embrace. Namely, to
research and analyse the large body of
data submitted by the pharmaceutical and
biotechnology industries to provide basic
information and understanding that would
improve the design, efficiency and costeffectiveness
of future clinical trials. A
few examples of the type of research that
could profitably be undertaken follow.
Control Group or Baseline Data
To prove the effectiveness of a medicinal
product for a given indication, as well as
assessing its safety profile, comparative
studies are undertaken in appropriate
patients either against a placebo, a reference
treatment, or occasionally both. Each
company submits such data when filing
for registration of its drug. The number of
patients needed in the placebo-control or
reference-treatment group is determined
XL
and Biotechnology (started as early as
1995 and organized biennially) and the
Balaton-Baltic-Bled-Bosphorus Symposia
(planned to start in 2005) should earn
significantly more attention, not only in
terms of offering the patronage but also coorganization,
co-sponsoring and related
activities in order to bring pharmaceutical
sciences in these countries closer to the
mainstream.
Many efforts have been invested
in further progress of pharmaceutical
sciences in the new EU countries so far,
however, the majority of activities are just
ahead of us, both in the 10 and in the 15
EU countries.
Malcolm Rowland, Professor Emeritus
from some prior information. This historic
information may be gained in house, if the
company has engaged previously in the
therapeutic area, or from some external
source. Yet, in most cases, the company
in-house baseline data are limited, and
are also not made generally available to
others. In contrast, the EMEA (and other
national agencies) often receives clinical
trial information submitted by several or
more companies for the same therapeutic
indication, such that the placebo-control
and reference-treatment data pertains
to a common patient group, which if
collectively analysed would provide
important baseline information not only
about the placebo group but also the
reference group, who are often receiving
some agreed standard drug treatment,
thereby providing updated information on
its efficacy and safety profile. Furthermore,
the more that is known about these groups
the more accurate (and often the smaller)
the corresponding patient size needed in
subsequent studies, without significant loss
of statistical power, and hence the lower

the cost of the overall clinical trial. As
each new trial is undertaken, the resultant
information can be added to the existing
pooled database, thereby providing more
confident population data.
Pharmacokinetics
Apart from a few exceptions, such as
enzyme induction, transporter up or
down regulation, and possibly cardiac
output-induced changes in clearance,
the pharmacokinetics of drugs reflect
rather than alter the state of an individual.
Hence, all other factors being constant,
all substrates for a given enzyme should
equally reflect the underlying functional
variation of that enzyme within the
population. This being the case, collective
analysis of pharmacokinetic data on say
all substrates of CYP2C9 or 3A4 should
provide information not only on the
inherent functional variability of these
enzymes within the patient population, but
also allow one to determine quantitatively
the contribution of such factors as age,
gender, disease, and inhibitors of these
enzymes to the variability. Each company
has specific data on its drug, such as
knowledge of the enzymes responsible
for its elimination, but only on a limited
number of subjects, whereas the collective
data held within the EMEA would
provide a far more comprehensive and
informative dataset to address the above
questions on variability. Armed with this
generic information, one should be able to
predict a priori the likely variability of the
pharmacokinetics of a new drug within
the patient population, under a variety
of situations, thereby facilitating future
design of clinical studies and subsequent
product labelling, and also improve the
cost-efficiency of such studies.
What are the impediments to the
EMEA engaging in this research?
Arguably, there are three impediments.
One is the resistance of the pharmaceutical
and biotechnology companies to allow
their data to be collectively analysed.
Second are potential legal restrictions
imposed on the EMEA (and other national
agencies) in pooling and analysing
collective data. And, finally, is the issue
of adequate resources to undertake this
research. Each is considered in turn.
Company resistance. It may be
argued that companies concerned with
confidentiality would not agree to allow
the pooling of their data with that of
other companies. However, the proposed
research would only deal with placebo
or reference treatment data, and there are
many ways of ensuring the anonymity
of such data. Furthermore, informal
discussions with some company persons
would suggest that there would be support
for this type of research if the results of
the research were made publicly available,
as it would aid in the efficient design and
cost-effectiveness of their future clinical
studies.
XLI
Legal Restrictions. There may be
legal restrictions to what the EMEA
(and national agencies) can do with
data received from companies, which
currently limits what research can be done
on the submitted data. If so, this problem
would need to be addressed and should be
resolvable, particularly if the proposal has
the support of the industry.
Research Resources
Money, additional to what the EMEA
receives in its recurrent budget, would be
needed to engage in the type of proposed
research. As the beneficiaries within
Europe of the results of this research
would be numerous, including companies
developing innovative medicines, the
scientific and clinical community,
regulatory agencies, and interested patient
groups, it is argued that the resources
should be made available from the EU
Framework programme scheme, with
a starting point, as part of the Seventh
Framework proposed Pharmaceutical
Technology Platform for Innovative
Medicines. Furthermore, while the
research could be undertaken solely within
the EMEA (or in collaboration with the
national agencies) it is argued that it would
best be undertaken as a collaborative
activity between the EMEA, academia,
industry, and appropriate professional
scientific organisations.

EUFEPS Newsletter, 2005, vol. 14, issue 2
Pharmaceutical Sciences:
Towards a more
Competitive Europe
Ole J. Bjerrum, Professor
EUFEPS President
EUFEPS coordinated a workshop
on “How to Establish a European
Technology Platform for Innovative
Medicines” in conjunction with the 3rd
World Conference on “Drug Absorption,
Transport and Delivery Medicines” at
Barceló Hotel Sants, Barcelona, Spain,
April 21–22, 2005.
The Consortium
The workshop was supported by
the EU under the Sixth Framework
Programme Life Science, Genomics and
Biotechnology for Health. A consortium
consisting of: EUFEPS, the European
Clinical Research Infrastructure Network
(ECRIN), the European Federation
for Medicinal Chemistry (EFMC), the
European Federation of Pharmaceutical
Industries and Associations (EFPIA),
EUROTOX and the University of Cyprus
planned the workshop.
The workshop was originally planned
in the autumn 2003. However, it became
part of the European Commission and
EFPIA’s work on a Strategic Research
Agenda for Innovative Medicines for the
Citizens of Europe, providing input for the
Seventh Framework Programme.
The First Day
It started with a series of lectures on the
background for the workshop. They
concerned:
• European Technology platform for
Innovative Medicines (Octavi
Quintana Trias)
• European Strategic Research Agenda
(Jonathan Knowles)
• Reports of recent workshops on
Safety (Friedlich Pfannkuch), Efficacy
(Ian Ragan), Knowledge Management
(Nicolas Grandjean), and Education &
Training (Jorgen Dirach)
The introduction was followed by four
parallel workshop discussions on topics
suggested for the Strategic Research
Agenda:
1) Knowledge Management to resolve
current and future needs
2) Approaches and means to optimise
development of efficacious drugs and
effective treatment strategies
3) Understanding and predicting drug
safety and ways to secure safe drug
therapy
4) Appropriate education and training to
fill existing gaps and to meet emerging
needs throughout drug research,
development and evaluation.
The Second Day
Through SWOT analyses, a series of
stakeholders gave their views on their
involvement and possible contributions to
the Platform;
Academia (Daan JA Crommelin)
Clinical sector (Josep Torrent-Farnell)
Biotech SME (Axel Mesheder)
Regulatory (Rolf Bass)
Learned Societies (Christian R Noe)
Patients (Yann Le Cam).
After this, four parallel workshop
discussions took place around key
questions;
1) How to start and sustain a European
stakeholders’ collaboration for new
safe medicines? How to attract relevant
stakeholders, good talent and potential
collaborating partners through an
attractive working environment in
Europe?
2) How to exploit existing assets and
resources in Europe better and build
on European strengths, e.g. academia,
clinical sector, regulatory world,
XLII
La Sagrada Familia in Barcelona,
Spain.
government, learned societies, IT
development etc., to gain competitive
advantage and to create value,
including for biotech SMEs?
3) How should postgraduate training
be organised to increase the European
competitiveness in drug discovery,
development and evaluation?
4) How should European university
research and education support
the European Strategic Research
Agenda, particularly, in fostering
better collaboration between basic and
clinical research?
Finally, the outcome of these parallel
workshop discussions was discussed in
plenum.
Like the first EUFEPS-organised
New Safe Medicines Faster workshop
(April 2000, Brussels), this workshop
brought in all the stakeholders of the drug
development process. Of the 134 delegates
from 21 countries, who accepted the
invitation, one third represented industry
(19 from big pharma and 31 from SMEs),
one third academia and the remaining
third represented other institutions, such as
the European Commission (8), Regulatory
agencies (5) patients’ organisations (4) and
additional organisations (18). The female
to male ratio was 1 to 5.
Outcomes
The concept of a Technology Platform for
the pharmaceutical sector was discussed
from the basics upwards, and many
constructive ideas were brought forward.
There was general agreement
throughout the workshop that
implementing the European Technology
Platform for innovative Medicines
is an important component of reestablishing
Europe as the primary

location for biopharmaceutical research
and development. The stakeholders
acknowledged the value of industry
leadership, the importance of the four
topics of the Strategic Research Agenda,
and the pre-competitive approach. The
public-private collaboration as support for
the platform was also positively received.
Education & Training is a critical
component of the Strategic Research
Agenda, and the need for a pan-European
organisation of academic institutions
engaging in drug development became
obvious.
Stakeholder Input
For Academia, improvements are needed
in the critical mass of research groups,
scientist and student mobility, new
technologies, cross-disciplinary issues
and positive public perception.
The Clinical Sector’s contribution to
European competitiveness builds on the
quality of clinical research infrastructures,
capacity of investigation, databases and
biobanks. In addition, the industry needs
Europe-wide networks to make clinical
research more efficient.
For SMEs, weaknesses include
inefficient technology transfer from basic
research, too few management experts
and broadly educated drug developers, as
well as lack of existing accessible biology
facilities, GMP units and toxicology
databases.
For Regulatory, more research,
conducted at the agencies, was
recommended, e.g. by compilation of
relevant generic data from old application
files. Openness to modern methodologies
and reorientation of the regulatory
assessment demands were also seen as
important.
Learned Societies, which already
organise scientists from academia,
industry, the regulatory agencies and
clinical fields, have a long tradition,
based on a discipline-oriented European
structure. However, they will need to create
a European organisation, which covers
the complete drug development process.
They could contribute by participating in
a number of the coordination functions
needed for the forthcoming Platform.
Active involvement of Patients and
Patients’ Associations will promote drug
development in line with patients’ needs,
foster their enrolment in studies, and
encourage the implementation of new
treatment strategies.
First reporting available
A summary outcomes report from
the workshop is already posted on the
EUFEPS website; www.eufeps.org (New
Safe Medicines Faster). A full report will
be issued in the summer, at the same
time as the Strategic Research Agenda is
published, together with the outcomes of
the series of the four workshops regarding
Efficacy, Safety, Knowledge Management
and Training & Education.
Innovative Medicines replace New
Safe Medicines Faster
The heavy involvement of EFPIA and EU
in drug science R&D means that you may
not hear so much about the well-known
“New Safe Medicine Faster” in the future,
but instead about “Innovative Medicines
XLIII
Project for the Citizens of Europe”. It is
interesting to note that the new initiative
covers many of the same issues as
EUFEPS presented in 1999;
• Optimising the drug development
process by removing bottlenecks
• Giving Europe the best drug
development system in the world by
early introduction of state-of-the-art
technologies
• Rethinking all regulatory procedures
from a science-based view to minimize
bureaucracy and maximize validity
Further visions
The wording is different but the content
is along the same lines. The current
platform leadership now rests with EFPIA
and EU, and EUFEPS is in the loop as a
stakeholder. EUFEPS is also a consortium
member of the EU-supported integrated
research project InnoMed that will bring
the initiative further forward. As an
ambassador and promoter of the platform
initiative, Hans H. Lindén plans to visit to
several of the European stakeholders this
autumn.
In addition, EUFEPS is creating
further visions on how pharmaceutical
sciences can be advanced in Europe. A
number of working parties have also been
established to transform such visions into
workable strategies, to be presented and
discussed at the forthcoming EUFEPS
Council in September this year, in
Hungary.

EUFEPS Newsletter, 2005, vol. 14, issue 3
The First
PharmSciFair
– a Highly Successful
Event
Professors Ole J. Bjerrum, Dominique Duchêne, Pia Vuorela and Dr. Peter Williams
More than 1200 participants were
attracted to the PharmSciFair, which
took place between June 12 and 17 2005,
in wonderful weather in Nice in France.
Indeed, they were not disappointed.
The PharmSciFair has given us a new
platform, which allows the best and newest
European pharmaceutical achievements
to be presented, in an excellent spirit of
collaboration.
The 26 partners of the PharmSciFair,
according to their individual strengths,
collected a series of very interesting
sessions, which encompassed the modern
areas of the pharmaceutical sciences (see
EUFEPS NewsLetter 2005/2 for conditions
of becoming an active PharmSciFair
Partner). This new combination of the
diverse learned societies associated with
the pharmaceutical sciences in Europe into
one assembly shows the combined strength
of European pharmaceutical sciences in a
way, which will gain recognition globally.
The scientific session of the
PharmSciFair opening programme
was highlighted by the presentation of
Nobel Laureate, Prof. Kurt Wüthrich,
who had taken time from his busy
schedule as professor of Biophysics at the
Eidgenössische Technische Hochschule
(ETH) in Zurich, Switzerland, and Ida M.
Green Professor of Structural Biology at
the Scripps Research Institute in La Jolla,
CA USA.
The Spirit of EUFEPS Infused
PharmSciFair
The PharmSciFair had a great diversity
of attendees, including scientists from
industry (e.g. big pharma and biotech),
academia (professors and students), non
profit/government institutions, authorities
and the vendor community. Attendees
from these diverse groups came with
unique perspectives, experiences, insights,
and questions.
We truly believe the strength and
uniqueness of PharmSciFair stems
from the diversity of its providing
Partners, EUFEPS being the assembling
organisation. The advantage of diversity
is realised when experiences are shared
— when, for example, congruent, but
also differing or opposing opinions/
perspectives lead to new European
platforms as the Pharmaceutical Sciences
Fair & Exhibition. Clearly, to optimise the
PharmSciFair experience for the future,
we need to maximise the opportunities for
interaction.
Opportunities
The following were some of the
tremendous opportunities for interaction
on the new PharmSciFair platform.
One opportunity for interaction
occurred at the oral sessions, particularly
during the question-and-answer period,
which was a great way to share ideas with
a large group. The oral sessions covered
a broad spectrum of pharmaceutical
and related disciplines, and were much
appreciated by the attendees. Monday
covered;
• Drug metabolism and disposition: from
molecule to man
• Pharma BioTec
• Compound profiling
in drug discovery
• Clinical pharmacy
• Natural products
• Clinical development and optimal use
of macro-molecular drugs
• Regulatory procedures and
organisation
The parallel sessions on Tuesday
contained, in addition to the first three
XLIV
Professor Pierre Potier (left) receiving
the European Pharmaceutical Scientist
Award from Professor Dominique
Duchêne (right), PharmSciFair Chair,
and Dr. Didier de Chaffoy (centre)
Johnson&Johnson Pharmaceutical
Research and Development, Lead Sponsor
of the Award and of PharmSciFair
above, presentations on Functional
proteomics, Systems biology and
Pharmacoeconomics.
Wednesday continued with drug
metabolism and disposition, which
was one of the most extensive topics
and started another on Pharmaceutical
technology and Drug delivery, which
also continued the next day with several
simultaneous sessions. Additionally New
trends in bioanalysis were described on
two days. Thursday added “Key role for
quality within the regulatory system” to
the PharmSciFair topics.
The Last Day was Devoted to;
• Quality, safety and regulatory facets in
the excipients universe
• Anticancer agents
• Biomarkers in drug development:
research into practice
• Gene and cell therapy: current
regulation
• Bioequivalence and biologic activity of
biopharmaceuticals.
Just to mention some, highly informative
lectures were given on;
• Idiosyncracy and reactive
intermediates
• Biopharmaceutics and in silico
technology
• In-silico ADME-tox prediction
• ADMET in drug and neutraceuticals
development
• Cyclodextrins and bioadhesion
• Modified release delivery systems
• Micelles, vesicles, emulsions, nano and
microparticles
• Protein, vaccine and nucleic acid
delivery
• Clinical development and optimal use
of macromolecular drugs
• Modern procedures in protein analytics

and characterisation; Proteomics/
Metabonomics/Metabolomics/Drug
metabolism
• Process analytical technologies
(PAT): opportunities and barriers to
implementation;
• Risk management and excipients:
a challenging benefit or a concern to
industry?
• Safety considerations on excipients: are
all impurities equal?
Another place for interaction was at the
poster sessions. With around 400 posters,
and very many oral contributions there was
a lot to absorb, and interaction benefits both
to the presenter and attendee. This was a
great means to meet other people involved
in pharmaceutical problems, learn about
new science (targets, technologies/tools,
approaches, etc.), and receive direct
critique and feedback on your work. The
one-on-one poster conversations are often
cited as the most rewarding segments of
meetings.
PharmSciFair was fortunate to have a
very knowledgeable and supportive vendor
community. The vendor participants
are valuable assets to the meeting,
providing novel tools to assist scientists in
pharmaceutical research. Vendors interact
closely with scientists often on a technical
level, working to understand the needs
and future directions of their research. It
is truly a symbiotic relationship, since we
need each other to succeed.
Stands — a special section of the
exhibit/poster floor — were created in
support of the PharmSciFair mission
to foster communication among the
academic/non-profit institutions,
authorities, scientific societies and
industrial communities.
The PharmSciFair offered several
networking events, including the opening
reception and the gala dinner, several
gatherings organised by scientific
societies, as well as vendor-sponsored
activities. While these events can be great
fun, they are also wonderful opportunities
to meet new people and exchange ideas.
European Pharmaceutical
Scientist Award
It had been decided to create a prestigious
award in recognition of excellence in the
research of a European Pharmaceutical
Scientist for the PharmSciFair. It
should recognise the significant input
of a researcher in any domain of the
pharmaceutical sciences such as: drug
modelling, medicinal chemistry, gene
therapy, pharmacology, pharmacokinetics,
metabolism, toxicology, pharmaceutical
formulation, drug delivery, pharmaceutical
physico-chemistry, new in-vitro/invivo
models, etc. It should not, however,
recognise a life devoted to science,
XLV
but rather a discovery, which could be
considered as a decisive breakthrough
in drug discovery and development.
The most prestigious European research
centres were invited to nominate one
or more candidate(s) for the European
Pharmaceutical Scientist Award.
In the Opening Session, this new
Award, sponsored by Johnson & Johnson
Pharmaceutical Research & Development,
was presented to Prof. Pierre Potier,
Emeritus Director of Research CNRS and
President of Maison de la Chemie, Paris,
France.
In conclusion
The congress centre Nice-Acropolis
provided excellent surroundings with high
quality meeting and exhibition facilities
(www.nice-acropolis.com), located in the
centre of Nice, France, within walking
distance for most of the participants. Nice
is also a pan-European city with great
restaurants, coffee bars, beaches, hotels,
and shopping. Public parks, the old city
and the harbour gave the city a relaxed
ambience. Nice is in addition a cultural
and artistic city with several art museums
and painters collections. Whatever
your interests, Nice had something to
offer, besides the main attraction of
PharmSciFair.

EUFEPS Newsletter, 2005, vol. 14, issue 3
The Role of Learned Societies
in Forming a European
Technology Platform for
Innovative Medicines
Christian R. Noe, Professor, EUFEPS President
Ole J. Bjerrum, Professor, EUFEPS Past-President
At the EUFEPS-initiated workshop
on “How to Establish a European
Technology Platform for Innovative
Medicines”, held in Barcelona April
21–22 2005, six lectures were given by
delegates from European organisations
representing academia, clinical sector,
biotech SME’s, regulatory, learned
societies and patients. We feel that the
views of learned societies, put into a
EUFEPS perspective, have a general
interest for our readers.
The scene
The present ‘European crisis’ in drug R&D
is characterised by following trends: the
pharmaceutical industry is moving out of
Europe and financial support of the existing
health system is becoming increasingly
difficult. Each national pharmaceutical
sector is too fragmented to be seen as one
‘community’ and one ‘market’. In addition,
the financing of academic research is
disastrous in many countries, and the
universities are going through fundamental
reforms, which have unclear outcomes.
Hence there are challenges for strategic
planning in drug research, as well as for
implementation and financial implications.
Complexity of the task
The ‘Tower of Babel’ problem arises
because different disciplines have
different scientific cultures and languages,
and the ‘players’ involved in the various
phases and fields of drug research do not
recognise, understand and respect each
other sufficiently. Thus there is much need
for interdisciplinary and trans-disciplinary
components in drug R&D.
A superficial view of the drug R&D
process makes it appear linear from
target discovery ➞ lead discovery ➞
lead optimisation ➞ drug development
➞ marketed drugs. It is well known,
however, that this is by no means the case.
As pointed out in, for example, the New
Safe Medicines Faster concept, innovative
strategies that combine discovery and
development are needed to cultivate drug
discovery. Furthermore, the complexity
of pharmaceutical science processes or
systems is ever increasing (Figure 2).
Obviously, pharmaceutical science is the
core discipline, along with biology and
economics.
Figure 2. Complexity of disciplines in the drug R&D process
Pharmaceutical Science: a scientific core discipline
It covers: Finance; Molecular Biology; Genetics; Transgenic Animal Pharmacology;
Cell Biology; Biochemistry; Bioinformatics; Computational Biology; Structural
Biology; Pharmacoinformatics; Medicinal Chemistry; Molecular Pharmacology;
Molecular Modelling; Physical Chemistry; Analytical Chemistry; Biotechnology;
Pharmaceutical Biology; Pharmacognosy; Functional Pharmacology; Law
(Intellectual Properties); Regulatory Science; Toxicology; Pharmacokinetics;
Statistics; Galenics; Pharmaceutical Technology; Nanotechnology; Pharmaceutical
Analysis; Quality Assurance; Physiology; Radiopharmacy; Biopharmaceutical
Sciences; ADME-Research; Animal Pharmacology; Clinical Chemistry; Clinical
Pharmacy; Pharmaceutical Medicine; Clinical Pharmacology; Nuclear Medicine;
Medical Clinical Sciences; Process Engineering; Plant Engineering; Project
Management; Marketing; Public Relations; Human Resources Management;
Ethics; Logistics, etc.
XLVI
Christian Noe, Professor
The Mission and Task of the
European Technology Platform
As we see it, the mission of the European
Technology Platform for Innovative
Medicines should be:
• To work out novel strategies to prevent
and treat diseases efficiently
• To speed up the process of drug
discovery and development while
focusing on efficacy and safety
• To utilise the fruits of 25 years of
(molecular) biology-driven life sciences
research: e.g. personalised medicines to
prevent and treat common as well as
rare (orphan) diseases
Thus, the European task would include:
• How to create a spirit and enthusiasm
for European drug research
• How to generate a ‘European
Community of Drug Researchers’ by
reducing fragmentation, be it political,
national, organisational or scientific
• How to build up a unified European
pharmaceutical sector by bringing
together all stakeholders involved in
drug R&D
• How to generate one European market
for medicines by harmonising activities
The Role of learned societies
The involvement of learned societies
in drug R&D may well represent a
straightforward tool for fast development
of a European Technology Platform for
Innovative Medicines. It would facilitate
implementation if relevant societies, as
stakeholders, would organise themselves
into e.g. a ‘European Pharmaceutical
Sciences Forum’, where the complex
matrix and network of societies will be
harmonised and utilised at the European
level.

It is also noteworthy that learned societies,
with their independent scientific and social
commitment, represent a ‘third force’ not
yet exploited and willing to act. Thus
learned societies should be involved in the
development of the European Technology
Platform, not least because universities at
present are poorly organised in terms of
drug development and sometimes hesitate
to leave their ‘ivory towers’. On the other
hand, the pharmaceutical industry is
driven by economic requirements, acts
globally and cannot be made responsible
for sustainable development in a specific
area. Learned societies represent science
as a whole, as well as fields or subfields
of scientific disciplines. The membership
structures differ; they can have elected
membership, require qualification in
specific career sectors or be open to all.
Geographical organisation can be local,
regional, national, international and even
global.
The European learned societies
exist for most disciplines of drug R&D.
They organise researchers in terms of
disciplines, house academic, industry
and regulatory body scientists, and
they provide an effective infrastructure
for their membership. They take rapid
initiatives and move quickly. Money
allocated to them would increase their
output immediately.
Contributions of learned societies
to the European Technology
Platform
Learned societies could spearhead
the European Technology Platform
for Innovative Medicines. They could
help harmonise research in different
phases and fields of drug discovery and
development, and identify emerging topics
and new techniques for drug discovery,
development and evaluation early on.
Provided they organise them selves
into a drug discovery and development
functional network (Pharmaceutical
Sciences Forum), they can play a pivotal
role in organising training and education
as they house every required expertise.
Learned societies could also help
transfer promising science-related
activities from the local to the regional/
European level, and promote the common
scientific and educational programmes
of European universities. They would be
able to support intra-European mobility
and the exchange of researchers and
professionals by building a European post
doc market. Vertical (local to European)
and horizontal (different disciplines)
integration would emerge.
Challenges to learned societies
One challenge is that lectures, symposia
and training courses are becoming
increasingly commercialised, frequently
competing with the traditional activities of
learned societies. This is because learned
societies are dependent on a money flow
between industry, academia, journals
and courses. Dominating private vendors
would drain this money flow.
While using new media (Internet, data
bases) helps learned societies, it can result
in information ‘overload’, if not handled
correctly.
However, the greatest threat to
learned societies is that they will become
XLVII
marginalised, not being professional
enough due to lack of investments in
building a modern infrastructure (office,
secretarial assistance and communication).
Furthermore, if their main driving force is
only the desire to get significant EU money
for their own organisation, the European
Technology Platform for Innovative
Medicines will be biased and not
sufficiently strong in global competition.
Thus a unique chance to move towards
a globally competitive European drug
research community would be lost.
Conclusion
It is our fervent hope that the professional,
social and ethical commitment of scientists
and decision-makers involved in the
discussion of the new platform will initiate
a process that will convince everyone to
join forces to create a powerful European
Technology Platform for Innovative
Medicines.

EUFEPS Newsletter, 2005, vol. 14, issue 4
The First BBBB Conference
on Pharmaceutical Science, a
successful start to a new drug
research conference in East
Europe
More than 200 participants from 20
countries were attracted to the 1st BBBB
Conference on Pharmaceutical Science,
which took place in wonderful weather
between September 26 and 28 2005, at
Siófok, on the edge of Lake Balaton in
Hungary.
The 1st BBBB Conference on
Pharmaceutical Science reflects the birth
of a new drug research forum in East
Europe. With the earlier agreement of
the EUFEPS Committee, this forum was
initiated by the national Pharmaceutical
Societies of Estonia, Finland, Hungary,
Slovenia and Turkey. This collaboration
is additionally regarded as a continuation
and an extension of the trilateral cooperation
among the Estonian, Finnish
and Hungarian Societies that began in
1934, but was interrupted by the Second
World War and resumed only in 1990.
The aim of this scientific event is to
invite the members of these Societies
and also colleagues from other European
countries under the umbrella of EUFEPS
to gather biennially on the shore of a
lake or on the sea coast with a view to
building up closer collaboration between
pharmacists and other members of
the scientific community dealing with
drug research and development, and to
strengthening the European spirit in this
region of Europe. The initial letter of “big
waters” gave the four B: Balaton, Baltic,
Bosphorus, and Bled.
Prof. István Hermecz, chairman of
the conference, opened the meeting and
the audience was greeted by the President
of EUFEPS, Prof. Ole J. Bjerrum, and
by Prof. Sándor Görög (a member of the
Hungarian Academy of Sciences, a former
member of CIR).
The conference included 3 plenary,
10 keynote and 10 oral lectures, which
were accompanied by 67 posters. The
first plenary lecturer, Prof. Nicholas
Bodor (University of South Florida,
USA), discussed the retrometabolic drug
design concept, soft drugs and chemical
delivery systems, which are similar to the
EUFEPS-initiated “New Safe Medicines,
Faster” program (http://www.nsmf.org).
In a brilliant lecture, Prof. Michel Bauer
XLVIII
Prof. Zelko Romana (SOTE)
(Sanofi-Aventis, France) surveyed the
determination of the amorphous phases in a
drug substance and excipients by dielectric
spectroscopy. Prof. Kálmán Magyar
(Semmelweis University, Budapest,
Hungary) dealt with the discovery of the
first selective MAO B inhibitor, selegiline,
and its fundamental place in the treatment
of Parkinson disease.
The keynote lecturers discussed
different hot topics in drug research
and development. Prof. Martti Marvola
(University of Helsinki, Finland) spoke
about colon-specific formulations in
the prevention of super-infections and
colon carcinomas. Prof. Krisztina
Takács-Novák (Semmelweis University,
Budapest, Hungary) characterized the
physico-chemical profiling of poorly
soluble molecules. Prof. Seppo Lapinjoki
(University of Kuopio, Finland) presented
an overview on the quality and stability of
biopharmaceuticals. Prof. Yasemin Yazan
(Anadolu University, Eskisehir, Turkey)
introduced the audience to molecular
imprinted polymer systems for drug
delivery and controlled release. Prof.
Finnish delegation... Profs. István Erös Klebovics Imre Prof. Nyiredi Szabolcs president of
Hung Soc. To Pharmaceutic Sciences.

Matjaz Jeras (Blood Tranfusion Center
of Slovenia) surveyed cell therapies and
tissue engineering, as a new perspective
of pharmaceutical science and expertise.
Prof. Eve-Irine Lepist (University of Tartu,
Estonia) summarized the extrapolation
methods of pharmacokinetics-pharmacodynamics
from animals to man. Prof.
Sulev Köks (University of Tartu, Estonia)
lectured on the application of transgenic
animals in pharmaceutical research.
Prof. Selma Sahin (Hacettepe University,
Ankara, Turkey) analyzed the effects
of the route of administration on the
hepatic disposition of compounds. Prof.
Danielj Kikelj (University of Ljubljana,
Slovenia) introduced novel inhibitors of
the blood coagulation enzymes. Prof.
László Vereczkey (Hungarian Academy
of Sciences, Budapest) discussed the
pharmacokinetic interactions related to
cytochrome P-450 enzymes.
Oral lecturers arrived from 5 countries:
Prof. I. A. Revelsky from Moscow State
University (Russia); Prof. J. L. Augilar
from Universidad Peruana Cayetano
Heredia (Lima, Peru); Dr. T. Püssa from
the Estonian Agricultural University, Dr.
K. Naelapää from and Dr. U. Soomets from
the University of Tartu (Estonia); Dr. D. J.
Smith from Biotie Therapies Corporation
(Turku, Finland); and Prof. L Barthó from
the Medical University of Pécs, Prof. Gy.
Falkay and Dr. T. A. Martinek from the
University of Szeged, and Dr P. Krajcsi
from Semmelweis University, Budapest
(Hungary). Their presentations were well
received and initiated very interesting
scientific discussions concerning their
specific topics.
In the poster section, many talented
young scientists presented their interesting
research results covering the wide field of
drug discovery and drug development.
Their findings were discussed in depth
by the conference participants during
the afternoon of Tuesday, September 27.
Hungarian pharmacists and chemists
exhibited the majority of the posters (41),
while Estonian (12) and Finnish (10)
scientists likewise presented significant
numbers of posters, but good-quality
posters arrived from Turkey, Slovenia,
Scotland and Sweden, too. Some
interesting results were achieved in
international co-operations.
The Hungarian folk-dancers and
musicians supported the intimate
XLIX
atmosphere of the conference at the
Conference Banquet, and the Grill
Party on the second evening offered a
unique possibility for the participants
to initiate new scientific collaboration
and to broaden earlier common research
programs between different countries and
university departments.
On behalf of EUFEPS, Prof.
Dominique Duchêne congratulated
Prof. Szabolcs Nyiredy, President of the
Hungarian Society for Pharmaceutical
Science, for the excellent organization
works, and for the high scientific level of
the conference. After the closing plenary
lecture, Prof. Peep Veski, President of
the Estonian Society for Pharmaceutical
Science, showed some really beautiful
pictures of Estonia and invited the scientific
community to Tallinn to participate on the
2nd BBBB Conference in June 2007. Prof
Attila Hincal, from the Turkish Society,
announced that the 3rd BBBB Conference
would be held in Turkey in September
2009, probably at Antalya.

EUFEPS Newsletter, 2006, vol. 15, issue 1
New Safe Medicines Faster
European Technology Platform
Strategic Research Agenda
Innovative Medicines for Europe
EU Joint Technology Initiative
Ole J. Bjerrum, Professor
EUFEPS Immediate Past-President
Support to pharmaceutical research in
the European Union under Framework
Programme 7 will now be in the form of
public-private partnerships through the
Innovative Medicines Initiative (IMI).
The snowball started by EUFEPS´ New
Safe Medicines Faster initiative, in 1999,
has grown exponentially. All the terms
given in the title above prove this. The
initiative is now so large that EUFEPS can
no longer be in the eye of the movement.
Other forces have joined and indeed given
the initiative the necessary muscles, but
EUFEPS will still be in the loop.
There are still many loose ends and
uncertainties, but due to the created
momentum, further development will not
stop. The current situation is described
below.
New Safe Medicines Faster
(NSMF)
The NSMF concept still stands, as does the
need to increase the capacity of and to shorten
the drug development process. It is even
more valid today than when the first Position
Paper was written. Now the activities to fulfil
the original goals have got new branding
and promoters but the stakeholders together
with their organisations remain the same:
industry, regulators, academia, the clinical
sector and patients.
The NSMF initiative fulfilled its
role when it had a direct influence on
Framework Programme 6 through the
many calls for research projects conducted
in relation to the drug development
process. Thus the NSMF concept is still
in our thinking when EUFEPS plans or
engages in new activities, but the acronym
NSMF has, in the European context, been
overtaken by the IMI. This stands for the
new Innovative Medicines Initiative.
European Technology Platforms
(ETP)
One major objective for the European
Union is to build the most competitive
and dynamic knowledge-based economy
in the world by 2010. A key element of
this objective is the strengthening of the
science base in Europe through FP7.
Since the biopharmaceutical environment
is characterised by its focus on science and
innovation, it is essential to revitalise this
area to become more competitive.
One of the instruments to be used in
this connection has been the Technology
Platform concept covering the major
industrial sectors in Europe. The pharma
industry represents such a key area and
Dr. Fergal Donelly, from DG Research of
the EU Commission, presented the first
concept for a pharmaceutical Technology
Platform at the EUFEPS/APGI conference
on Material Science in Versailles in 2003.
However, the original Technology Platform
concept has lost some of its appeal, as the
financing of the ETP would come through
a Joint Technology Initiative.
Strategic Research Agenda (SRA)
To engage the pharmaceutical industry in a
JTI, the Commission invited the European
Federation of Pharmaceutical Industries
and Associations (EFPIA) to work out
a Strategic Research Agenda (SRA),
describing the necessary research to be
carried out in public-private partnerships
to secure the future competitiveness of the
pharmaceutical industries in Europe. In
this connection, during Spring of 2005, the
stakeholders have discussed the strategic
pharmaceutical research needed for
Europe, through 13 workshops organised
by EFPIA together with one organised by
EUFEPS (all paid for by the Commission).
L
For EUFEPS, it is encouraging to see that
most of the precompetitive research topics
suggested in the SRA correspond to those
published in the preceding EUFEPS
reports on New Safe Medicines Faster
(cf. www.EUFEPS.org). They concern
development of in vitro, in vivo and in
silico models predictive of clinical efficacy
and safety, stimulation of translational
medicine, validation of biomarkers and
new clinical trial designs as well as
sharing of core reference databases. The
first draft for the SRA was published on
July 27, 2005.
The SRA was further considered
during Autumn 2005, when additional
workshops were organised to reinforce
the SRA in the following areas:
pharmacovigilance, infectious diseases,
SMEs and finance. On basis of the
incoming comments, the final SRA is
close to publication. However, it should be
noted that the final governance structure of
the IMI initiative is still under discussion.
Innovative Medicines Initiatives
(IMI)
This initiative, also named Innovative
Medicines for Europe, is the heir to NSMF.
The content is based on the Strategic
Research Agenda, which is divided into
4 sections regarding Safety, Efficacy,
Knowledge Management and Education
& Training.
One project has already been
implemented from December 1, 2005, as
an Integrated Project under FP6 namely
INNOMED. It has 44 Consortium
Members and is supported with 14 Mio.
Euros from the Commission. EUFEPS is
participating but does not receive any EU
grants. The project is intended to validate
the ETP concept through two research
projects:

• NeuroMed, which will develop and
validate novel surrogate markers based
upon in vitro and in vivo models in
animal and humans, using Alzheimer´s
disease as a testing platform.
• PredTox will deliver new biomarkers
of toxicity and a greater understanding
of mechanisms of toxicity.
The experience gained here will be used
in the Joint Technology Initiative for
Innovative Medicines in Europe under
FP7.
EU Joint Technology Initiative
(JTI)
A Joint Technology Initiative, via Art.
171 of the EC Treaty, should finance
the Innovative Medicines Initiative,
with its SRA and ETP. However, this
does not happen automatically as 6 JTIs
are currently competing; Innovative
Medicines, Aeronotics, Hydrogen and
Fuel Cells, Embedded Systems, Nano
Electronics, GMES (Global Monitoring
for Environment and Security).
The decision will be taken by
a “Competitiveness Council” of all
European Research Ministries, later this
year. Their decision will be based on;
• European added value
• Inability of existing instruments to
achieve their objectives
• Degree and clarity of definition of
objectives to be pursued
• Strength of financial/resource
commitment by industry
• Contribution to broader policy
objectives
• Scale of the impact on industrial
competitiveness and growth
The IMI JTI is high on the priority list, but
nothing is certain. Therefore it needs your
support, see Mirror Platforms below.
The overall intentions for the JTI on
Innovative Medicines are to;
• provide a mechanism for rapid and
systematic take up, evaluation and
translation of research results into new
methods and techniques for use in the
medicines development process
• facilitate the provision of advice by
regulators for setting up “tailor made”
validations
• provide “neutral ground” for the necessary
collaboration between all
stakeholders, thereby removing the
suspicions of “biased collaborations”
that undermine collaborations today
• foster the development of a new «tool-
box» (toxicology tests, biomarkers,
clinical trials protocols, etc.) for drug
developers to reduce the risk of failure
during clinical trials
• provide the infrastructure for validation
of the new tools in view of rapid uptake
into regulatory and industry practice
• set up ‘knowledge platforms’ pooling
data from toxicology testing and
biomarker validation, which will be
available to all researchers (industry
and academic)
Since the necessary R&D cannot be done
by any one member of the stakeholders
group alone, the IMI will facilitate the
participation of all stakeholder groups
in the research, following open calls and
peer review. Research can be done by
“anybody” as long as it is carried out in
Europe.
At the present stage, March 2006, the
EU money allocated to FP7 are expected
to be considerably less than originally
anticipated. So instead of 400 Mio. Euro
per year, the Commission works with a
plan where they allocate 50 Mio. Euro in
the first year, followed by an increase in
subsequent years, when money becomes
more abundant in the EU system. The
money will be given to public-private
partnerships where industry pays for all of
their own costs and the Commission pays
for the rest. The industry has bound itself
to spend the same amount of money as the
Commission per year.
Proposed governance structure of
the IMI JTI
The IMI JTI Board shall be composed by
the Founding Members (EC and EFPIA)
and by potential new funding members.
The Executive Office is responsible
for day-to-day management regarding the
implementation of the SRA.
The Scientific Committee is an
advisory body to the Board. Collectively
it shall have the competencies to cover the
complete drug development process and
have a balance composition of academia,
patients, industry and regulatory
representatives. In particular it shall advise
on the continued relevance of the SRA
and review the scientific achievements of
the SRA implementation and advise the
board accordingly. Finally it shall advise
on the composition of the peer review
committees.
The Stakeholder Forum should be
LI
open to all stakeholders and convene
annually. It shall ensure the openness and
transparency of IMI and it can provide
strategic advice to the Board.
The Member States Group shall
approve the composition of Scientific
Committee. It shall facilitate rapid
dissemination of information and ensure
co-ordination with national activities.
Especially it shall be responsible for
the implementation of Education and
Training.
It is noteworthy that the organisation
of the Stakeholder Forum is so vaguely
presented. This leaves room for European
organisations linked to the drug
development process to act on this stage.
Conventional support through FP7
If the JTI for Innovative Medicines is
adopted at its intended scale, one should
not expect to see many calls specifically
related to the pharmaceutical research in
the ordinary FP7. However, it will still be
possible to apply for general instruments
like Marie Curie fellowships etc.
Mirror Technological Platforms
In parallel to the European Innovative
Medicines Initiative, corresponding
regional and national platforms have been
established in Denmark-Sweden, The
Netherlands, Spain, France and Romania.
In this connection, it is important that
all researchers engaged in pharma in one
way or another support these initiatives;
indicating to the national governments that
there are local researchers, who will step
in, if their respective ministers support the
JTI on Innovative Medicines. In this way,
your personal effort can strengthen the
pharmaceutical sciences in Europe and
vice versa.
Conclusion
The NSMF initiative has grown in size
and importance, but it has also been
substantially added to and changed
branding, appearing under a new name:
Innovative Medicines Initiative (IMI).
Still the decisive step of significant funding
has not yet been taken, for which reason
I appeal to all EUFEPS membership not
to lose any opportunity to promote and
support the idea in your local environment:
namely that Europe needs the Innovative
Medicines Initiative to compete in the
global arena for pharmaceuticals.
Together we can do it!

EUFEPS Newsletter, 2006, vol. 15, issue 2
Public-Private
Partnerships and
‘Le défi Americain’
revisited
Daan J.A. Crommelin, Professor
Dutch Top Institute Pharma, Leiden, The Netherlands
Le Défi Americain: The Challenge
European academic groups strive for
excellence in science; pharmaceutical
groups for excellence in the pharmaceutical
sciences. There are several ways to
measure academic success. One way is
to look at the number of publications and
their impact on progress in science. Figure
1 clearly indicates that Europe, scattered as
it may be, is doing rather well in terms of
impact when compared to our American
and Asian colleagues. But, what about the
ensuing economic activities? Statistics tell
us that 5 of the top-ten pharmaceutical
companies are Europe based, the other 5
have their base in the USA. But with R &
D activities, the balance is different. Only
17% of pharmaceutical R & D activities are
performed in Europe, compared to 53%
in the USA and 29% in Japan (PhRMA
Annual Membership Survey, 2004). When
one looks at small pharma companies,
the situation is not very different. The
US definitely has the lead and Europe is
lagging behind. Twenty years ago these
statistics were very different with Europe
in a leading position. Why did this happen?
The answer most often given is: the pricing
of drugs in the USA is more favourable
than in Europe. That means there is an
economic drive. But, that is not the only
factor. There is more to it: the mentality
within the academic community. Among
my scientifically successful academic
colleagues in the USA, very few have
never started or been involved in one or
more start-up companies. It is part of their
academic scientific business, it is part
of the mission of academic institutions.
This long-term tradition has also created
the financial infrastructure for these
developments. Venture capitalist driven
initiatives have flourished. And the
money required was partly provided by
European institutions. In Europe we have,
‘grosso modo’, not followed that strategy.
Academic and industrial activities were
more separated. ‘It was not done’, as an
academic, to pursue transformation of
academic concepts into products. The
lack of financial and legal infrastructures
was the result and not the reason for
lack of success. A number of originally
European inventions were developed
and commercialised in the USA. Can we
change this trend? In other words can
we find in Europe an answer to ‘le défi
americain’, the American challenge, a
theme already addressed in the famous
book by the French author and politician
Servan-Schreiber published in 1967. Can
we find an answer for Europe, culturally
and economically divided as it is? This
contribution briefly discusses a number of
issues that may help to successfully deal
with ‘le défi americain’.
Academic Excellence and
Industrial Success
There are differences in Europe with regard
to the relationship between academic
research centres and industry. Table 2
indicates that in Sweden, Denmark and
the UK, industrial activity as a percentage
of expenditure in the pharmaceutical/
biomedical field is considerably higher
than elsewhere in Europe. The UK,
Denmark and Sweden are also among
the high scoring countries with regard to
scientific impact (table 1). Is this the key
to success? Good academic and industrial
research go together? If that is the solution,
what can we do to regain momentum in
pharmaceutical R & D in Europe? To turn
a ‘brain drain’ into a ‘brain gain’? To turn
the transatlantic flow of money around?
LII
Daan J.A. Crommelin, Professor
University Leadership
The European academic system should
be sensitised to the idea that striving for
commercialisation of academic research
is part of the mission of universities. Not
in and through academic groups. These
groups should excel in their field of the
pharmaceutical sciences. Academic
research should lead to new concepts. To
develop a pharmaceutical product from a
concept is not an academic responsibility.
To sensitise the scientists is one thing, to
make the academic leadership appreciate
and support these efforts is a second
challenge. My colleagues in the USA
bring in a lot of dollars to their universities
by their industrial activities, be it through
upfront money, milestone payments or
royalty payments. They also personally
benefit from these endeavours. Is that
good? It certainly gives an extra drive.
A professional business attitude, based
on realism and familiarity with business
ground rules, is a first requirement for
the university leadership. Only leadership
appreciating that excellence in sciences
goes together with a strong academicindustry
link should be chosen. This also
implies that in the quality assessment of
academic groups, the academic-industry
interaction should be factored in.
Technology Transfer
Concept development leads to patent
applications and the university should
have mechanisms to support patent
submission and to do its part in the process
of value creation from this know-how by
industry. In my experience, technology
transfer offices at universities are not
the most flexible and inventor-friendly
institutes. The culture is still too much
‘us against them’. One reason I can see

is lack of respect from the side of the
scientist for the legal expert who runs
away with ‘his baby’. Another is the lack
of feeling of technology transfer officers
for the mindset of basic scientists and the
typical academic culture. In the section on
Education and Training, I will offer some
solutions.
Transparency
Then the issue of ‘transparency’. Flexibility
in an academic system, where value
creation is taken as part of the mission,
is essential and here again leadership is
required, as a primary human reaction
such as jealousy can be detrimental to
the performance of research groups.
Total transparency of procedures and
agreements is a prerequisite so that there
is a firm basis for discussions on perceived
unfairness and possible conflicts of
interest.
Education & Training
An interesting hybrid set of skills is
required to successfully run a high
tech pharmaceutical business. A basic
understanding of scientific concepts
and academic culture is definitely an
advantage. Therefore, that hurdle is low
for entrepreneurs with a PhD in science.
It just makes it easy to communicate and
understand the intricacies of the academic
science world. But, at present, relatively
little attention is paid at the Master and
PhD training levels to the managerial,
financial and legal (e.g. intellectual
property) structure in the high tech
pharma industry. This could be attributed
to lack of expertise in the academic world
and the difficulties in bringing in experts
from outside. Here lies a challenge for both
the academic and industrial world: to set
up education and training programmes for
workers in the high tech pharmaceutical
industry and... technology transfer officers
to bridge the gap.
From Concept to Product: Filling
the gap
How to give this process: ‘from concept
to product’ a smooth ride? Prerequisites
are excellence in science, a determined
academic management and interest for
new concepts from the pharma and biotech
industry. A stimulation programme should
consist of a number of supporting elements,
each for a specific stage of the process. It
is essential to take into account the long
horizon of pharmaceutical research.
Typically, a full drug development
programme takes 10+ years and those
Table 1
Worldwide rankings based on publication output and citation impact, 1998-2001
Production of research Relative citation impact
articles
of articles*
United States 1,269,036 1 1.42 2
United Kingdom 354,724 2 1.21 4
Japan 337,810 3 0.85 18
Germany 313,712 4 1.09 9
France 231,550 5 1.01 13
Canada 164,182 6 1.21 5
Italy 150,013 7 0.95 17
Russia 127,965 8 0.32 29
China 115,403 9 0.41 27
Spain 106,023 10 0.85 19
Australia 103,648 11 1,01 12
The Netherlands 93,129 12 1.25 3
India 73,787 13 0.37 28
Sweden 72,469 14 1.13 8
Switzerland 65,878 15 1.44 1
South Korea 57,399 16 0.65 21
Belgium 47,685 17 1.09 10
Israel 46,336 18 1.06 11
Taiwan 44,457 19 0.65 22
Poland 43,518 20 0.55 24
Brazil 43,373 21 0.55 25
Denmark 37,086 22 1.17 6
Finland 34,371 23 1.15 7
Austria 33,854 24 0.98 15
Norway 23,195 25 1.01 14
Turkey 23,013 26 0.44 26
Greece 21,736 27 0.71 20
Mexico 21,014 28 0.60 23
New Zealand 20,961 29 0.96 16
Ukraine 20,304 30 0.28 30
* The citation impact is normalised for the worldwide average per discipline. This is
the average number of citations received by all research articles in the professional
journals (worldwide average*). Self-citations of researchers of their own articles are
excluded.
Source: CWTS/ISI. Adjusted by CWTS
LIII
who design financial support programmes
should be aware of this long horizon. An
interesting development is the appearance
of Public Private Partnerships (PPPs). The
Dutch Top Institute Pharma (TIPharma)
just started and is an example of such a PPP.
Academic and industrial groups submit
projects to this virtual (so no ‘bricks and
mortar’) institute. The projects must have
a pre-competitive, translational character
and are financed (60 million euro/ year)
via a 1-1-2 mechanism: the academic and
industrial groups are committed to bring in
25% each and the Dutch government 50%
of the funding. The funding mechanism has
a multiplier effect which makes it attractive
for each group. This initiative brings the
academic and industrial world together
in an early stage of research: concept
development with a strong translational
character: ‘from bench to clinic’. Later, the
industry will work on the development of
interesting concepts or spin-offs can be
set up for value creation purposes. For this
later development stage, other supporting
mechanisms are available resembling the
American SBIR (small business innovation
research) program. With increasing
competitiveness the subsidy level decreases.
Subsidy schemes can be set up via national
initiatives. Why not set up PPPs along the
lines of a Dutch Top Institute Pharma,
but then within the framework of the EU?
An European Top Institute Pharma in the
seventh framework programme of the EU?
Will the Innovative Medicines Initiative
(IMI) evolve into a PPP structure?
Conclusion
Le défi americain: the American
challenge. It is clear, Europe has the strong
science base that is needed. But, presently
the set-up of a coherent response to the
challenge is more a national than an EU
initiative. This should change! PPPs may
be part of the answer. PPP stands for
Public Private Partnerships, but one can
also read: Profit for the academic world,
Profit for the private industry and Profit
for our economy and society.
Table 2. The participation of Industry
in medical/pharmaceutical research
Sweden 66%
UK 65%
Denmark 61%
US 48%
Norway 40%
The Netherlands 40%
Germany 35%

EUFEPS Newsletter, 2006, vol. 15, issue 2
How to develop
academic drug
research in Europe
Rodolfo Paoletti, Professor
University of Milan, Italy
In this article, Professor Paoletti,
formerly an Executive Committee
member of EUFEPS and long-term
contributor to the EUFEPS Committee on
Academic Research Relations, gives his
views on important future developments
in the academic institutions, which are a
core element of pharmaceutical sciences
in Europe.
Rapid Development and
Restructuring
The pharmaceutical sciences are currently
undergoing rapid development and major
restructuring. The revolution of molecular
biology and progress in mapping the human
genome have created new challenges and
opportunities for drug research covering
all aspects from discovery to clinical use
of drugs. To meet the challenges, there
is a pressing need for pharmaceutical
scientists with interdisciplinary training
coupled with an academic and industrial
research perspective.
Enormous Potential to Exploit
Unleashing the full potential of European
universities is a key part of the Lisbon
Strategy to create jobs and growth in
Europe. With 4 000 institutions, over 17
million students and some 1.5 million
staff - of whom 435 000 are researchers
- European universities have enormous
potential. However, this potential is not fully
exploited and is not working effectively to
strengthen Europe’s drive for more growth
and more jobs. Universities also have to
accept that research is no longer an isolated
activity and that the emphasis is shifting
from individual researchers to teams
and global research networks. Scientific
problems tend to go beyond traditional
disciplinary structures: cutting-edge
research is increasingly being conducted
at the interface between academic
disciplines or in multidisciplinary settings.
Universities’ research environments are
more competitive, globalised and require
greater interaction.
Process Approach Preferred
Academic groups have traditionally
worked on one aspect of the drug discovery
or development process. Pharmacology or
pharmaceutical technology departments
in academic centers defined their own
research goals and worked in more or less
splendid isolation. While they were small,
this has led to important new findings and
an understanding of basic mechanisms.
The idea of following the industrial
pipeline approach for creating new drugs
was neither appreciated nor followed.
Nowadays, one can observe trends
towards increasing group size in order to
reach a critical mass, focusing research
on particular subjects and structuring
academic drug research institutes more
along the lines of industrial operation:
the drug pipeline including the feedback
loops. This process is driven, for example,
by advice from internal and external
review panels and by networks. Currently,
research institutes concentrating entirely
on different aspects of drug research can
be found in selected European countries
including Denmark and the Netherlands.
Despite the willingness of the universities
to spin off their expertise, encouraged
by national governments, Europe is
facing a knowledge paradox: academic
research groups do an excellent job, but
the activities, business and products
resulting from this are limited. Further
attuning of research directions and
stimulation of academic drug research
through innovation platforms, both at
the national and international level,
LIV
Rodolfo Paoletti, Professor
is required. For instance, centers for
Good Manufacturing Practice (GMP)production
of biotechnological drugs
(antibodies, vectors, cell therapies) are
needed. Several deficiencies hamper the
drive for innovation in healthcare;
• a lack of qualified people
• insufficient start-ups from universities
• an inadequate clinical biotechnical
research structure in most academic
centers
• slow introduction of biologicals
• a lack of funds.
EMEA Important Role
Current regulation is not able to cope
with new developments. The European
Medicines Agency (EMEA) is the main
drug regulation and registration agency
in Europe, and so decisions of the EMEA
should quickly apply to individual
countries.
Intellectual Property in Focus
A more professional approach towards
protection of intellectual property by
academic medical centers is important
just as is a more professional approach
towards seed capital funding for
biotechnological companies. Some fifteen
years ago, a good publication in a highlevel
scientific journal used to be the
start of a small company. Experience has
shown that it is not that easy any more.
The intellectual property rights that gave
rise to such a start-up company should in
future stay in the parent institution. It is of
great importance that intellectual property
becomes a focus in the process of drug
development, together with the experience
of the employees. Universities cover both
the educational and the research aspects,
which make them the ideal place for this
focus. The education system needs to be

adapted to the current multidisciplinary
approach in drug development. Many new
people are not trained in a multidisciplinary
way, but focus on one area. Teaching them
to focus on multiple areas can increase
these people’s productivity. In addition,
medical schools and teaching hospitals
have largely abdicated their responsibility
to educate physicians, leaving that to drug
companies. To solve these problems the
training of clinicians should be improved:
more emphasis should be laid on
molecular pathology, biotechnology and
on drug development/regulation. This will
stimulate innovation in drug research.
Drug Development Challenges
Drug companies often concentrate on
producing minor variations of top-selling
drugs already on the market – called
“me-too” drugs. Most of the research and
development funding goes into clinical
trials, the last stage of drug development.
Innovative drugs are much rarer and
stem from publicly funded research at
university and government laboratories.
Yet much industry-sponsored clinical
research is carried out at academic medical
centres. Studies show that such research
is more favourable toward the sponsors’
drugs than publicly funded research,
and it is often biased in design – e.g., a
clinical trial may compare a new drug
with a placebo, when what doctors really
want to know is how it compares with an
old drug. GCP, Good Clinical Practice, is
an international set of ethical and quality
standards that applies to medicinal trials
in humans. These standards indeed
relate to research and have been in effect
for many years pertaining to all trials
intended to generate data for marketing
authorization procedures whether they be
new medicinal products or line extensions
for already marketed products. As a
general rule, academic research involving
already marketed products and not
intended to generate results for marketing
authorization purposes has been exempt
from these rules. Yet within the EU, these
rules, as of May 1st 2004, pertain to any
medicinal trials in humans, including
those involving already marketed drugs
and trials performed without industry
engagement. This represents a serious
challenge to the academic independent
drug related research, as systems to assure
GCP compliance must be developed,
which in turn requires allocation of
appropriate resources.
European Diversity Benefits
Modernisation of Europe’s universities,
involving their interlinked roles of
education, research and innovation, has
been acknowledged not only as a core
condition for the success of the broader
Lisbon Strategy, but as part of the wider
move towards an increasingly global and
knowledge-based economy. The European
LV
dimension offers the potential benefits of
larger scale operation, greater diversity
and intellectual richness of resources,
plus opportunities for cooperation and
competition between institutions. In this
respect, the European Commission has
already proposed the establishment of the
European Institute of Technology (EIT).
This new organization could contribute to
improving Europe’s capacity for scientific
education, research and innovation,
while providing an innovative model
to inspire and drive change in existing
universities, in particular by encouraging
multi-disciplinarity and developing the
strong partnerships with business that
will ensure its relevance. Interaction with
the outside world will gradually make
universities’ activities more relevant to
the needs of citizens and society at large.
It will help universities to promote their
different activities and to convince society,
governments and the private sector that
they are worth investing in.
Urgent Modernisation Needed
Universities are key players in Europe’s
future and for the successful transition
to a knowledge-based economy and
society. However, this crucial sector of the
economy and of society needs in-depth
restructuring and modernisation if Europe
is not to lose out in the global competition
in education, research and innovation.

EUFEPS Newsletter, 2006, vol. 15, issue 3
15 th Anniversary
Sunday, September 24, 2006
Radisson SAS Scandinavia
Hotel, Copenhagen, Denmark
In conjunction with the EUFEPS
Conference on “Membrane Drug
Transporters: Impact on Drug Discovery,
Development, Regulation and Usage”
Aim
Founded in Strasbourg in 1991, EUFEPS
exists to serve and advance excellence in
pharmaceutical sciences and innovative
drug research in Europe.
It is there to help to meet the challenges
and seize the opportunities created by
the consolidations occurring both within
Europe and globally, driven on by a
combination of rapid advances in science
and technology, economic pressures, and
by political will.
Constituency
Currently, EUFEPS links 24 Member
Societies in 24 countries. The total
membership of all EUFEPS Member
Societies comprises more than 20 000
individuals. In addition, there are more
than 600 Individual Members.
EUFEPS is the only pan-European
body to represent the interests of scientists
in industry, academia, government and
other institutions engaged in drug research
and development, drug regulation, drug
utilization and drug policy making
throughout Europe.
Foundation
Before the inauguration of EUFEPS,
the need for an independent, scientific
European body to promote the interests
of pharmaceutical sciences had been
discussed for years. Also, there were
scientific organisations established in
several countries. In the invitation to a
scientific meeting, held in conjunction
with the 100th Anniversary of the
German Pharmaceutical Society, in
1990, it was suggested that a European
federation of pharmaceutical sciences
associations should be considered. At the
meeting, attended by representatives from
Austria, Croatia, Czechoslovakia, Greece,
France, Hungary, Italy, The Netherlands,
Poland and Sweden, this idea was further
discussed, and there was a general and
enthusiastic agreement to proceed along
these lines. A working group was formed,
an important task of which was to prepare
for a formal founding meeting in 1991.
On September 21, 1991, the inaugural
meeting was held in Strasbourg at the
Council of Europe Congress Centre.
Mr. Anders Björck, President of the
Parliamentary Assembly of the Council
of Europe, opened it. He stressed, in
his inaugural speech, the importance
of working together for increased
competitiveness. For this, he would
rather see joint European efforts than
uncoordinated actions, country by country.
At this meeting, 16 national associations
(cf. current list of Member Societies, on
last page) agreed to formally establish the
European Federation for Pharmaceutical
Sciences (EUFEPS).
Leadership and Council
EUFEPS is governed by a ten-member
Executive Committee, meeting 4-5 times
a year. The Members of this Committee
are elected by EUFEPS Council, which
meets once a year. The Council comprises
representatives of all Member Societies
and of the Individual Membership. Former
members of the EUFEPS Executive
Committee, include:
Dominique Duchêne, France (Past
President)
Douwe D. Breimer, The Netherlands
(Past President)
Ernst Mutschler, Germany (Past President)
LVI
Malcolm Rowland, United Kingdom
(Past President)
Stig Agurell, Sweden (Past Secretary-
General)
Piero Sensi, Italy (Past Treasurer)
Björn Lindeke, Sweden (Past Secretary-
General/Treasurer)
Bernd Clement, Germany
Henk J. de Jong, The Netherlands
Tony Fell, United Kingdom
Anders Grahnén, Sweden
A. Atilla Hincal, Turkey
Yvette Michotte, Belgium
Karoly Nikolics, Hungary
Fernand Pellerin, France
Paul Rossignol, France
Michel Veillard, France (Past Treasurer)
Altan Demirdere, Turkey
Aleš Mrhar, Slovenia
Conny Bogentoft, Sweden (Past Treasurer)
The current Executive Committee
members are:
Christian R. Noe, Austria (President)
Daan J.A. Crommelin, The Netherlands
(President-elect)
Ole J. Bjerrum, Denmark (Immediate
Past-president)
Hans H. Lindén, Sweden (Executive
Director)
Per From, Sweden (Treasurer)
Rodolfo Paoletti, Italy
Theo Dingermann, Germany
Chris Doherty, United Kingdom
Hilda Köszegi-Szalai, Hungary
Pia Vuorela, Finland
Hans H. Lindén has served as Executive
Director since 2002.
Strategic Plan
The leadership works out a strategic plan
to be adopted by the Council every 4 years.
It is updated midterm. Plans have been
issued in 1994, 1998, 2002 and 2006.

Engagement in EU Supported
Pharmaceutical Sciences
Consortia
EUFEPS participates actively in the
following publicprivate partnerships:
BioSim Network of Excellence dealing
with simulation and modelling (from
2004).
EUMAPP Special Support Action on
microdosing (from 2005).
InnoMed Integrated Project on new
approaches for accelerated development
of new safe and more effective medicines
(from 2005).
Help and advice
To help initiate, monitor and execute
activities of EUFEPS, there are a number
of advisory panels.
They include, currently:
The Committee on Academic Research
Relations (CARR)
The Committee on Awards and Prizes
(CAP)
The Committee on Industrial Research
Relations (CIRR)
The Committee on Training and Education
(CTE)
Working Parties/Adhoc Groups
These are being created when appropriate.
Currently, the following ones are active:
• Creating a Pharmaceutical Sciences
Forum
• Permanenting the Pharmaceutical
Sciences Fair
• Exploring a Pharmaceutical Sciences
Academy
• Mapping Pharmaceutical Sciences
Funding
In this connection, it is noteworthy that
EUFEPS will host the first meeting
about a Pharmaceutical Sciences Forum
of European sister federations and
associations. In addition, ad hoc scientific
programme and organising committees
plan and steer EUFEPS´ congresses,
conferences and courses.
EUFEPS Presidents’ Conferences
To establish direct contact with the
Presidents of the national Member
Societies, regular meetings have been set
up e.g. in Barcelona, April 2005; in Nice,
June 2005; in Versailles, November 2005;
and in Vienna, June 2006.
European Congress of Pharmaceutical
Sciences & PharmSciFair
The European Congresses are biennial
gatherings with focus on advances in
the pharmaceutical sciences. They were
held in Amsterdam (1992), Berlin (1994),
Edinburgh (1996), Milan (1998), Budapest
(2000), Stockholm (2002) and Brussels
(2004).
With the wish to make these general
meetings into a true European event,
involving the larger number of the most
active European scientific societies in the
pharmaceutical science field, EUFEPS
ended the series by introducing the
Pharmaceutical Sciences Fair & Exhibition
(PharmSciFair) held for the first time in
Nice in 2005. The following stakeholders
invested financially and scientifically, and
shared the revenue:
• Academy of Pharmaceutical Sciences
of Great Britain (APSGB)
• Association de Pharmacie Galénique
Industrielle (APGI)
• Association Francaise des Affaires
Réglementaires (AFAR)
• Associazione Docenti e Ricercatori
Italiani di Tecnologie e Legislazione
Farmaceutiche (ADRITELF)
• Austrian Pharmaceutical Society (ÖPhG)
• Belgian Society of Pharmaceutical
Sciences (BSPS)
• Deutsche Pharmazeutische
Gesellschaft (DPhG)
• European Association of Pharma
Biotechnology (EAPB)
• European Directorate for the Quality
of Medicines (EDQM) & European
Pharmacopoeia (PhEur)
• European Federation for Medicinal
Chemistry (EFMC)
• European Federation for
Pharmaceutical Sciences (EUFEPS)
• European Pharmaceutical Students´
Association (EPSA)
• European Society of Clinical
Pharmacy (ESCP)
• Finnish Pharmaceutical Society (FPhS)
• Hungarian Society for Pharmaceutical
Sciences (SSPH)
• International Pharmaceutical
Excipients Council Europe (IPEC
Europe)
• International Society for the Study of
Xenobiotics (ISSX)
• Italian Society for Pharmaceutical
Sciences (SISF)
• Netherlands Society for
Pharmaceutical Sciences (NVFW)
• Pharmaceutical Society of Denmark
(DPS)
• Slovenian Pharmaceutical Society (SFD)
• Société de Chimie Thérapeutique, in
France (SCT)
LVII
• Swedish Academy of Pharmaceutical
Sciences (SAPS)
• Swedish Proteomics Society (SPS)
• Turkish Pharmaceutical Technology
Scientists’ Association (TÜFTAD)
• University of Helsinki (HY)
To make PharmSciFair a widely
recognised scientific event and to
acknowledge a scientist, who has
contributed to pharmaceutical sciences
research and discovery at an exceptional
level, EUFEPS launched the European
Pharmaceutical Scientist Award, with a
€15000 prize.
Because of the Pharmaceutical Science
World Congress, only a PharmSciFair
Exhibition will be held in 2007. The next
full Fair is planned for 2009 in Nice.
Optimising Drug Development
Conferences
These represent a unique discussion forum
for scientists from the pharmaceutical
industry, regulatory agencies, and
academic institutions on specialised
themes. This series started in 1994, and
twelve conferences on Optimising Drug
Development will have been held through
2006 with Basel as host city.
Two conferences were held on
Optimising Biotech Medicines, in Berlin
(2002), and in Brussels (2004). The next
one is planned for Munich (2008).
Two conferences on Optimising Drug
Delivery and Formulation were held in
2003 and 2005, together with APGI,
Versailles being host city.
Conferences on Compound Profiling
and Lead Optimisation were held in Nice
(2005) and Zürich (2006), respectively, and
a third one on Drug Candidate Selection is
planned.
BBBB Conference on
Pharmaceutical Sciences
Comprising Balaton, Baltic, Bled and
Bosphorus partners of EUFEPS, the first
event was held in Siofok, at Lake Balaton
(2005). The next one will take place in
Estonia in 2007.
Other Conferences
Two world conferences on Drug
Transporters have been held in
Copenhagen (2004 and 2006), and two
World Conference on Drug Absorption,
Transport and Delivery, in Copenhagen
(2004) and in Barcelona (2005).
In addition, recent special conferences
were done on ‘When poor solubility

ecomes an issue’ in Verona (2006), and
on ‘Scientific progress underpinning
process analytical technology (PAT)’,
Gothenburg (2006).
New Safe Medicines Faster
Initiative
A research proposal was launched in 1999
to strengthen the European competitiveness
in innovation, development and use of new
and safe drugs, including stronger links
between industry, academia, hospitals
and regulatory authorities, to the benefit
of the European citizens. More efficient
use of modern technology, new methods
of drug exploration and better training
of scientists, doctors and regulators are
all vital elements for streamlining this
process.
It obtained support from the EU
Framework Programmes and a number
of activities have been launched on this
basis:
New Safe Medicines Faster
Workshop I, Brussels (2000), Workshop
II, Copenhagen (2003), and Workshop III
Barcelona (2005). In addition, the topic has
been handled in Afternoon Sessions at the
EUFEPS Congresses (2002 and 2004).
All have been followed by extensive
reports and EUFEPS was responsible for
post workshop dissemination from the
Barcelona 2005 event. These efforts have
built the foundation for the Joint Research
Initiative for creating a Technological
Platform for Innovative Medicines under
the 7th Framework Programme.
EUFEPS Networks
To assist coordination of new European
initiatives within the pharmaceutical
sciences, EUFEPS engages in and
supports various networks:
• Safety Sciences (2004)
• Process Analytical Technology (PAT)
Sciences (2004)
• Pharmacogeneticts and
Pharmcogenomics (2006)
• Bioavailability and Biopharmaceutics
(2006)
• The Programme Providing Partners
Network for PharmSciFair
• The Membership Network for the
BBBB Conference
European School of Excellence in
Pharmaceutical Sciences
Rapidly changing demands, created
by newly emerging science and
methodologies in pharmaceutical research
and development, call for new training
options. Five EUFEPS post-graduate
courses on HT Drug Metabolism/
Disposition in Leiden/Amsterdam have
been held since 2002. Further courses are
planned.
European Journal of
Pharmaceutical Sciences
This is the Official Scientific Journal of
EUFEPS, published monthly by Elsevier,
Amsterdam.
EUFEPS NewsLetter
Published quarterly and electronically
circulated to the EUFEPS membership,
as well as to all members of all EUFEPS
Member Societies.
EUFEPS Flash
Established in 2004 as direct
communication to those on the EUFEPS
mailing list, who want to be updated about
scientific activities and meetings.
EUFEPS Membership Bulletin
Established in 2005 to inform all members
about recent items of interest e.g. the
outcome of Presidents’ Conferences.
EUFEPS Online
Website established in 2000 for more
rapid, easy access and direct contact with
the scientific community.
EUFEPS Member Societies
• Academy of Pharmaceutical Sciences
of Great Britain, United Kingdom
• Association de Pharmacie Galénique
Industrielle (APGI), France
• Austrian Pharmaceutical Society,
Austria
• Belgian Society of Pharmaceutical
Sciences, Belgium
• Croatian Pharmaceutical Society,
Croatia
• Czech Pharmaceutical Society, Czech
Republic
• Dutch Association of Pharmaceutical
Sciences, The Netherlands
• Finnish Pharmaceutical Society,
Finland
• German Pharmaceutical Society
(DPhG), Germany
• Hellenic Society of Medicinal
Chemistry (HSMC), Greece
• Hungarian Society for Pharmaceutical
Sciences, Hungary
• Israel Society of Clinical Pharmacy
and Biopharmaceutics (ISCPB), Israel
• Italian Society for Pharmaceutical
Sciences, Italy
LVIII
• Norwegian Pharmaceutical Society,
Norway
• Pharmaceutical Society of Denmark,
Denmark
• Polish Pharmaceutical Society, Poland
• Portuguese Society for Pharmaceutical
Sciences, Portugal
• Romanian Society of Pharmaceutical
Sciences
• Slovak Pharmaceutical Society, Slovak
Republic
• Slovenian Pharmaceutical Society,
Slovenia
• Spanish Society of Pharmaceutics and
Pharmaceutical Technology, Spain
• Swedish Academy of Pharmeceutical
Sciences, Sweden
• Swiss Society of Pharmaceutical
Sciences, Switzerland
• Turkish Pharmaceutical Technology
Scientists’ Association (TÜFTAD),
Turkey
International Relations
EUFEPS has regular close relations
with a number of international scientific
organisations such as:
• Food and Drug Administration (FDA)
which actively participates in many of
the EUFEPS conferences,
• American Association of
Pharmaceutical Scientists (AAPS)
for a Conference Exchange Programme
between USA and Europe,
• Board of Pharmaceutical Sciences
of the International Pharmaceutical
Federation (FIP-BPS) with whom
EUFEPS actively collaborates on
the organization of the Pharmaceutical
Sciences World Congress (PSWC)
which will take place in Amsterdam in
2007.
Other EUFEPS Memberships
EUFEPS also hosts a growing group of
Individual Members (>600), who support
EUFEPS directly. Further EUFEPS is
preparing to open up for a new category:
Universities and Research Institutions.
Secretariat and Location
The EUFEPS Secretariat is located in the
premises of the Swedish Pharmaceutical
Society/Academy of Pharmaceutical
Sciences in Stockholm, Sweden. It
is chaired by the Executive Director
and serves the Executive and other
committees. The Secretariat also manages
and administers the EUFEPS´ meetings,
special projects and other activities.

EUFEPS Newsletter, 2007, vol. 16, issue 1
Pharmaceutical
Science in Europe
Part 1: Analysis
Christian Noe, Professor
EUFEPS President, Vienna, Austria
On Science
The fresco on the ceiling of the festival hall
of the old university in Vienna – now the
festival hall of the Austrian Academy of
Sciences – portrays the allegory of science.
In addition to the visual impression of a late
Baroque work of art, the painting can also
be interpreted as the political objectives of
a far-reaching university reform; a reform
which can be given a European dimension.
None other than Francis III Stephen, Duke
of Lorraine (later Francis I, Holy Roman
Emperor), the last heir of the Duchy of
Lorraine, who married the “best catch”
in Europe at the time – Maria Theresa of
Habsburg – was the “spiritus rector” of
the largest university reform around the
middle of the 18th century. Through this
reform, the spirit of enlightenment was
introduced into the university on a longterm
basis.
On the four sides of the painting one
can see the remarkable portrayals of the
four faculties: “Divinarum Rerum Notitia”
represents the Theological Faculty and
means: “Take notice” of divine matters.
The term “notitia” is very subtle: The
range of interpretations goes from the mere
“perception” all the way to “knowledge
that something like this exists”. Under
the portrayal of the Philosophical Faculty
one can read: “Causarum investigatio”:
“Examining the causes/reasons”. This is
what we nowadays define as central task
of scientific work. “Iusti atque iniusti
scientia” represents the Faculty of Law:
“Scientia” means “profound knowledge”
but also the “ability to differentiate” – to
differentiate between right and wrong.
Finally, the Faculty of Medicine is
described with the words “Ars tuendae
et reparandae valetudinis”: The “art of
maintaining health and restoring it”. Here
“ars” stands for the “individual capability”
– the term “art” has not been rid of the
“practical and purpose-related” yet. The
artist does not only perform in the circus
tent but also within the university.
In our time of expanding and
interpretable neurobiology, the terms
“Notitia”, “Investigatio”, “Scientia”
and “Ars” can at the same time also be
interpreted as a logical progression within
the process of generating knowledge and
implementing knowledge. “Perceiving
– examining – knowing – acting”: with
this, the tasks of scientists are fully
described. This was valid 250 years ago.
It should also be valid today. The fresco
on the ceiling of the old university in
Vienna is a portrayal of science and
academia, which can be especially
helpful to bring the terms “science” and
“academia” out of their current narrow
constraints. Nowadays, we may be too
much fascinated by and focused on the
“causarum investigatio”, which defines the
fundamental motive for “basic research”.
However, all scientific disciplines, which
are structured in a complex manner, such
as the pharmaceutical sciences, suffer
from a onesided equation of “causarum
investigatio” with science.
Pharmaceutical Science
What do “divinarum rerum notitia”,
“causarum investigatio”, “iusti atque
inuisti scientia” and “ars tuenda et
reparandae valetudinis” really mean for
“Pharmaceutical Science”? The question
can be answered quite simply: the terms
characterise its “scientificness”. The basic
motivation of all pharmaceutical work is
an ethical one, namely to take notice of the
needs of people and to help them with the
aid of “medicines”. This ethical dimension
obliges the pharmaceutical scientist to be
LIX
The fresco on the ceiling of the festival
hall of the old university in Vienna.
aware of fundamental questions affecting
mankind. The tremendous number of
unsolved questions – mainly those of
origins of and cures for diseases – bring
the study of the causes into the focus of
our experimental work. The anchoring of
health and the health sector within a strict
legal and regulatory framework means
that profound knowledge and decisionmaking
capabilities are needed with every
pharmaceutical step or action that one
undertakes. Discovering and developing
new drugs, manufacturing these under the
highest of quality standards and ensuring
that the population is supplied with
enough of these, demands a high level
of qualified capabilities and is therefore
an art in its classical definition. Mirrored
within Pharmaceutical Science are all of
those tasks, which are portrayed in the
fresco on the ceiling of the old university
and which characterise the four faculties.
This manifold variety of tasks makes
Pharmaceutical Science one of the most
comprehensive fields in which people
can scientifically work. They are not just
in a peripheral field of “applied research”.
However, only where science is fully
lived from the perception of a problem
to the competent implementation (from
“notitia” to “ars”) - and not just limited
to the “causarum investigatio” - can
Pharmaceutical Science develop in an
adequate manner.
On “Structures” in Science
The four faculties face each other on an
equal footing when looking at the ceiling
fresco of the old Viennese university.
However, this “ranking” was not always
so. In the university of the Middle Ages, the
Philosophical Faculty as “Artists’ Faculty”
provided a type of basic education that
included the “Trivium” and “Quadrivium”

on which “Theology, Jurisprudence
and Medicine” built as careeroriented
faculties. Back then, Pharmacy was a
branch of Medicine. Astronomy, as one of
the four subjects of the Quadrivium, was
credited with the first great success story
of occidental natural science. Galileo
Galilei, as a consequence, is first of all a
symbol for the transition in the natural
sciences from its primary research method
of observing nature to the reductionistic
approach of experimental research: “From
astronomical observation to experiments
on free fall”. The reductionistic form
of experimental research takes certain
specific, partial problems out of the
whole context and works on these in
a systematic manner under controlled
conditions (“nature in a nutshell”). With its
validated results, it provides a reliable and
authoritative way of researching causes
and origins. It was this approach, which
– as no other – shaped the development
of occidental science and also society. It
is not surprising that, at the time of the
university reform of the 18th century, the
Philosophical Faculty with its success
stories in the “search for the causes and
origins”, the “causarum investigatio”, had
drawn level with the other faculties when
it came to the jockeying for positions.
In the following 200 years, the
original “Philosophical Faculty” became
more and more important. The “building
of sciences” was being set up and was
also being split into major fields and
disciplines. The assurance of working
“stone for stone” on this building with
their own efforts gave the scientists
and academics the feeling that what
they were doing basically made a lot of
sense. Working on the foundations of the
building of knowledge was – and is, just
as before – without a doubt a worthwhile
undertaking. At the start of this new
dynamic process, fierce disputes arose
between the idealistic philosophers and the
positivistic natural scientists as to “Who
embodies real science and academia?”. In
the end it came to a schism between the
humanities/arts and the natural sciences.
One example: in the year 1750 – at the
time of the enlightening university reform
– “Aesthetics” was founded by Gottlieb
Baumgarten, as a mainly natural scientific
discipline. However, shortly thereafter
“Aesthetics” was seen to be a pure arts
and humanities term. Nowadays, and
at a very slow pace, “Aisthesis” is being
discovered again as a natural science
discipline. Continual splitting up and
categorisation of the natural sciences
was inherent in the process of their
evolution: “Chemistry” and “Physics”
were among the first important natural
science disciplines that were created.
Thereby, the traditional pharmaceutical
experimentoriented education was an
important element when it came to the
foundation of Chemistry. Pharmacy itself,
in the course of this change, moved from
the Faculty of Medicine to the Faculty of
Philosophy and to the Faculty of Natural
Sciences, respectively, that had been
created out of this.
Pharmaceutical Disciplines
Splitting up into fields and disciplines
used to – and to this day still does –
follow a certain pattern: an emerging
scientific discipline defines itself – if it
has enough critical mass – as a field of its
own, including sub-fields, and – speaking
in real pictures here – it will get its place
in the “building of natural sciences”.
Also within “Pharmacy” such splitting
up into fields and disciplines took place.
Pharmacognosy, the study of medicinal
plants, was definitely a pharmaceutical
discipline from the very start. Just the
same, Pharmaceutical Chemistry under
the term “Alchemy” is a rather traditional
field. Pharmacology and Pharmaceutical
Technology were brought in as new
subjects in the second half of the 20th
century. Restructuring Pharmacognosy
into a comprehensive Pharmaceutical
Biology and the setting up of further
new subjects such as Biopharmacy,
Pharmaceutical Biotechnology or Clinical
Pharmacy are, for the moment, the steps
within this process established most
recently.
The Industrial Revolution and
“Tradition” of Knowledge
The European university, without a doubt,
was and is the most important factor
when it comes to scientific development
in Europe. It is a quite significant pillar
of the occidental civilisation as a whole.
The universities exert their influence on
society all the time. They are, however,
also intensely shaped by society – mostly
through political influence. It was the
Industrial Revolution, which in the middle
of the 19th century, introduced the massive
changes that led to the industrialisation
of society as a whole. At that time, the
power of change was mostly coming
from the new industrial entrepreneurs
and businessmen. These events also led
LX
to consequences for the university sphere.
What had been taught in universities
since the Middle Ages was complex
education which required mastering
the “art of books”, the “artes liberales”.
The trade and handicraft arts, the “artes
mechanicae”, were taught by apprentices
and journeymen paying attention to the
master and learning from him, all of
this being organised into trade guilds as
well. With the Industrial Revolution the
“machinerelated” knowledge quickly
grew. In the new situation, the traditional
ways of passing on trade and handicraft
knowledge were at a severe disadvantage
and could not cope. As a consequence
and in reaction to the developments,
“Polytechnical Institutes” were founded –
these are the institutes of technology and
universities of technology nowadays. This
means that now, after the “artes liberales”
were passed on in a canonised manner, the
“artes mechanicae” were also transmitted
in this manner. From the handicraft
techniques, technologies were created. The
new disciplines at these institutions were,
amongst others: Mechanical Engineering,
Electrical Engineering, Construction
Engineering and Architecture. However,
the subject “Industrial Pharmacy” cannot
be found in the list of major new disciplines
at the “Polytechnical Institutes”.
Driving Forces in Pharmaceutical
Science
At the end of the 19th century, the
Industrial Revolution led to the founding
of the pharmaceutical industry in Europe,
with most significant activities in the
Rhine-Main region: “Germany – the
pharmacy of the world”. The driving force
behind this was the development of the
Chemical Sciences which allowed drugs
and medication to be developed not just
from natural sources but to be invented
these medicines through the new and
fascinating opportunity of “creative”
synthesis. A time jump: about 100 years
later – this time in California – techniques
for transferring genes from one organism to
another were being developed. From now
on it was Biology, particularly Molecular
Biology, which determined the dynamics
taking place within the Pharmaceutical
Science. The heavily research-oriented
“Biotech Industry” was established.
Pharmaceutical research nowadays takes
place in globally operating pharmaceutical
industry, in biotech companies, in research
institutes and in universities. Significant
scientific results are produced in biocentres

just as they are in medical, chemical or
pharmaceutical research institutions. Due
to all these developments, in the course of
time “Pharmacy” at the universities also
changed. However, it oriented itself, as a
respectable and traditional science, first of
all towards the needs of the professional
pharmacists. In most places it responded
to new scientific developments in a
hesitant manner only. Today sub-fields
of Pharmaceutical Science are being
competently taught in a variety of nonpharmaceutical
institutions. Nevertheless,
a comprehensive pharmaceutical
education is, just as before, still only being
provided at pharmaceutical faculties and
universities. However, still too few of
these institutions are prepared to meet
the fascinating challenge. Many of them
are still not capable of adequately dealing
with the manifold pharmaceutical science
in a comprehensive manner.
On Europe
“Europe” is a region in which nearly
half-abillion people live. “Europe” is a
rich region, in which most people have a
comfortable life and enjoy prosperity as well
as social security. “Europe” is the region
whose culture and civilisation shaped the
world the most. “Europe” is responsible
for a lot of the things that are happening
in the “globalised” world. “Europe” has
the duty of taking on responsibility for
a humane society, also in the future, due
to its common cultural tradition. The
motto so far has been: “Europe – the
region which gives positive impulses to
the world!” However, the research centres
of the large pharmaceutical corporations
are currently being moved to the United
States. The production is being relocated
to India and China. At the moment, a
new motto is threatening to take effect:
“Europe – a museum!” The chemical
and pharmaceutical industry in Europe
– probably even the whole European
industrial society – is without a doubt
in a crisis. If Europe wants to remain a
leading region with regard to science
and technology, then the dimension
of “togetherness” must above all be
strengthened. This means strengthening
the common market, but also providing
standardisation for laws and regulations. It
also means setting up a much more tightly
knit scientific and academic network.
The Integration of the
Pharmaceutical Sciences in
Europe
Fifteen years ago the disparate situation
of the Pharmaceutical Sciences in Europe
and the implication thereof for European
integration was realised and acknowledged
by some of the best scientific minds in
Europe. Going from “Pharmaceutical
Sciences in Europe” to a “European
Pharmaceutical Science”: was and is the
big aim. The “European Federation for
Pharmaceutical Sciences”, EUFEPS, was
founded.
“EUFEPS” is a “learned society”.
Scientific societies are – in their
significance often underrated – supporting
pillars, which probably best represent and
mirror the “scientific community” within
a discipline. Europe today comprises
almost 50 states. Just integrating the
group of national pharmaceutical
societies at a European level is a quite
complex endeavour. With this, though,
the problems still are not solved. In nearly
every European country there are a whole
LXI
bunch of societies, which, at least in part,
define themselves as being involved with
medicines. These, as a rule, are usually
not interconnected or within one network.
In fact, there are hundreds of scientific
societies in Europe, which could “in
principle” come together to constitute a
“pharmaceutical scientific community”.
From the very start, EUFEPS has taken
on the challenge of integrating all of these,
both successfully and on an altruistic basis.
The national pharmaceutical societies
are nearly all integrated at this stage.
Nevertheless, the self-understanding
within the European dimension still has
to be strengthened. The national societies
should make even more of an effort to
“go European” than before – knowing
that one gets a lot more out of a European
dimension than what one has to put in from
the national level. In the meantime, due to
the initiative of EUFEPS, the presidents of
a number of European learned societies,
which are related to pharmaceutical
research, have come together to create
a “European Leadership Forum of
Pharmaceutical Sciences” and to promote
the horizontal integration process. In Nice
last year – coordinated by EUFEPS – the
first European pharmaceutical science and
trade fair, the “PharmaSciFair”, was held
with ringing success. In this framework
a number of European scientific
societies also presented themselves quite
effectively. In addition, the “Innovative
Medicines Initiative”, planned for the 7th
Framework Programme of the European
Commission, has its roots in a concept,
initiated by EUFEPS and supported by
EUFEPS through all stages.

EUFEPS Newsletter, 2007, vol. 16, issue 2
Pharmaceutical
Science in Europe
Part 2: “Where to go”
Christian Noe, Professor
EUFEPS President, Vienna, Austria
Understanding Pharmaceutical Research
On a European level, “New Safe
Medicines Faster” was the initiative, with
which EUFEPS was successfully able to
make known that “drug discovery” is
pharmaceutical research, which should
be supported and promoted, but also that
“drug development” deserves the same
recognition and funding as research. The
success story of the “New Safe Medicines
Faster” initiative signified a growing
public awareness of a comprehensive
definition of science from “notitia” all
the way to “ars” – from perception to the
well managed realisation.
Redefining Fields of
Pharmaceutical Research
The setting up of subjects or individual
disciplines in science has already been
discussed. The cumbersomeness, which
has come about due to this division – all
the way to the much quoted ‘ivory tower’
syndrome – has been implied as well.
Abandoning the classical division of
disciplines seems to be necessary to live
up to the new requirements and to pave the
way for a new dynamism within science
as a whole. Also in the Pharmaceutical
Sciences, a coherent new definition of
the research fields is urgently needed.
The fields should orient themselves
primarily – but not exclusively – on the
pharmaceutical discovery, development
and drug utilization pathways and will
be all encompassing. EUFEPS will
discuss with the best researchers within
the individual fields and will try to get
their advice and input. These experts will
include trained pharmacists, in addition to
biologists, chemists, medical doctors and
health professionals, as well as scientists
from other disciplines. The “scientific
community” of the Pharmaceutical
Sciences should be open to all those
who’s professional life are principally
dedicated to the task of helping people
through the use of medicines and drugs.
The commitment to the complexity of
this science and the need, as well as the
obligation, to constantly further educate
oneself is quite clear from the start for
these scientists and academics. It should
be clear to the trained pharmacists, who
have the privilege of being placed right
in the centre of this science, that only the
dedication to be the best will consolidate
their position in the future.
The Integration of Sectors
In the end, the integration of Pharmaceutical
Science also means bringing together
researchers that work in industry with
those that work in academia and with
those scientists that work in regulatory
authorities. It is just this bringing together
of the three important professional fields
within Pharmaceutical Science – academia,
industry, regulatory – where EUFEPS is so
successful at a European level. The formula
for success is high-quality workshops,
symposia and conferences that are also
up-to-date. Only in this manner can one
interest scientists in industry – who are
under a lot of time pressure as well as
pressure to succeed – to meet creative
“underfunded” university researchers, as
well as the more reserved experts from the
regulatory authorities so that they all enter
into a scientific discourse.
Main Topics in Pharmaceutical
Science – Systems Biology
As examples of up-and-coming topics, which
were recognised early on by EUFEPS as
being significant and which were the subjects
of conferences and workshops organized by
EUFEPS, one can name “Safety Sciences”,
LXII
“Biomarkers” and “Systems Biology”.
Due to its fundamental importance, the
term “Systems Biology” will be explained
here in more detail. “Systems Biology”
defines – after decades of over-deterministic
orientation in research – a nearly
“liberating” new approach within “Life
Science” research, by which the genotypes
and phenotypes within a biological system
are examined in an interlinked and jointly
correlated manner. Genome, proteome,
metabolome: these are the levels which
are being examined to the same degree
and in the same manner. Applying the
new approach, we can draw from an evergrowing,
gigantic wealth of data, which can
only be handled and interpreted with the
help of “in silico” methods (Bioinformatics).
“Systems Biology” is almost tailor-made for
pharmaceutical research. Pharmacists have
for a long time been working with biological
systems and examine these at various levels.
The range goes from biochemical systems,
e.g. the arachidonic acid cascade, all the way
to physiological systems, e.g. the nervous
system. For pharmaceutical research as
a whole, “Systems Biology” nowadays
provides a refreshing challenge to examine
and work on problems comprehensively.
“Block a receptor with an antagonist
or prevent its expression”; that is the
therapeutic alternative in the era of Systems
Biology. However, with the deactivation of
the receptor one has not reached one’s goal.
The rebuilding of the homeostasis of the cell,
of the tissue and, finally, of the organism –
i.e. the recovery of the human being – is
the aim. To attain this, detailed knowledge
of all of the processes that occur after the
introduction of the drug into the system
and after its interference with the system
should be sought. These are exciting times
for committed pharmaceutical researchers.
It is also a big chance for the Pharmaceutical
Sciences.
The “New” Industrial Revolution
For more than 40 years, researchers at
universities have been constantly hearing
about crises for universities and have taken
part in many reforms. It seems worthwhile
to reflect on the causes of such a situation.
Is it all coincidence? When the present
generation of professors was younger,
they read books such as “Brave New
World” by Aldous Huxley or “1984” by
George Orwell. Many of the things, which
back then we shuddered to think about,
have been surpassed in the modern world
by reality. Drastic changes have already
taken place and we barely notice them.

The basic tools to make a real science out
of History were “ricorsi” – this means:
observing and analysing the recurrence
of events – of course always within the
framework and conditions of a new era.
This is how Giambattista Vico, the founder
of historical research, did it. It is most
notable that we are not taking note of such
a recurrence, which is taking place in our
time. We are in the middle of an Industrial
Revolution in which human labour is being
replaced by machines, just as in the middle
of the 19th century. However, this time
around it is not the mechanical work of
mankind which is being replaced; rather, it
is the mental work which is being taken on
by “thinking machines”. This is a challenge.
But, of course, one should not just point out
the negative effects of this development.
On Knowledge Coding and
“Tradition” of Knowledge
We are delighted about computers just as
we are about cars. However, the human
mind is something very special. Being
human has to do with biological evolution
only in a limited manner, in particular
if we have a look at our intellectual and
cultural achievements. It is not the DNAcoded
tradition, which promotes this
development. Rather, it is a 60,000 year old
tradition, which has led to the word, then the
picture, then to spoken language, to music
and poetry, on to written language, to the
book roll, the codex, to the printed book
and finally to electronic communication.
This development is now ready and poised
for a type of “quantum leap” with the help
of “in silico” knowledge generation.
In reality, every insight made for the
first time by man anatomically manifests
itself within the human brain as a new,
synaptic link. This link has so far not existed
in any other human brain. “An exit is found
out of a labyrinth” or “Long processes of
thought are shortened” is what one could
say, metaphorically speaking. Even the
neuronal architecture of an intelligent
human being takes on the most fantastic
forms in the space of his or her lifetime.
It is not genetically pre-programmed and
therefore lost in the short or long term,
unless the knowledge is transmitted i.e.
shared. The most important basis for this
transmission is human language. It is coded
as written language. Only through the
progressively more efficient transmission of
knowledge from one generation to the next
was it possible to create the quite complex
knowledge and cultural society of mankind
that we have nowadays.
On the Evolution of Machine
Knowledge
The amount of generated data
(“knowledge”), effectively supported by
Information Science, i.e. in Bioinformatics,
is overwhelming. New algorithms are
being developed continually, not only
to collect and record the everincreasing
data wealth, but also to be able to answer
questions and problems posed in a more
efficient and relevant manner. Maybe,
in the near future, to also conceive new
questions. New insights and findings are
not cropping up for the first time in human
brains as new synaptic links; rather they
are being generated in a machine and
emerge as the “output” of this machine.
Even the evolution of the method to
generate new knowledge is disconnecting
itself more and more from mankind and
is being geared towards machines and
their machine language. Here we have a
paradoxical situation. The universities,
which are teaching institutions using book
knowledge and which should feel just as
challenged nowadays by this development,
just as the trade guilds were at the time
of the first Industrial Revolution, do not
perceive or take note of this fundamental
“questioning” of their functions. They
more or less indulge in half-hearted, quite
irrelevant, reforms – maybe due to a type of
unconscious unease. However, in the light
of the new developments, it is obvious, if
there is going to be a “European Institute
of Technology” then – in the “historical
recurrence” of the polytechnical teaching
institutions – it should be a “European
Institute of “in silico” Technology”!
Pharmaceutical Sciences “in silico”
Ever since the evolution of the “Rational
Drug Design”, for about the last 30 years,
“in silico” has become a regular topic
and working field within Pharmaceutical
Science. EUFEPS as well is – knowing the
significance of the “in silico” revolution/
evolution for the Pharmaceutical Sciences
– intensively working on this topic. It
is evident that “in silico knowledge
generation” and “in silico science
communication”, i.e. machine generation
and transmission of knowledge, are big
topics and they must be dealt with in a
detailed manner. However, one should
not forget that a parallel evolution of
knowledge, which is taking place outside
the human brain, also has significant
ethical consequences. “Humans should
determine the machine and not vice
versa!” Therefore the fundamental topic
LXIII
of “Ethics and in silico sciences” should
not be forgotten within the “in silico”
Pharmaceutical Sciences.
The New Pharmaceutical Scientist
When entire encyclopaedias can be stored
on a small “chip”, what is the knowledge
that is stored in a human brain worth?
Should students, in the manner of ancient
Egyptian scribes, take down all the notes
whilst sitting in a lecture and listening to a
professor so that they can take home with
them as much knowledge as possible?
The answer is crystal clear. If a lecture is
not an “event” in which the lecturer will
adequately present himself or herself, as
well as his or her interpretation of a certain
topic, if the lecture is not a “happening” in
which the student fully participates, then
this lecture actually does not have a claim
of validity anymore. Those who still sit in
the old “ivory tower” do not automatically
have the privilege of knowledge. The
knowledge in the “ivory tower” can also
be found on a chip. Knowledge – even
when it is of the highest level – is easily
accessible and available nowadays. In
the future, the researchers at universities
will not be able to limit themselves just to
generating new knowledge and passing
this on. Rather, going from generation to
generation, they must redefine the canon
of knowledge that deserves to be put into
the minds of people for them to work
with and ponder on. This is a huge task,
mainly for politicians dealing with science
as well as for universities. The European
Federation for Pharmaceutical Sciences
will do its utmost in contributing here.
In the long run, the tasks of scientists
and academics will have to do with being
able to deal with available knowledge and
with ensuring that the human dimension is
not lost. Scientific questions and academic
queries have to orientate themselves much
more towards the needs of society as a whole.
Food and nutrition, health, the environment –
these are all fully relevant themes. However,
one should also not forget that a meaningful
life experience and the freedom to shape
one’s life are fundamental human rights.
Only appropriate and relevant scientific
work can ensure that there is a chance in
reaching these goals. The fundamental
ethical commitment of the pharmaceutical
profession and the width and scope of the
requirements posed by this discipline should
mean that Pharmaceutical Science is capable
of bringing forth its next generation of young
scientists, researchers and academics, who
conform to this new picture.

EUFEPS Newsletter, 2007, vol. 16, issue 4
“Changing of the Guard”
– EUFEPS’ New
President and Past
President Share Views
Christian R. Noe, Professor, EUFEPS Past-President, Vienna, Austria
Daan J. A. Crommelin, Professor, EUFEPS President, Leiden/Utrecht, The
Netherlands
In this contribution the EUFEPS Past-
President, Christian R. Noe, and the new
President, Daan J.A. Crommelin, look
over their shoulder into the past and then
forward into the future. What has been
achieved? What are the challenges that
EUFEPS faces? What are the targets
for new activities? What forces can be
mobilised to fulfil the mission, alone or
with allies in Europe and outside this
region?
On the Organisation
Science is not “up in the sky”. Science
should not be kept in an “ivory tower”.
Science is the systematic application of
logical thinking and logical action for the
benefit of humankind. At the same time,
as a kind of art, it is an intrinsic element
of human culture. Scientific organisations
should provide a bridge between their
member scientists and society. Therefore,
such organisations are subject to an
obligation far beyond the activities of
cultural and social clubs.
At the time of its foundation, EUFEPS
was very aware of this obligation. The best
pharmaceutical scientists of Europe joined
forces to tackle the European challenge,
to generate a strong and committed
pharmaceutical scientific community in
Europe. Amazingly (or not) nowadays
and after a series of Presidents, this first
challenge is still high on the agenda of
EUFEPS. A lot has been achieved. Many
of the national organisations in European
countries are members and a high
percentage of European pharmaceutical
scientists are connected to EUFEPS
through their national organisations.
The EUFEPS initiated PharmSciFair is
the first pan-European meeting point for
scientific organisations of many countries
and pharmaceutical disciplines. The voice
of the scientists has reached Brussels
through EUFEPS. Important initiatives
like the “New Safe Medicines Faster”
and the “Innovative Medicines Initiative”
would not be there without EUFEPS.
More than one year ago, the Presidents
of 10 European scientific organisations
dealing with drug research had their
first meeting in Vienna to discuss the
formation of a “European Pharma
Sciences Leadership Forum”. At that
meeting, which had been organised by
EUFEPS, about 200,000 pharmaceutical
scientists were – through the Presidents
of the organisations – virtually present
at the table. In follow-up meetings, the
enthusiastic atmosphere of the first meeting
suffered somewhat from the attitude of
some trying to “stake their claims” and
“divide the cake”, instead of implementing
joint initiatives and planning for a coherent
community of pharmaceutical scientists
in Europe. Nevertheless, common ground
is recognised and there is commitment to
proceed. Without doubt, EUFEPS will
actively contribute to further development
of the Forum, fully aware that complex
situations are not unusual in human society
and that sorting complexity out requires
patience. EUFEPS does not want to devour
or suppress any other organisation, but it
feels obliged to continue the initiative to
bring together pharmaceutical scientific
organisations in Europe and to shape the
pharmaceutical scientific community of
this region.
While the meetings with Presidents of
European sister organisations has the long
term goal of broadening the community of
our science as a whole, the meetings of the
Presidents of our Member Societies have
been installed to optimise cooperation of
EUFEPS with its members and between
its members. An increasing number of
LXIV
conferences, jointly organised by Member
Societies with and without participation
of EUFEPS, indicates progress in this
area. Nevertheless, there is still a strong
demand by members of our Federation,
including the Individual Members, who
ask for more joint action. EUFEPS is
committed to address these demands.
Actions include;
• use of the EUFEPS Online (website)
for announcing events
• a EUFEPS database for education and
training courses
• EUFEPS-coordinated “in silico”
learning programmes, as well as
strengthened and harmonised national
websites
• increased membership of national
organisations and EUFEPS
• inspiration of pharmacy students,
young pharmacists and those with a
Masters Degree in pharmaceutical
sciences, to be interested in the science
underlying their discipline from the
beginning of their professional careers
• a widened European network to
improve chances for successfully
receiving research grants and
participating in debates on ‘hot’ topics
in the pharmaceutical sciences.
The fact that the competence of our
members in such areas ranges from very
high to non-existent is a further indicator
of the importance of such pan-European
cooperation.
For the last year, there has also been
a new membership category within
EUFEPS – Member Institutions. This
category is open to universities and
research institutions and/or clusters
of them. As will be discussed below,
actions have started to address common

needs among academic institutions,
producing science and scientists useful
for the discovery, development and use of
medicines. Furthermore, it was recently,
suggested that EUFEPS look into how
to provide useful support to Small and
Medium Size Enterprises (SMEs).
EUFEPS does not only look around
within Europe to collaborate with sister
and member societies. EUFEPS has
also operated and will operate on the
global scene. Of course, “EUFEPS and
the world” means above all close and
loyal co-operation with the FIP Board
of Pharmaceutical Sciences. Such a cooperation
that will benefit from the fact
that the current EUFEPS President is also
Chair of the FIP Board of Pharmaceutical
Sciences. Since EUFEPS is, probably,
the most efficiently organised regional
pharmaceutical scientific organisation in
the world, it can be an efficient partner
on the global scene elsewhere. Bilateral
regional work (e.g. with AAPS, DUPHAT
and the newly established Asian
Federation for Pharmaceutical Sciences)
will be continued and further co-operation
may be initiated. The fundamental ethical
commitment of our science does not allow
us to ignore needs in other parts of the
world.
On Science and Scientists
Pharmaceutical R&D is certainly a huge
endeavour. It is a billion dollar undertaking
to bring a new active compound to the
market. After discovery, the development
work of a specific new drug candidate
may take eight years or more before
the product reaches the market. The
disciplines involved range from molecular
biology and genetics to economics and
even ethics. Certainly, the variety of
different scientific languages spoken by
the involved scientists has contributed to
the long lasting decline in the number of
new drugs (NCEs) reaching the market.
The complexity of huge pharmaceutical
research projects renders overall
competence a desirable but very rare skill.
The impossibility of solving the problems
of scientific language and complexity
just by interdisciplinary work is certainly
one of the reasons for the massive
reorientation, which nowadays takes
place in all fields of sciences. Classical
disciplines are more and more reduced to
areas of “general scientific competence”
and technical skills. Areas of importance
(e.g. nutrition, health, environment,
materials) connecting scientific progress
directly to societal requirements are
taking precedence over the classical
scientific disciplines of the “academic
ivory tower”. This situation offers a
unique chance for the pharmaceutical
sciences to develop into a core field of
the natural sciences, instead of remaining
a loose conglomerate of cooperating
scientists from different disciplines. The
goal is clear: pharmaceutical research
and development is moving to cover all
scientific activities aimed at curing and
preventing diseases through medicines.
On Credibility and Competence
Credibility and competence are closely
connected to each other. It is easy to
claim a leading role in a science, which
has huge future importance. But there
is no credibility of such claims without
competence. Of course, over time,
EUFEPS has built up significant and
structured competence in its Executive,
Steering and Advisory Committees. This
competence is truly proven; it is credible
and has been the basis of both the general
line of development of EUFEPS and of
its specific actions, like conferences,
workshops and courses. The ambitious
goal to lead the European pharmaceutical
sciences to as much excellence as
achievable has fostered the decision to set
up, in addition to the existing instruments,
a body of European top experts, covering
all areas of competence of pharmaceutical
science. This body will be named the
EUFEPS Senate and will give advice to
the Executive Committee, primarily, in
strategic scientific planning Hopefully,
the Senate will become a think-tank to
help EUFEPS reach a highly recognised
position in the European scientific arena.
On Relevance and Excellence
However, excellence should not only be a
feature limited to a few selected people,
the elite, but it should be the goal that
each pharmaceutical scientist should aim
for. Nowadays, funding of sciences is a
real problem in the academic world. It is
obvious that, in times of shortage, funds
will be assigned according to a number
of rules, such as the relevance of the
topic, and the excellence of the project,
which frequently goes hand in hand with
the excellence of the scientists involved.
There is no doubt about the relevance of
pharmaceutical research itself. It is so
important that it is even frequently abused
as an “ivy leaf” for research, which, in
reality, has – at least in the medium term
LXV
– little to do with medicines. Sometimes
otherwise excellent scientists, in particular
molecular biologists, seem to use this
“ivy leaf” approach in their fund-raising.
A significant portion of public research
money, earmarked for pharmaceutical
research, has been channelled into
projects, which may be important for
other reasons, but which are of little
pharmaceutical relevance. Hopefully, the
EU “Innovative Medicines Initiative”
will primarily support projects which are
clearly oriented to develop “new safe and
effective medicines faster”. Achieving
professional excellence is a challenge
for every scientist, in particular for those
responsible for academic education.
The regular activities of EUFEPS with
cutting-edge conferences, workshops and
courses help those pursuing excellence.
To further promote the inter-institutional
dialogue, EUFEPS has created the
category of Institutional Members, which
already includes several prestigious
academic pharmaceutical research
centres. However, support for educational
and co-operational approaches will not
be enough. Of course, the question of
assessing quality of research is a critical
one. Regular evaluation of research
institutions, and ranking of papers and
scientists, comprises a significant element
of competition for funding and thus for
performing research. Parameters for fair
evaluation of work are required. The
different national peer reviewing systems
are an important element of this qualitydriven
approach. The debate on ‘best
practices’ in institutional peer reviewing
is high on the EUFEPS agenda.
On Contents and Challenges
Leadership is a prerequisite to make
progress, but it is even more important
to know, where to go. It is a particular
ambition of EUFEPS to be a leading
institution in generating new ideas and
taking up new lines of thinking in the
drug discovery and development process,
long before they become part of the
mainstream ‘routine’. The EUFEPS New
Safe Medicines Faster Initiative (NSMF)
was a very successful “translational
science” activity at a time when this
term was not even coined. EUFEPS
can now watch, in full confidence, the
development of its “baby”, the Innovative
Medicines Initiative (IMI), without being
concerned that it might not be sufficiently
recognised and rewarded for being one
of the early initiators. EUFEPS has taken

important steps towards a comprehensive
implementation of “systems biology in
pharmaceutical sciences”. This is at a time
when the scientific community has just
started to be fully aware of this paradigm
shift in life sciences. Consequently, during
the 2007 EUFEPS Basel Conference, a
next step was taken as “biosimulation” and
“modelling” research were discussed in
the light of systems biology. “Biomarkers”
and “PAT science” describe other topics,
which were brought up and handled by
EUFEPS as a pioneer. EUFEPS has
proven, from the very beginning, that it
has a good feeling where pharmaceutical
sciences are going. It is competence, based
on knowledge. Certainly, this feeling for
future trends will enable EUFEPS to
retain this leadership role in the future.
What will be the major scientific
challenges for EUFEPS, in the years to
come, both within its traditional field
of competence and beyond? Certainly,
the translational science aspect will
continue to play a significant role, because
‘monodisciplinary’ and ‘silo’ thinking
is perceived as a cause of the existing
inefficiency in the drug discovery and
development process. Translational
approaches in the pharmaceutical science
– ‘translational pharmaceutical science’
– are meant to make drug discovery
and development more successful by
stimulating direct interactions between
the different tasks and disciplines
forming the building blocks of the full
process. Such science aims facilitate the
translation of ideas, findings and concepts
into products. Specifically, it addresses
phases and steps in the drug discovery
and development processes, such as
the discovery-development transition
or the preclinical-clinical transition.
Clearly, emerging paradigms such as
individualised medicines and therapies
will specifically ask for translational
approaches to ensure rapid introduction in
the health care system.
A further major task will certainly be
to contribute to a harmonised integration
of biotech pharma into pharmaceutical
sciences. It is amazing to observe the
general lack of the notion in the biotech
field that a biotech product will have
to be developed according to similar
scientific and regulatory criteria as small
molecules. On the biotech side, one can
observe an insufficient knowledge of the
rules and relevance of drug development,
while many of the “conventional”
pharmaceutical scientists forget that they
must embrace new scientific fields – like
molecular biology and genetics – to be
able to claim full scientific competence in
their own area.
Concerning systems biology, it has
not been too difficult for EUFEPS to
generate awareness of the importance of
systems approaches in a science that is
intrinsically based on interference with
biological systems. However, beyond this
“general systems biology” awareness,
LXVI
“specific pharmaceutical systems
biology” is a rapidly growing field of
research, where genomic, proteomic and
metabolomic data are correlated by the
use of biomathematics, bioinformatics and
other “in silico” methods. “Metabolomic
networks based drug discovery” –
together with “biosimulation” and
“rational drug design” – will significantly
change approaches and efficiency in
drug discovery. In fact, the “in silico”
world has grown up over the years not
only to complement almost every area of
experimental pharmaceutical research,
but also to provide us a tremendous wealth
of scientific information via the Internet
and other sources. Bearing this important
development in mind, EUFEPS will
strengthen its efforts to promote the use
of the full scope of “in silico” methods
and applications in pharmaceutical
sciences both for experts and for those
scientists for whom these methods will
be complementary elements in their
research.
On the Mission to be Completed
At this moment of change in Presidency,
both the President and the Past President
are convinced that EUFEPS is right on
track to fulfil its mission. It has embarked
on a spectrum of initiatives with active
participation of colleagues from academia,
industry and regulatory bodies to further
shape the future of the pharmaceutical
sciences in Europe.

EUFEPS Newsletter, 2007, vol. 16, issue 4
Birth of the EUFEPS
BABP Network
Henning Blume, Professor, Frankfurt Germany
Clive Wilson, Professor, Glasgow United Kingdom
The initiation of a EUFEPS Network on
Bioavailability and Biopharmaceutics
(BABP) appears to be a natural
progression of the EUFEPS vision as
biopharmaceutics forms the bedrock of
many of the activities of the contributing
societies. It is also an important
opportunity to assist legislature in
defining a harmonised approach across
Europe.
The proposed changes in European
Guidelines for Bioavailability/
Bioequivalence (BA/BE) have prompted
the scientific community to engage in
a more comprehensive communication
with regulatory scientists and to stimulate
exchange between both groups. In
particular, efforts should focus on
scientific questions, which arise from
poorly resolved areas and on provision of
a framework from which best practice can
be developed.
Why a BABP network?
Biopharmaceutics is an encompassing
discipline of pharmacology, material
sciences, analysis and toxicology. Each
year, many of the member organisations
within EUFEPS host workshops and
conference sessions to hear key opinion
leaders talk about their research and
viewpoints. It is a broad church; with so
many disciplines represented, there will
be a growth of knowledge and disparate
standpoints, which do not always mesh
smoothly. Naturally, this activity provides
the basis of new thoughts and debate, but
being geographically dispersed, there is no
tendency to self-propel towards consensus
statements, and clear messages may not
emanate. Regulators want to follow best
practice but if different viewpoints cannot
be heard and reconciled, progress towards
uniformity will be painfully slow. This
was appreciated by both the regulators
and the scientific communities across
pharmaceutics. A core group, consisting
of Professor Dr Henning Blume, Dr
Gerald Beurle and Dr Erich Brendel,
prompted by industry and the regulators
took on the task of addressing these
issues. They resolved to generate a focus
group or network representing regulatory,
generic and traditional strongly researchbased
industry assisted by academics
from different countries. The outcome
is a regionally balanced network and
steering group, which meets regularly to
progress activities, including conferences
and workshops within a EUFEPS-based
Bioavailability and Biopharmaceutics
Network.
What will the BABP Network
provide?
The purpose of any EUFEPS network is
to join scientists together. A mission of the
BABP will be to provide an opportunity
for EUFEPS members to get to know
LXVII
Most of the BABP Network Steering
Committee in October 2007, at the Socratec
Headquarters, Oberursel, Germany. The
Steering Group include: Gerald Beurle,
Henning Blume (Chair), Erich Brendel,
Andrzej Dzierbicki, Hilda Köszegi-Szalai,
Hans H. Linden, Henrike Potthast, Tomas
Salmonson and Clive G Wilson.
each other, to explore important issues
in bioavailability, bioequivalence and
biopharmaceutics through conferences
and workshops and ultimately to propagate
learnings through various published
media. The effect of these activities will
be to help Europe to lead debate rather
than work in a reactive mode, confident
that resolutions are well-rehearsed and
strongly scientifically justified.
The starting point is communication
and it is hoped that the BABP Website
(www.babp-network.org) will develop
into the common information platform.
An additional early activity will be a twoday
conference on science and regulation
planned for June 2008. Topics will include
BCS-based waiver beyond Class 1,
considering transporter-excipient interplay
and the interpretation of data from acidic
BCS Class II and Class III substances,
for the first day. The second day will
consider the design of steady state studies
and ideas for testing novel drug delivery
systems including orally dispersible
forms. It is intended that the conference
topics will provide a stimulus for debate
and resolution, providing an opportunity
for airing issues and looking for avenues
which will facilitate consensus. A further
conference is planned on publication of
the guidelines at an appropriate point in
the future.

EUFEPS Newsletter, 2008, vol. 17, issue 1
Innovative Medicines
Initiative (IMI)
kick-off
Ole J. Bjerrum, Professor
EUFEPS Past-President
The long awaited grants, specially
designated for research related to drug
development, are within reach. Now that
the lists of topics are known, it is timely to
form consortia of interested stakeholders
beyond the founding EFPIA companies.
Current status in a historical
perspective
The long endeavour to create solid
European support for research, as well
as education and training, related to the
drug development process is almost
finished. The kick-off meeting for calls
for IMI grants will take place in Brussels
on April 30, 2008. Table I shows some
of the many events, initiatives and steps
that have preceded the present Innovative
Medicines Initiative Joint Undertaking
(IMI-JU).
Various unofficial lists of the EFPIA
proposed calls have circulated in Europe
since December 2007. The European
Commission (EC) kept the books closed
so that nobody outside really knew what
the end results would be. However, at
monthly telephone conferences held in
the EUFEPS University Membership
Network, the participants have kept each
other updated as much as possible on the
progress of IMI-related issues. The minutes
of those conferences are published on the
Network’s website. Finally, on March 3,
2008 when the IMI Governing Board was
founded, the list shown in Table II was
released from the EC for comments at
the interim Member State Contact Group.
Once feedback has been incorporated, the
final text will be available.
Call and peer review process
In short the IMI Executive Office will
issue calls according to the following
mechanism:
TABLE I - History of the IMI-JU
September 1999 Publication of New Safe Medicines Faster (NSMF) Vision
Paper
March 2000 First EC funded EUFEPS Workshop on NSMF, Brussels
New, safer and more effective drugs” in FP6
March 2002 Launching calls for “Rational and accelerated development of
new, safer and more effective drugs” in FP6
April 2003 Second EUREKA funded EUFEPS Workshop on NSMF,
Copenhagen
April 2003 Application through FP6 of a EUFEPS organised workshop
“On creation of biopharmaceutical development platform”
(subsequently transformed to an IMI technology platform)
November 2003 First contact between EC and EFPIA
May 2004 Start of official discussions between EC and EFPIA
June 2004 EFPIA agreement to take leadership of the European
Technology
Platform for Innovative Medicines (IMI)
December 2004 Publication of IMI Vision Paper
April 2005 EUFEPS organised the Workshop on “How to establish a
European Technology Platform for Innovative Medicines”,
Barcelona
August 2005 Publication of IMI Strategic Research Agenda (SRA)
October 2005 Start of the pilot project InnoMed funded under FP6
September 2006 IMI SRA version 2 (Including governance and IP policy)
May 2007 Adoption of IMI legal package by the EC
August 2007 Adoption of IMI Intellectual Property Policy
November 2007 Adoption of IMI legal package by the European Competitiveness
Council
December 2007 Adoption of the European Parliament opinion
December 2007 Approval of the establishment of IMI Joint Undertaking by the
European Council
December 2007 First EFPIA unofficial IMI calls for Expression of Interests
March 2008 Founding of IMI Governing Board
April 2008 Announcement of 1st Call for Expression of Interest
June 2008? Founding of IMI Member State Contact Group
June 2008? Founding of IMI Scientific Committee
July 2008? Deadline for Application of Expression of Interests
October 2008? Deadline for (final) project applications
December 2008? Funding and contract agreements of 1st round of IMI calls
LXVIII

• In a first stage, the Executive Office will
present a list of topics, application forms
and evaluation criteria on the IMI website
(www.imi-europe.org) and in relevant
scientific journals. Academics, SMEs
and Patient organisations, operating in
public consortia, will be invited to submit
Expressions of Interest (EoI). These will
be reviewed by one of the four Standing
Peer Review Committees. The first stage
will be completed when the EFPIA
Consortium asks that the highest ranked
Expression of Interest be developed and
submitted as a full project proposal.
In a second stage, the Public-Private
Collaboration (a grouping of the Public
Consortia and the EFPIA Consortium)
will submit its full project proposal to the
IMI Executive Office. In a second peer
review round, the relevance and eligibility
of the project for each topic will be
addressed. Successful projects will then
be invited to enter into a grant agreement
with the Executive Office.
The reviewing of the project follows
a transparent peer review process,
based on scientific excellence and the
applicant’s ability to deliver. The EU’s
7th Framework programme will fund
academic participants in Public-Private
Collaborations and support SMEs, while
the EFPIA-organised companies will
fund their own contributions 100%. Other
TABLE II - List of titles of the individual calls, duration and allocated funds*)
1. Improve Predictivity of Immunogenicity 5 yr, Euro 13 m
2. Non-genotoxic carcinogenesis 2 + 3 yr, Euro 2.5 + 10 m
3. Expert systems for in silico toxicity prediction 5 yr, Euro 5 m
4. Improved predictivity of non-clinical safety evaluation 3 yr, Euro 10 m
5. Qualification of translational safety biomarkers 5 yr, Euro 21 m
6. Strengthening the monitoring of the benefit/risk of medicines 5 yr, Euro 15 m
7. Islet cell research 5 yr, Euro 10 m
8. Surrogate markers for vascular endpoints 5 yr, Euro 20 m
9. Pain research 5 yr, Euro 7.5 m
10. New tools for the development of novel therapies in psychiatric disorders 5
yr, Euro 10 m
11. Neurodegenerative disorders 5 yr, Euro 7.5 m
12. Understanding severe asthma 5 yr, Euro 12.5 m
13. COPD patient recorded outcomes 5 yr, Euro 10 m
14. European Medicines Research Training Network 7 yr, Euro 5 m
15. Safety sciences for medicines training programme 5 yr, Euro 3 m
16. Pharmaceutical medicine training programme 4 yr, Euro 4 m
17. Integrated medicines development training programme 5 yr, Euro 3 m
18. Pharmacovigilance training programme 5 yr, Euro 3.5 m
*) List as of March 3, 2008
types of organisations participating in
Public-Private Collaborations will be
supported on a case-by case basis.
EUFEPS’ role
For partnering, EUFEPS may help to
organise a kind of fair in connection to
one of its conferences during spring 2008.
Furthermore, the EUFEPS Secretariat
will share information on consortia, as
known, under formation with interested
researchers who approach EUFEPS.
Currently, EUFEPS is engaged
in formation of a consortium on
“Safety sciences for medicines training
programme”. The Secretariat has also
received information about potential
research projects on biomarkers, safety
and pain.
How to form consortia
At present no official pan-European
website exists where the researchers can
search for partnering. What initiatives
EC will set up in this regard awaits the
official calls. However, at the national
and regional level many activities and
fora for partnering have been launched.
It is beyond EUFEPS capacity to keep
track on such activities. Here interested
parties have to address the local nodes or
agencies.
LXIX
Embark now
The pharmaceutical sciences are all
pertinent for the IMI topics. For this reason,
the majority of the EUFEPS membership
should get engaged. If you want to launch
a consortium: better start today.

EUFEPS Newsletter, 2008, vol. 17, issue 2-3
EUFEPS Today
Hans H. Linden, M.Sc.
Executive Director EUFEPS
Background
EUFEPS was founded 17 years ago. Since
then, its membership, activities, relations
and collaborative operations have
expanded a lot, even beyond European
borders, as it has entered the global arena.
The Swedish Pharmaceutical Society/
Academy of Pharmaceutical Sciences
(SAPS) provided substantial support
during the first years, to run a professional
secretariat. As this support came to an
end, funding has been replaced by project
grants from the European Commission,
by income from congresses, conferences,
workshops and courses, by more members,
as well as by uncommitted support from a
number of pharmaceutical companies.
Nearly ten years ago, EUFEPS
started initiating and setting up the New
Safe Medicines Faster Project (NSMF),
obviously, the successful forerunner of the
current Innovative Medicines Initiative
(IMI Joint Undertaking). The IMI is
funded and run in close collaboration by
the European Commission (EC) and the
European Association of Pharmaceutical
Industries and Associations (EFPIA).
So, what is EUFEPS today, at the
beginning of the post-IMI-launch era?
At the EUFEPS President’s Conference,
in April this year, a set of slides were
prepared for information and update. This
rhapsodic article is based on them, together
with some additional update material.
The Central Office of EUFEPS is
still located in the SAPS building in
Stockholm, Sweden. Since one year ago,
there has also been the Branch Office
Systems and Learning, at the University
of Vienna, Austria. Additional Branch
Offices have been considered, but these
plans did not yet materialise.
Mission
What is the mission of EUFEPS? You
know it, but why not refer to it as a reminder
of the role of EUFEPS and achievements
anticipated. It reads (Strategic Plan 2006-
2010):
“The mission of the European
Federation for Pharmaceutical Sciences
(EUFEPS) is to serve and advance
excellence in the pharmaceutical
sciences and innovative drug research
in Europe, including in training and
education, and to represent the interests
of scientists engaged in drug research
and development, drug regulation, drug
utilisation, and drug policy making.”
Implementation
Why invest time, energy and money in an
organisation like EUFEPS? There was –
and there is still – a job to be done, which
cannot be delivered by any other current
European organisation. For example,
• To underpin the only pan-European
body for pharmaceutical scientists
(whatever their origin, domain or
discipline)
• To proactively support systems
approaches in European collaboration,
co-operation and co-ordination for
better drug research, development and
use
• To further strengthen the European
voice and platform for needs and
progress communication along with
beneficial networking, including
globally
Operational platforms
How to get the job done? The current
structure, as it developed over the years,
includes a number of “platforms of
operation”, the ultimate responsibilities
LXX
Hans H. Linden, M.Sc.
for which are shared by the Council, the
Executive Committee and the Secretariat.
The Executive Committee, chaired by
Daan J.A. Crommelin, present President of
EUFEPS, includes the Executive Director
(with voice but no vote). In addition, there
are steering and other committees, many
scientific programme committees and
organising committees for meetings and
events, plus ad hoc project groups and
task forces, etc. The platforms are, in
summary:
• Membership Management
• Networks (covering certain specific
fields)
• Senate
• Research and Policy Initiatives
• PharmSciFair
• Meetings and Events
• Education and Training
• Communications
• Finance and Funding
• President’s Conference
• Council and Open Forum
• Central and Branch Offices
Membership
What constitutes the current membership
of EUFEPS? It is:
Member Societies
- 24 in 24 European countries (including
Israel and Turkey)
Member Institutions
- It’s a new category, at present including
15 European universities and research
institutions
Member Individuals
- Around 400, currently, including from
non- European region; the number is a
little lower than it has been for a number
of years

There is a EUFEPS Steering Committee
for Membership Development, chaired
and co-chaired by Buket Aksu, Executive
Committee Member, and Ole J. Bjerrum,
Past-President of EUFEPS, respectively.
Networks
What are they and why? They are there
to increase networking, of course, in and
between scientific domains that are both
relevant and important for drug discovery,
development and use, initiated and run by
scientists in the field. Current EUFEPS
Networks include:
BioAvailability and BioPharmaceutics
(BA/BP)
- Chaired by Henning Blume, Oberursel
DE
Process Analytical Technology Sciences
(PAT)
- Chaired by Peter York, Bradford UK
(retiring; new chair needed)
PharmacoGenetics and Pharmaco-
Genomics Research (PGPG)
- Chaired by Anke-Hilse Maitland-van der
Zee, Utrecht NL
Safety Sciences
- Chaired by Helmut Sterz, Paris FR
(retiring; new chair needed)
Additional Networks are emerging or being
considered, including on “Environment
and Pharmaceuticals” and on “Quality of
Medicines”, respectively.
For each EUFEPS Network, there
is a Steering Committee, composed of
members of the Network, as their time
and availability allow, with support from
the EUFEPS Executive Director and
Secretariat.
Senate
What is this? It is a new EUFEPS-linked
institution, formed as the outcome of
discussions on how to aggregate scientific
opinions relevant for drug discovery,
development and use. The discussions
started several years ago. Now, top scientists
in Europe have been identified and listed,
representing the full spectrum of scientific
disciplines. A first round of personal
invitations has been circulated, and most of
those approached have responded positively.
Additional invitation rounds will follow, to
arrive at as complete as possible a coverage
and representation of the pharmaceutical
sciences in Europe. Douwe D. Breimer,
Founding Father and Past-President of
EUFEPS, and Christian R. Noe, Past-
President of EUFEPS, are in the lead.
Research and policy initiatives
Is this activity platform crucial to the
further development of EUFEPS? Yes, it is.
It is a conglomerate of EUFEPS activities
and projects, many in collaboration with
each other. It’s all there to further regional
and global development of the science and
better serving the citizens. Significant
“old”, ongoing and new efforts include:
Projects in the European Arena
- Several projects funded by European
Research Framework Programmes, over
nearly 10 years
- Recent IMI JU Expressions of
Interests, where EUFEPS is engaged in
four out of five of the ones on education
and training, one of which through the
EUFEPS Network on Safety Sciences,
particularly
- The European Bio(Tissue)Bank Project
on Adverse Drug Reactions, initiated
and run by the EUFEPS Research
Network on PharmacoGenetics/
PharmacoGenomics
Additional collaboration in the European
region
- Good, high-level relations with
other (pan-)European institutions and
agencies, including the EMEA, the
EDQM (European Directorate for
Quality of Medicines, the European
Pharmacopoeia, primarily), ISPE Europe
(International Society of Pharmaceutical
Engineering), ESF (European Science
Foundation) and more – all having
instruments to be utilised for new
research initiatives
- The European Pharma Sciences
Leadership Forum (EuPSLF), comprising
the Presidents of ten European sister
federations/associations, in full operation
representing the European scientific
community devoted to contribute to new
and better medicines
Bilateral collaboration
- Links forged with associations and
agencies in the USA (including the FDA
and USP), Japan and in the United Arab
Emirates
Global collaboration
- The FIP Board of Pharmaceutical
Sciences (BPS) is seen as the only
current global platform. The presence of
EUFEPS is now changing from observer
to full member status
LXXI
Industrial and academic research
relations
Any other? As the NSMF has developed
into the IMI JU, contacts with industry
have been frequent, of course. However,
there is an even longer industrial research
relations initiative in EUFEPS, still
ongoing.
It is the EUFEPS Committee on
Industrial Research Relations (CIRR),
established in the very first years of
EUFEPS. Since 1994, it has been meeting
regularly, mostly twice a year. As a very
committed “think-tank” of EUFEPS, the
CIRR contributed a lot to, for example, the
meeting and course programme. Also, the
first NSMF ideas emerged in a visionary
and creative CIRR discussion.
Over the years the vast majority of
delegates in EUFEPS meetings have
been representing industry. This is not
surprising, since industry research needs
and progress, including in education and
training, have been given a high priority.
For a relatively short period, there was
also a EUFEPS Committee on Academic
Research Relations (CARR), producing an
important report on priority needs in the
field. Chances to meet were few, though,
because of limited funds among its
membership. As establishing a EUFEPS
Senate is now in progress, it is agreed that
the tasks of CARR could be continued in
this new group: the Senate.
Awards
Since it is important to recognise excellent
contributions to the development of
the research field, EUFEPS has an
award scheme. What are the EUFEPS
awards? There is the (biennial) Segré
Prize in PharmacoKinetics and
PharmacoDynamics, the (annual) NSMF
Award for new approaches, and the
(annual) Best Paper Award for articles
published in the European Journal of
Pharmaceutical Sciences.
PharmSciFair
How does it go? The first Pharmaceutical
Sciences Fair and Exhibition ever –
PharmSciFair – was successfully held
in June 2005 in Nice FR, and organised
by 26 Programme Providing Partners,
including EUFEPS. The initiative
was taken several years before within
EUFEPS. The idea was then that it
should be the start of a joint European
networking meetings platform, or the
“European Congress Week”, where all
relevant disciplines should come together

and set up their “own” programme. By
this, there would be a unique opportunity
to learn about progress in one’s own and
other disciplines. All this with the intent to
stimulate data and information exchange,
as well as many interactions.
Components of the PharmSciFair include:
Opening Session
Awards Ceremony
- Including a prestigious European
Pharmaceutical Sciences Award
Invited Speaker Sessions
Short Communication Sessions
Discussion Sessions
Poster Sessions
Partner Introduction Stands
Exhibition
Welcome Reception
Partner Receptions
PharmSciFair Dinner
In 2007, there was no full PharmSciFair,
because this was the year of the
Pharmaceutical Sciences World Congress
– PSWC2007 – in Europe. To link these
events, there was the PSWC2007 and
PharmSciFair Exhibition
The 2nd PharmSciFair is scheduled
for June 8-12, 2009, again in Nice FR.
Programming is in progress (7-8 parallel
sessions for five days, except the first
afternoon for the Opening Session),
coordinated by a PharmSciFair Planning
Team, chaired by Pia Vuorela, President-
Elect of EUFEPS. The general concept
will be the same as in 2005, but it will be
expanded with a first European Careers
Forum and a Young Scientists Meeting
- Pre-satellite with and for PhD Students
and PostDocs.
Meetings and events
What about them? EUFEPS´ conferences
and workshops – 4 to 8 per year, normally
– are widely communicated and wellknown.
They appear in three categories:
EUFEPS organised ones
- All responsibility, including risk and
revenue
EUFEPS co-organised ones
- Shared responsibility, including risk
and revenue
EUFEPS co-sponsored ones
- e.g. communication support, but neither
risk nor any revenue
In addition, to education and training
workshops, EUFEPS also set up a
number of exploratory and discussion
workshops, over the years, several funded
by the European Commission. Important
outcomes reports or articles have been
published following such meetings. The
number of delegates in such workshops
ranged between 12 and 120. This activity
should continue to ensure further
contributions to the science and to policy
making.
To run it all, there is an EUFEPS
Steering Committee for Meetings and
Events, chaired by Pia Vuorela, President-
Elect of EUFEPS.
Education and training
How does EUFEPS engage in education
and training? Courses, workshops and
the Young Students Meeting (see above)
are organised along similar lines as the
meetings and events.
After many years of discussions, the
EUFEPS Course DataBase or Catalogue
was launched earlier this year. The
information included in it is provided
in collaboration with universities and
research schools. A number of inclusion
criteria have been defined to set the
standard.
In silico Systems and Learning
is an additional new initiative. The
initiative originates from Austria, where
the University of Vienna is providing
support for a EUFEPS Branch Office.
One workshop has been held to engage
more groups and expand collaboration. A
second workshop is in progress.
EUFEPS organised two (exploratory)
workshops in safety sciences. One of them
a number of years ago (to feed into the
NSMF) and an additional one, last year, to
further address the needs of (integrated)
research education and training in safety
sciences. The primary outcome was
a tentative postgraduate level training
programme for safety scientists in
industry. In the first half of this year, it
has been further developed and refined
into a one-year modular curriculum, also
submitted as an IMI JU EoI (Expression
of Interest) by a specific consortium.
There are additional ideas, along the same
lines for additional topics, which will be
reported on in due course.
Having assessed the needs and
defined the goals and objectives, places
where effective and efficient education
and training (including lab courses, as
needed) can take place are required.
To start looking into how to assess the
quality of institutions, a workshop on
Institutional Peer Reviewing was set up in
LXXII
the beginning of this year. The workshop
outcomes have been presented in a recent
article in this NewsLetter.
Additional associations and groups
for education and training liaising with
EUFEPS include EAFP (European
Association of Faculties of Pharmacy);
EPSA (European Pharmaceutical
Students’ Association); and the ULLA
university consortium, running e.g. the
ULLA Summer School.
For many years, the Committee on
Training and Education (CTE) has been
the EUFEPS group to identify, initiate and
bring in courses to constitute the EUFEPS
training and education programme. It is
still there, but has, recently, been given
a broader role – the EUFEPS Steering
Committee for Education and Training,
charged to coordinate all education
activities. This Committee is chaired
by Ulrike Holzgrabe, Member of the
Executive Committee.
Communications
What are the EUFEPS communication
tools and channels? In preparing the slide
set, referred to in the beginning this article,
a surprisingly long list emerged:
European Journal of Pharmaceutical
Sciences (Eur J Pharm Sci or EJPS)
- Official Scientific Journal of EUFEPS;
the Impact Factor of which is gradually
increasing
EUFEPS NewsLetter
- Four issues per year, since a number of
years no longer printed, but available at
EUFEPS Online
EUFEPS Flash
- Email announcements of EUFEPS
meetings and events, as needed
EUFEPS Membership Bulletin
- Email circulation to the membership
EUFEPS Online www.eufeps.org
- The EUFEPS central website
EUFEPS Course DataBase/Catalogue
www.etplatform.eu,
- Linked to EUFEPS Online
EUFEPS Vienna Branch Office
(http://vienna.eufeps.org)
- systems and learning related website
PharmSciFair Website
- The Pharmaceutical Sciences Fair and
Exhibition partnership website (www.
pharmscifair.org)
- Operated by EUFEPS
EUMAPP
- EU funded microdosing and accelerated
mass spectrometry investigation project
(www.eumapp.com)

- Operated by EUFEPS
PSWC2007 Website
- The last Pharmaceutical Sciences
World.
- Congress website, still running (www.
pswc.org)
- Operated by EUFEPS
Network on BioAvailability and
BioPharmaceutics
- www.babp-network.org
- Linked to EUFEPS Online
Network on PAT Sciences
- On EUFEPS Online
Network on PharmacoGenetics and
PharmacoGenomics Research
www.epr-network.org
- Linked to EUFEPS Online
Network on Safety Sciences
- On EUFEPS Online
European Pharma Sciences Leadership
Forum (EuPSLF)
- Agreed to be set up (www.eupslf.org)
EUFEPS Ambassadors
- Members, meeting delegates and liaison
contacts promoting EUFEPS and its
activities
There is a EUFEPS Media Task
Force, chaired by Hans H. Linden,
Executive Director, available to discuss
improvements and resolve problems.
Enabling things
What support is there? Any organisation is
dependent on policy and decision-making
bodies to succeed. As important are sound
finances, hands to get the job done and
facilities in and from which to operate.
Such platforms include:
• Finance and Funding
• Membership dues
• Meetings registration fees
• General and specific sponsorship
• Budgets and outcomes reports
• President’s Conference
• Update, discussion and advice between
council meetings
• Council and Open Forum
• The membership representatives legal
meeting
• Strategic plans, progress and reports
approval
• Secretariat and contracted partners
• Central (executive) office and branch
office
• General management and
administration
• Project management and
administration
LXXIII
Where next?
Are there reasons to be satisfied? At the
forthcoming Council and Open Forum
(September 20, 2008, in Ljubljana,
Slovenia), there will be a Mid-term
Assessment of the current Strategic Plan
(2006-2010), reflecting on what happened
to date and discussing how to proceed.
Outcomes will be reported in this
NewsLetter.

EUFEPS Newsletter, 2008, vol. 17, issue 4
“Times are changing and we
change with time”
Reflections of the Past
President and President at the
turn of the year
Christian R. Noe Professor,
and Daan J.A. Crommelin, Professor
“Tempora mutantur et nos mutamur
in illis” – “Times are changing and we
change with time”. “Globalisation”
is a term implying rapid change. It is
associated also with the present financialeconomic
crisis, which demonstrates all
of a sudden, that the old Latin expression
is still relevant to a large extent. There
is little doubt that everybody will change
with time. However, with permanently
and swiftly ongoing changes in the world
around us, we are free to decide, when,
how and to which degree we have to
change our positions and ourselves.
Otherwise, it will be others that will
impose the changes upon us.
So, what is EUFEPS today, at the
beginning of the post-IMI-launch era?
At the EUFEPS President’s Conference,
in April this year, a set of slides were
prepared for information and update. This
rhapsodic article is based on them, together
with some additional update material.
The Central Office of EUFEPS is
still located in the SAPS building in
Stockholm, Sweden. Since one year ago,
there has also been the Branch Office
Systems and Learning, at the University
of Vienna, Austria. Additional Branch
Offices have been considered, but these
plans did not yet materialise.
Europe unified
The formation of a unified Europe is
another process of change, slowly going
on over the years. This movement is of
fundamental importance for all people
living in this region. It is obvious that,
within the European project, positive
effects of changes are by far prevailing
over negative effects. EUFEPS as a
federation has been founded to support
the European idea. EUFEPS, representing
pharmaceutical scientists and promoting
the pharmaceutical sciences, has done
its best to promote a common European
dimension of high quality research.
EUFEPS, representing scientists, has also
done its best to create a truly European
community of pharmaceutical scientists.
Last not least, all of EUFEPS´ activities
have taken place to secure sustainability
of successful pharmaceutical research in
the European region.
Bottom-up and top-down roles
A further aspect of changes in time are
those waves in politics, which favour
either democratic “bottom up” approaches
or feudalistic “top down” approaches.
As a matter of fact, this situation occurs
not only in politics, but in almost all
human organisational systems. Only a
harmonised relation between “parliament”
and “government” can assure justice
and benefit for the population. Taking
EUFEPS as an example, the “Council”
would stand for the “Parliament”, the
“Executive Committee” would stand
for the “Government”. It is clear that the
membership, represented by the Council,
is the core of the Federation and that the
Council has to act according to the wish
of this membership. Being aware of this
important Committee, which over the
years has taken a series of measures to
strengthen the role of membership, the rock
on which EUFEPS stands. This not only
led to increasing the number of member
organisations or introducing the category
of individual members. It also meant
establishing the President´s Conference, a
‘twice-a-year gathering’ of the presidents
of the EUFEPS member organisations.
This forum should discuss initiatives and
needs arising across the continent in an
open debate with the EUFEPS leadership.
LXXIV
New initiatives strengthen
An even further reaching step was taken in
view of the complexity of pharmaceutical
research. The “European Pharmaceutical
Sciences Leadership Forum” was
established to create a platform, where
the leadership of scientific organisations
related to the pharmaceutical sciences
meet to discuss problems, to share views,
to identify areas of common interest and
to co-ordinate planning on both broad and
detailed levels. For EUFEPS, this forum
is of particular interest, because it is the
only organisation in Europe standing for
pharmaceutical sciences in its full scope,
comprising the main areas of discovery,
development, production and utilisation
of drugs (see scheme 1). It is EUFEPS´
interest to strive for the common goal of
promoting top quality pharmaceutical
research in Europe jointly with the other
organisations. The EUFEPS Senate,
made up of the best European researchers
in the field, regardless their educational
background, will hopefully be a
particularly effective think tank reacting
quickly to changes and giving answers to
the needs of the pharmaceutical scientists´
community, in particular concerning the
future of research. All these initiatives
constitute, in principle, “top down”
actions of the Executive Committee to
provoke “bottom up” activities, which will
strengthen the Federation and will help to
reach the overall goals.
IMI now operational
As a matter of fact, the “daily” work at
the executive level of EUFEPS is mainly
focused on the implementation of the
strategic plan as decided by the Council.
This means a lot of specific activities and
actions, e.g. organisation of conferences,
workshops, arranging the work of the

committees and networks, co-ordination
of the PharmSciFair and many others. One
of the most important projects, the support
of the implementation of the Innovative
Medicines Initiative (IMI) within the 7th
Framework Programme of the EU has
just been finished with the IMI starting
to be operational from now on. Without
any doubt, the IMI is a very promising,
important and, due to the financial options,
also effective “top down” instrument
from the European Commission to
promote the pharmaceutical sciences in
Europe. Hopefully several of the present
EUFEPS activities will be continued by
IMI on a financially stronger basis. This
will hopefully set free the required energy
and capacity for important new EUFEPS
Executive Committee (ExCo) activities.
One of these new tasks will be to raise
awareness of the potential of the IMI and
to connect the instruments and activities
of IMI to the EUFEPS membership.
New pharmaceutical medicine
There is one particularly important
initiative within IMI, which will result
in a significant change in the setting of
organisations dealing with pharmaceutical
sciences. Promotion of “pharmaceutical
medicine” is one of the goals of IMI. The
term “pharmaceutical medicine” was
coined some time ago. In brief, it describes
“pharmaceutical sciences” from the
standpoint of medically trained scientists,
just as “medicinal chemistry” describes
our science from the standpoint of chemists
or “pharmaceutical biotechnology” does
so from the standpoint of molecular and
cellular biologists. Of course, clinical
drug development is at the core of
pharmaceutical medicine, but it aims to
be more and it should be more. It should
comprise the best possible contributions
that medical doctors with their educational
and professional background can give to the
pharmaceutical sciences. This is certainly
not less relevant than the contributions from
the other main disciplines. This awareness
of the importance of pharmaceutical
sciences within the medical community
and the wish for new organisational
and educational approaches have to be
welcomed, in view of our ambition to
promote the best possible science in
Europe.
EUFEPS’ mission stands
In a recent discussion within the
miniExCo of EUFEPS, the opinion was
shared that it is the duty of EUFEPS to
support initiatives to develop the field of
“pharmaceutical medicine”. This will
speed up implementation of new findings
in the drug development process, add
quality and will help to avoid duplications.
Thus, the overall quality of pharmaceutical
research, concerning the full drug
discovery and development process, not
forgetting drug utilisation (scheme 1), will
increase.
Please contribute views
Of course, involvement with
“pharmaceutical medicine” means a
change for EUFEPS. It is however not
at all a change with respect to reaching
the central goal of promoting the quality
of pharmaceutical sciences in Europe.
Within the Leadership Forum and the
Senate, contacts have already been
established and will be further established
with organisations from different areas
and scientists of different disciplines,
including medicine. The change is much
more related to the question of “who are
our members?” Most of our membership
organisations at present are national
pharmaceutical organisations. In the heart
of their scientific competence is preclinical
pharmaceutical development. Of course,
there is also high competence in the field of
pharmacotherapy and drug utilisation, due
to the professional qualification associated
LXXV
with pharmacy education. At present,
the discovery competence is shared with
chemists and molecular biologists. And
without any doubt, nobody would have
questioned the medical competence in
clinical development. Therefore, there is
no major obstacle for EUFEPS to support
activities aiming at the promotion of the
science side of pharmaceutical medicine.
As a consequence, we propose EUFEPS to
open up its membership to “pharmaceutical
medicine” scientists and to actively seek
collaboration with European organisations,
existing or to be established, in the field of
pharmaceutical medicine.
Some mental change might be
required. The present pharmacists and
pharmaceutical scientists tend to fear
domination by medical doctors, and
discussions on “staking of claims” and on
“importance of fields and pecking order”
will continue. However, such discussions
seldom bear fruit. It has been the mission
of EUFEPS from its foundation to serve
pharmaceutical scientists and to promote
and foster the pharmaceutical sciences.
To us, it is in line with this motto to seek
an active interaction with our colleagues
in pharmaceutical medicine. Your Past-
President and President look into the
future with great expectations and invite
you, EUFEPSonians, for comments. ‘Top
down’ and ‘bottom up’ – in a strong and
healthy organisation, there is this twoway
street where the leadership invites
its members to a debate on opinions and
strategies. Therefore, ending with the
Greek philosopher´s version of the Latin
expression cited at the beginning: “Panta
rhei kai ouden menei”, ”everything
changes and nothing remains the same”
does – in mid-term perspective – apply to
the “everyday life of EUFEPS”, but does
not apply to the EUFEPS basic principles
and tradition. The debate remains and the
floor is yours…

EUFEPS Newsletter, 2009, vol. 17, issue 1
The PharmSciFair
is the premier European Platform for
Advancing Pharmaceutical Sciences,
initiated by EUFEPS. This became
absolutely clear during the first
PharmSciFair in 2005, where 26 National
and International organisations in
Pharmaceutical Sciences joined together.
More than 700 scientists, coming from all
pharmaceutical disciplines, contributed
and set up a truly interdisciplinary meeting
of the highest standard. The meeting
was accompanied by a comprehensive
exhibition.
The Scientific Programme
Commitments to the 2009 event include
40+ organisations. An exciting programme
has been set up, which promises up-to-date
presentations of front line pharmaceutical
research and development. In addition to
6–8 parallel Invited Speaker Sessions,
over 400 abstracts have been submitted
and processed for Short Communications
and Posters. The preliminary programme
is constantly updated – and there will
be a final one available soon. For all
information, consult the PharmSciFair
Website at: www.pharmscifair.org
The Careers Forum
is there to provide an opportunity
for companies, institutions and other
organisations to meet with candidates,
and to interview them at PharmSci Fair.
These opportunities will principally be
of great interest to graduate students,
and to those in the early stages of their
professional careers in industry. It is
anticipated that there will be opportunities
available within a variety of scientific
disciplines, including chemistry,
biology, physics and informatics. Please
visit the Careers Forum Website at:
www.careersforum.org for details!
The Exhibition
will take place over three days - on the
Tuesday, Wednesday and Thursday –
and will once again feature key players
from the European Pharmaceutical
Industry and beyond, as well as leading
international companies from the supply
chain. There will also be a number of
PharmSciFair Programme Providing
Partner Stands. Poster sessions, with new
posters each day, and catering places will
be in the Exhibition area. For floor-plan
and rates etc., access: www.healthlinksevents.co.uk/
pharmsci2009.htm
LXXVI
The 2009 PharmSciFair Young
Scientists Meeting
will be organized as a pre-satellite meeting,
by and for young scientists. It is open to
our next generation of pharmaceutical
scientists. PhD students and postdoctoral
fellows will convene in Nice to exchange
ideas and discuss the latest developments
in pharmaceutical sciences. For progress
and programme, visit the Website at:
www.apgi.org/presatellitePharmSciFair/
You should be there, of course.

EUFEPS Newsletter, 2010, vol. 19, issue 1
Update from the
President
Clive G. Wilson, Professor
EUFEPS President
July 2010
The European Federation for Pharmaceutical
Sciences represents affiliated
scientific societies in Europe and provides
activities that nurture information
exchange, training programmes and
scientific events for academia, industry
and regulatory bodies.
Time to celebrate
The organisation celebrates its twentieth
anniversary in 2011 and we will mark this
important event with a yearbook, launched
at PharmSciFair. EUFEPS strives to
encourage participation – from individuals
and from member organisations –
that strengthens the progress to better and
safer medicines. This is achieved by many
interactions at conferences, workshops
and collaborative partnerships, and the
exploration of common interests with
other learned societies that are relevant to
membership needs. At the time of printing,
EUFEPS has 24 member societies in 24
countries, including Israel and Turkey,
fifteen European universities and research
institutes and more than four hundred
individual members.
Networks and events
An important engine for the EUFEPS
is the network structure, and you will
be able to find further details in the
upcoming yearbook or on the EUFEPS
Online site. The networks gradually
evolve by crystallisation of interest and
are led by steering groups as shown
in the plan. Currently there are five
established networks and two more,
regulatory sciences and nanomedicine,
under development. The activities of
both member societies and the network
structures contribute to PharmSciFair, a
celebration of European pharmaceutical
sciences held on a biennial basis. The event
hosts activities of the member societies and
the networks and has a strong programme
for young scientists. In addition, EUFEPS
plays an important role in programmes
organised by FIP, and cosponsors events
such as the BBBB (Balaton-Baltic-Bled-
Bosporus) conference series, helping to
contribute to southern, eastern and central
European activities. The European Journal
for Pharmaceutical Sciences publishes
EUFEPS conference reports, NewsLetter
and announcements, keeping members up
to date with new events.
Current governance
Instruments of policy and training, and
interaction with industry are taken care
of by committee structures. Other events
are held within the aegis of EUFEPS,
directed by members with assistance of
the executive committee. The Executive
Committee meets on a quarterly basis and
Member Societies propose candidates for
election for a two-year term.
Recently, the formation of a Senate
structure was initiated. The Senate serves
the president in generating ideas for
strategic planning, monitoring the health
of the organisations and other appropriate
tasks. It provides access to a larger and
senior network, which can assist in
creative solutions about the expansion of
EUFEPS.
Central Office
The Headquarters of the EUFEPS has
moved but is still based in the Stockholm
area under the direction of the present
Chief Executive Officer, Hans H.
Linden. The federation was previously
based within the Swedish Academy of
Pharmaceutical Sciences, and strong
links across Scandinavia have continued.
LXXVII
EUFEPS Committee and Network
Structure.
New offices in the Veddesta Business
Centre provide central coordination and
support of the networks and committees,
and link into important European
initiatives such as Innovative Medicine
Initiative platform (IMI JU) under the 7th
Framework Programme for Research and
Technological Development through the
activity of the CEO.
Going Forward
EUFEPS is unique in that it is the only
pan-European organisation that supports
pharmaceutical/drug scientists, whatever
the origin, domain or discipline. It is
therefore a powerful rallying point
that has the ambition to develop the
professional status of the pharmaceutical
scientist. This has yet to occur, but it will
happen and it will stretch beyond the
current constraints of pharmacy, which
in some countries (especially my own)
is failing as a scientific discipline. The
pressures for the formation of such a body
are strong, as pharmaceutical sciences are
represented at every level of the medicines
chain, from discovery in laboratories
in industry and academia through to
regulation and safety sciences. The
backgrounds of our participants include
biochemistry, pharmacy, physics and
engineering graduates and many others.
The contribution that we can make is
significant and well recognised but a stepchange
in setting standards long overdue.
Let’s make sure that we use the experience
of EUFEPS to represent the ambitions of
our members and member organisations
to set pan-European standards of the
highest order.

EUFEPS Newsletter, 2010, vol. 19, issue 1
Alain Cuiné,
Chair Organising Committee
PharmSciFair is an important event in
the European meetings calendar, and we
are building the next one to attract always
more people and especially more industrial
interest. The two first events were in Nice,
France, and we have decided to move
towards Eastern Europe with the objective
to encourage flow of information across
the member societies and professions in
this fast growing part of the world. The
provision of a scientific venue to new,
younger scientists assisting in career
development will be also vigorously
addressed.
The Opening Session will take place
in the afternoon of Monday, June 13, 2011.
A prestigious group of influential leaders
will contribute to a common vision of
pharmaceutical sciences, in both the short
and the long term.
The pharmaceutical science as a
multifaceted concept will be reflected in
the program of this event, which will be
wide ranging in terms of content, activities
and participating partners. Exhibition
and networking opportunities will be
promoted. These are the tracks that are
planned and tentative programme flow.
The First Announcement including
session topics, keywords and deadlines
will be circulated before the summer, but
we already urge you all to participate in
the 2011 PharmSciFair and to invite your
colleagues to do so as well!
Prague Congress Center, June 13–17, 2011
LXXVIII

���������
�� ������������������������������������������
�����������������
�� ���������������������������������������������
�������������������������������������������������
�������������������������������������
���������������
�� �������������������������������
�����������������������������������������������
���������������������������������
�� ��������������������������������������������
�����������������������������������������
�������������������������������������������
�� ������������������������������������
�����������������������������������������
�����������������������������������������������
�����������������������������������������������
�� �������������������������������������������������
������������������������������������������������
�������������������
�
��������������������������������������
�������������������������������������
��������������������������������
��������������������������������������
���������������������������������
�
���������������������������������������������������
������������������������������������������������������
�����������������������������������������������������
������������������������������������������������������
�����������������������������������������������������
�������������������������������������������������
�������������������������������������������������������
��������������������������������������������������
�����������������������������������������������������������������������������������
�� ��������������������������������������������
������������������������������������������
��������������������������������������������������
�����������������������
�� ����������������������������������
�� �����������
�� �����������������������������������������
� ������
�� ���������
�� �������������������������������������������
���������������������������������������
�����������������������������������������
�� ����������������������������������������������
���������������������������������������������
����������������������
�� ����������������������������������������������
�����������������������������������������
����������������������������������������������������������������������������������������������
��������������������������������������������������������������������������������������������������
��������������������������������������
�
���������������������������������������������������������������������������������������������������������